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INTRODUCTION 
1 INTRODUCTION 
1.1 Hematopoiesis and hematopoietic stem cells 
The term hematopoiesis refers to the formation and development of the cells of 
the blood. In humans, this process begins in the yolk sac in the first weeks of 
embryonic development. By the third month of gestation, stem cells migrate to 
the fetal liver and then to the spleen. Between 3 and 7 months of gestation these 
two organs play a major hematopoietic role whereas later on the bone marrow 
becomes the major hematopoietic organ and hematopoiesis ceases in the liver 
and spleen (Fig.1).  
 
Figure 1. Ontogenic emergence of the hematopoietic system (figure adapted from 
Bonnet, 2003) 
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As the embryo develops, this primitive hematopoiesis is superseded by the de-
finitive multilineage blood system (Bonnet, 2003). Every day, the body 
produces billions of new blood cells. All of these are derived from rare cells in 
the bone marrow called the hematopoietic stem cells (HSC). Adult stem cells 
are defined as cells that have the ability to perpetuate themselves through self-
renewal and to generate mature cells of a particular tissue through differentia-
tion (Reya et. al., 2001). The first evidence for the existence of such a cell–type 
came from experiments by Ray Owen and co-workers in 1945, which showed 
that bovine fraternal twins, sharing a single placenta and blood circulation, re-
tained production of blood cells genetically defined to be from both throughout 
their life. The hallmark properties of the hematopoietic stem cells (HSCs) were 
defined in 1963 by Till and McCulloch (Siminovitch et. al., 1964). In the mur-
ine model, the authors provided evidence for the existence of HSCs in bone 
marrow. These HSCs could reconstitute the hematopoietic system, and hence 
rescue lethally irradiated recipient animals. Using serial transplantations, they 
showed that HSCs possess the ability of self-renewal. Based on these experi-
ments, HSCs were defined as cells with the abilities of multilineage 
differentiation as well as unrestricted self-renewal.  This discovery marked the 
beginning of modern-day stem-cell research (Bonnet, 2003). The first attempts 
at purifying HSCs came from experiments carried out by Till and McCullogh 
in the Netherlands (Van Bekkum et. al., 1979; Worton et. al., 1969). Based on 
their work, it has become possible to routinely identify and isolate highly puri-
fied murine and human HSCs based mainly on characteristic cell surface 
proteins that are either present (Sca1 and c-kit) or absent (using markers of 
lineage committed cells such as CD38, Mac-1 and CD8) (Weissman, 2002). 
In the hematopoietic system, stem cells are heterogeneous with respect to their 
ability to self-renew and can be divided into three different populations: long-
term self-renewing HSCs, short-term self-renewing HSCs, and multipotent 
progenitors without detectable self-renewal potential (Morrison and Weissman, 
1994; Morrison et. al., 1997). These populations form a lineage in which the 
long-term HSCs give rise to short-term HSCs, which in turn give rise to multi-
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potent progenitors (Morrison et. al., 1997). As HSCs mature from the long-
term self-renewing pool to multipotent progenitors, they progressively lose 
their potential to self-renew but become more mitotically active. Whereas long-
term HSCs give rise to mature hematopoietic cells for the lifetime of the 
mouse, short-term HSCs and multipotent progenitors reconstitute lethally irra-
diated mice for less than eight weeks (Fig.2). 
 
Figure 2. Development of hematopoietic stem cells. HSCs can be subdivided into long-term 
self-renewing HSCs, short-term self-renewing HSCs and multipotent progenitors (red arrows 
indicate self-renewal). They give rise to common lymphoid progenitors (CLPs) and common 
myeloid progenitors (CMPs). Both CMPs/GMPs (granulocyte macrophage precursors) and 
CLPs can give rise to all known mouse hematopoietic cells (Figure adapted from Reya et. al., 
2001) 
1.2 Self-renewal and leukemogenesis 
HSCs that enter cell division are faced with the fundamental options to self-
renew or differentiate. Once multilineage cells are committed to differentiation, 
they either engage in myeloid differentiation to generate common myeloid pro-
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genitors (CMP) or take the lymphoid path to generate common lymphoid pro-
genitors (CLP) (Akashi et. al., 2000; BitMansour et. al., 2002; Hoang, 2004). 
The process of differentiation can be studied experimentally (spleen colony as-
say) through the capacity of these multipotent cells to give rise to other 
multipotent cells in their progenies and therefore to sustain multipotency. In 
contrast, the emergence of committed progenitors with restricted differentiation 
potential would lead to an extinction of multipotency (Hoang, 2004). 
The characteristic of self-renewal is often described as a hallmark of normal 
stem cells and is perhaps the most important intrinsic cellular property that is 
subverted during stem cell tumorigenesis (Jordan and Guzman, 2004). Human 
cancer stem cells, identified in acute myelogenous leukemia (AML) (Bonnet 
and Dick, 1997), myeloid blast crisis of chronic myelogenous leukemia 
(Jamieson et. al., 2004), breast cancer and brain tumors (Al-Hajj et. al., 2003; 
Singh et. al., 2003) share functional properties with normal stem cells such as 
self-renewal, high proliferative potential, some differentiation capacity and 
ability to be serially transplanted (Jamieson et. al., 2004b; Passegue et. al., 
2003). Huntly et. al. showed in a mouse model that leukemia-associated onco-
genes have the capacity to confer self-renewal properties to hematopoietic 
progenitors that inherently lack the ability to self–renew (Huntly et. al., 2004). 
Constitutive expression of the AML1-ETO translocation product has been 
shown to increase the self-renewal frequency of stem cells (Mulloy et. al., 
2002). 
If dysregulation of signaling pathways that normally regulate stem cell self-
renewal leads to tumorigenesis, then stem cells themselves might be the target 
of transformation in certain types of cancer. There are two reasons to think that 
this hypothesis may be correct: first, because stem cells have the machinery for 
self-renewal already activated, maintaining this activation may be simpler than 
turning it on de novo in a more differentiated cell; that is, fewer mutations may 
be required to maintain self-renewal than to activate it ectopically. Secondly, 
stem cells often persist for long periods of time, instead of dying like many ma-
ture cells in highly proliferative tissues. This means that there is a much greater 
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opportunity for mutations to accumulate in individual stem cells than in most 
mature cell types. Alternatively, self-renewal could also be acquired in certain 
leukemia’s by the critical genetic alterations in downstream progenitors which 
convey stem cell characteristics to these cells. Though the molecular mecha-
nisms of stem cell self-renewal are poorly understood, several genes and gene 
families have been implicated in the process including the Hox (Antonchuk et. 
al., 2001; Buske et. al., 2002) and Wnt gene families (Fig.3) (Reya et. al., 
2003). 
 
Figure 3. Oncogene hierarchy and role of self-renewal in the pathogenesis of leukemias. 
A. Normal myelopoiesis is distinguished by the orderly differentiation of HSC, which are the 
only cells with self-renewal capacity, into committed myeloid progenitors and their respective 
terminally differentiated progeny. B. Chronic diseases, such as chronic phase CML, are asso-
ciated with preleukemic events that result in increased survival and proliferation within the 
stem and myeloid progenitor populations but continued production of terminally differenti-
ated progeny. Acquisition of BCR-ABL, overexpression of BCL2, and inactivation of JunB 
expression are examples of such events that initially take place in HSC. C and D: Acute dis-
eases such as blast crisis CML and AML are marked by acquisition of self-renewal capacity 
by progenitors that normally lack it or by enhanced self-renewal in HSC. β-catenin activation 
during the progression of CML to blast crisis is an example of such a leukemogenic event 
occurring in myeloid progenitors. MOZ-TIF2 and MLL-ENL are AML-associated transloca-
tion products that may enhance HSC self-renewal or endow myeloid progenitors with self-
renewal potential. Together with a subsequent block in differentiation, these leukemogenic 
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events result in the accumulation of immature blast progeny and development of AML at ei-
ther the HSC or myeloid progenitor stage (Figure adapted from Jamieson et. al., 2004b) . 
1.3  Role of homeobox gene in normal and leukemic he-
matopoietic cells 
The homeobox (HB) was first identified in the 1980s as a sequence motif that 
was shared among Drosophila homeotic genes (the HOM-C complex), where 
they play a key role in embryonic differentiation along the anterior–posterior 
(ap) axis, and is now known to be present in many genes in virtually all eu-
karyotic species (Stein et. al., 1996). It is estimated that the human genome 
contains at least 200 homeobox genes (Tupler et. al., 2001), of which only 39 
are members of the HOX family. Unlike the HOM-C/HOX genes, which are 
organized in gene clusters, most homeobox genes are dispersed throughout the 
genome (Abate-Shen, 2002).  
Homeobox-containing genes constitute a gene family characterized by a highly 
conserved 183-nucleotide sequence encoding a 61-amino acid domain, the ho-
meodomain (HD). These homeodomains are structurally related to the helix-
turn-helix motif of prokaryotic DNA-binding proteins and have sequence-
specific DNA binding activity (Fig. 4) (Buske and Humphries, 2000). Se-
quences flanking the HD also influence specificity by coordinating interaction 
with cofactor proteins that influence DNA-binding properties. Homeobox 
genes are divided into two classes. Class I include clustered HB (HOX) genes 
and that comprises 39 members, while the Class II divergent HB (non-HOX) 
genes are dispersed through the genome, and include small families, such as the 
MSX, ParaHox (CDX), PAX, DLX and Engrailed (EN) groups, and are inter-
mediate in size. Although individual members of homeobox families often 
share little sequence similarity other than the homeobox, some families have 
additional conserved sequence motifs that contribute to their distinct functional 
properties (Fig. 5) (Abate-Shen, 2002; Owens and Hawley, 2002)  
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Figure 4. The structure of the homeodomain. Despite its considerable variation in primary 
sequence, the three-dimensional structure of the homeodomain has been well conserved, and 
corresponds to three α helices that have a relatively unstructured amino-terminal arm. The 
consensus amino acids, which are invariant among all homeodomains, are essential in main-
taining structural integrity and making essential contacts with DNA. Amino acids that 
distinguish the various homeoprotein families contribute to differences in their DNA-binding 
specificities and other functional properties. The figure shows the Engrailed–DNA complex 
(Figure adapted from Abate-Shen, 2002) 
 
Figure 5. Generating diversity among homeoproteins. The distinct classes of homeopro-
teins show considerable sequence diversity within the homeodomain (top), and within the 
amino- and carboxy-terminal regions that flank this domain (bottom). The sequence diversity 
is believed to contribute to their distinct functional properties, by generating distinct DNA-
binding specificities, promoting unique protein–protein interactions, and other mechanisms. 
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Functional diversity is also generated by additional conserved domains or motifs that occur in 
particular homeoprotein families. HOX proteins contain a hexapeptide (HP) motif—a short 
stretch of conserved residues that are responsible for mediating interactions with PBX ho-
meoproteins. MSX proteins also have short stretches of conserved amino acids that flank the 
homeodomain, called the extended homeodomain (EHD), although their functions are un-
known. PAX proteins contain an additional DNA-binding domain, known as the paired box. 
Members of the SIX family have a conserved amino-terminal domain called the Six domain, 
and LIM homeoproteins are named after a protein interaction motif, the LIM domain (Figure 
adapted from Abate-Shen, 2002). 
1.3.1 HOX gene expression in normal and leukemic hemato-
poietic cells 
Numerous studies have now shown that, in addition to embryonic tissue, HOX 
genes are expressed in mammalian adult tissues, both normal and neoplastic. 
These include normal and neoplastic skin (Care et al., 1996), kidney (Barba et 
al., 1993), human colonic mucosa (De Vita et al., 1993; Wang et al., 2001), tes-
tis (Watrin and Wolgemuth, 1993) and hematopoietic cells (Antonchuk et al., 
2002; Buske et al., 2001; Giampaolo et al., 1995; Schnabel et al., 2000). These 
studies revealed that HOX gene expression in normal hematopoiesis is strictly 
regulated and differs strikingly between early progenitors and mature, differen-
tiated hematopoietic cells. HOX genes of the A, B, and C cluster are expressed 
in early CD34+ hematopoietic progenitors, whereas HoxD gene transcription is 
absent in this progenitor pool (Buske and Humphries, 2000). In sharp contrast, 
expression of certain Hox genes of the A, B, and C clusters is absent or sub-
stantially down regulated in the more mature CD34- compartment, (Giampaolo 
et. al., 1995; Lawrence et. al., 1996) indicating that HOX genes have a major 
role in primitive hematopoietic cells (Fig. 6). 
The function of HOX genes in hematopoiesis has been investigated through 
knockout mouse models and overexpression from retroviral vectors in hemato-
poietic stem cells from murine fetal liver and bone marrow and in human cord 
blood progenitors. Overexpression of Hoxb8/IL-3 in mice led to an aggressive 
transplantable leukemia in contrast to mice transplanted with IL-3 only (Perkins 
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et. al., 1990). Leukemic blasts from many patients with acute myeloid leukemia 
(AML) show an aberrant pattern of HOXA10 expression, further supporting the 
concept that dysregulated HOX gene expression may be a general feature of 
this malignancy (Kawagoe et. al., 1999; Lawrence et. al., 1995). Overexpres-
sion of HOXA10 in the progeny of human cord blood or fetal liver cells 
perturbs human lymphomyelopoiesis in vitro and in vivo (Buske et. al., 2001). 
Notably, the expression of HOXA9 has been identified as one of the most con-
sistent diagnostic markers of AML in humans and as the only single gene 
expression marker of more than 6800 cDNAs tested by DNA micro-array 
analysis that correlated with clinical outcome (Golub et. al., 1999). Overex-
pression of Hoxa9 and Hoxa7 caused AML in the BXH-2 mouse line 
(Nakamura et. al., 1996b). Aberrant expression of HOXA9 has been reported to 
be an important component of leukemogenesis driven by MLL translocations 
(Armstrong et. al., 2002). Beside the aberrant expression of wild-type HOX 
genes in AML, recent molecular characterization of the two translocations 
t(7;11) and t(2;11) proved that HOX genes themselves such as HOXA9 and 
HOXD13 are direct targets of leukemia-associated genetic alterations (Iwasaki 
et. al., 2005; Kroon et. al., 2001; Nakamura et. al., 1996a).  
 
CD34-CD34+/CD38low CD34+/
CD38med/high
HOXB4
HOXB3
HOXA10
Hematopoietic Cell Number
 
 
 
 
 
 
 
Figure 6. Expression of HOX genes in human BM cells. HOX genes are expressed in early 
progenitor cells. Their expression decreases during differentiation.  
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Figure 7. Homeobox genes are involved in leukemogenesis. The molecular characterization 
of chromosomal translocations has shown that Hox genes and their upstream regulators like 
members of the MLL and CDX family are directly involved as partner genes in leukemia-
specific fusions as demonstrated for HOXA9 and HOXD13 in NUP98 fusions, for PBX1 in the 
E2A–PBX1 fusion and CDX2, a non HOX homeobox gene, with ETV6. Furthermore, the 
HOX upstream regulator MLL is one of the most frequently altered genes in human leuke-
mia’s.  
1.3.2 Non-clustered homeobox genes in leukemogenesis 
Several non-clustered HD proteins have been shown to function as cofactors 
for HOX proteins, interacting with HOX genes by a conserved sequence 
YPWMK and are co-expressed during embryonic development. These include 
the three-amino-acid-loop-extension (TALE) proteins, PBX, MEIS, and 
PREP1/KNOX1. PBX genes are widely expressed in fetal and adult tissues, 
although PBX1 transcripts are notably absent from lymphocytes (Monica et. 
al., 1991). The hematopoietically expressed (HEX) gene as another example of 
a non-clustered homeobox gene was initially identified in human hematopoietic 
cells, where it is expressed in multipotential progenitors, myeloid cells, and B 
cells, but not T or erythroid cells (Bedford et. al., 1993). HEX expression has 
also been detected in peripheral blood leukocytes from leukemia patients 
(Manfioletti et. al., 1995). Other non-HOX HB genes like HOX11, and mem-
bers of the CDX, HLX, and PMX1 families are more restricted in their patterns 
of expression, and are involved in organogenesis or differentiation of specific 
cell types.  
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1.3.2.1 TALE homeobox genes 
Members of the TALE family of non-HOX HD cofactor proteins, which in-
clude PBX, MEIS, and PREP1/KNOX1 proteins, are distinguished from other 
HD proteins by the inclusion of an additional three amino acids between α-
helices 1 and 2 within the HD. Evidence from mouse models and human leu-
kemic cells has indicated that inappropriate expression of TALE cofactors with 
certain HD proteins may contribute to leukemic transformation, while overex-
pression of TALE cofactors alone does not lead to disease development. One of 
these proteins, PBX1, has oncogenic potential in the form of a fusion protein 
with E2A. The PBX1 gene was originally identified at the breakpoint of the 
t(1;19) translocation found in 10 to 20% of childhood pre-B-cell ALL (Shikano 
et. al., 1999). MEIS1, was capable of accelerating leukemogenesis when coex-
pressed with HOXA9, HOXB3 and the fusion protein NUP98-HOXA9 
(Thorsteinsdottir et. al., 2001). Overexpression of MEIS1 was reported in 50% 
of AML patients.  
1.3.2.2 CDX genes are members of the ParaHox gene family  
Cdx1, Cdx2 and Cdx4 are members of the caudal-related homeobox gene fam-
ily based on their homology to the caudal gene of Drosophila melanogaster 
(James et. al., 1994; Suh et. al., 1994). The caudal homeobox gene in Droso-
phila is required for anterior-posterior regional identity (McGinnis and 
Krumlauf, 1992). Cdx members are upstream regulators of HOX genes. Cdx1 
and Cdx2 loss of function models are associated with HOX gene inactivation. 
For example, a dominant negative Xcad3 (the frog Cdx homolog) affects de-
velopment of the posterior embryo in a manner that is reflected by loss of 
expression of a number of HOX genes, including Hoxc6, Hoxa7, Hoxb7 and 
Hoxb9. Cdx4 mutant kgg embryos show deregulation of hoxb4, hoxb5a, 
hoxb6b, hoxb7a, hoxb8a, hoxb8b and hoxa9a. The hematopoietic phenotype of 
kgg embryos can be rescued by overexpressing hoxb7a or hoxa9a but not 
hoxb8a (Davidson et. al., 2003), indicating that the hematopoietic defect results 
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from perturbations in specific HOX genes (Davidson et. al., 2003). CDX2 is 
expressed before most other HOX genes and it increases expression of HOXA9 
in cultured human colon cancer cells (Lorentz et al., 1997), indicating that Cdx 
family members are positive upstream regulators of HOX genes and play a role 
in embryogenesis. Cdx1 and Cdx2 which are expressed in the gut endoderm are 
involved in anterior-posterior patterning (Silberg et. al., 2000). Cdx2 expres-
sion starts in the proximal intestine and decreases posteriorly, whereas Cdx1 
expression starts in the distal intestine with overlapping expression of Cdx1 and 
Cdx2 in the midgut (Fig.8).  
 
Figure 8. Regional expression of transcription factors in the developing gut. The tran-
scription factors shown on the right have been mapped to specific regions of the endoderm, as 
shown on the left. There is a presumed rule of expression patterns of HOX genes in the devel-
oping gut. Each subdomain of the developing digestive tract (foregut, midgut and hindgut) 
seems to have a different HOX code: Cdx2 expression starts in the proximal intestine and de-
creases (lightening bar) posteriorly, whereas Cdx1 expression starts in the distal intestine and 
decreases anteriorly. Pdx1 expression has been observed in the antrum and duodenum. Sox2 
is expressed from the pharynx to the stomach. 
 
CDX2 plays an important role in development of the intestine and deregulated 
expression of CDX2 is found in intestinal metaplasia and carcinomas (Bai et. 
al., 2002; da Costa et. al., 1999; Eda et. al., 2003; Eda et. al., 2002). CDX2 is 
not normally expressed in adult hematopoiesis, but it has been identified as one 
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of the fusion partners in an AML-associated chromosomal translocation (Chase 
et. al., 1999). 
1.4 CDX2 
CDX2 (caudal type homeobox transcription factor 2) belongs to the caudal ho-
meobox family and encodes a transcription factor. CDX2 is located on 
chromosome 13 and mouse Cdx2 on chromosome 5. The gene has three exons 
and two introns (Drummond et. al., 1997; James et. al., 1994). Human and 
mouse Cdx2 share overall 93% homology at the amino acid level. CDX2 is a 
93kDa nuclear protein consisting of the N-terminal transactivation domain, a 
highly conserved pentapeptide domain, which allows binding of the TALE co-
factor and the DNA binding homeodomain (Fig.9). Transcriptional activity of 
Cdx2 is regulated by the mitogen activated protein kinase (MAPK). The CDX2 
activation domain is phosphorylated at serine 60 via the MAPK pathway. The 
S60-phosphorylated and S60-nonphosphorylated CDX2 have different tran-
scriptional activity, as well as different spatial  expression patterns in the 
intestinal epithelium (Rings et. al., 2001). p38 MAPK has been reported to 
regulate CDX2/3 function and intestinal cell differentiation (Houde et. al., 
2001). 
 COOH
Cdx2
NH2
Activation Domain
Interactive Motif
Homeodomain
 
 
 
 
 
Figure 9. Cdx2 protein structure. 
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1.4.1 Role of Cdx2 in embryogenesis and intestine devel-
opment 
Cdx genes have developmental roles and overlap in their expression patterns. 
Cdx2 is expressed at 3.5 days postcoitum (dpc) in the trophectoderm but not in 
the inner cell mass (Beck et. al., 1995). At 7.5 dpc (Theiler stage 11), it is pre-
sent in the chorion, ectoplacental cone, mesoderm of the developing allantoic 
bud, and posterior primitive streak. At 8.5 dpc (Theiler stage 13), expression is 
seen in all three germ layers at the posterior end of the embryo extending into 
the mesodermal root of the allantois, in the endodermal epithelium of the hind-
gut rudiment, and in the neural tube; the presegmented paraxial mesoderm 
expresses the gene, but the somites, lateral plate, and intermediate mesoderm 
do not. By 9.5 dpc (Theiler stage 15), the caudal pole of the embryo remains 
positive, as does the posterior neural tube and posterior gut endoderm. At 12.5 
dpc (Theiler stage 20), expression is confined exclusively to the gut endoderm 
posterior to the foregut-midgut junction (Beck et. al., 1995; Chawengsaksophak 
et. al., 2004). Cdx1 expression extends most anteriorly, followed by Cdx2 and 
Cdx4, with all three genes expressed posteriorly. 
Cdx2-null mutant embryos die between 3.5 and 5.5 dpc, and heterozygotes 
have tail abnormalities and exhibit anterior homeotic transformations involving 
the cervical and upper thoracic vertebrae, ribs, and midgut endoderm. 90% of 
Cdx2 heterozygote mutant mice develop multiple intestinal adenomatous pol-
yps, particularly in the proximal colon, suggesting that Cdx2 mutations might 
be the primary event in the genesis of some intestinal tumours 
(Chawengsaksophak et. al., 2004; Chawengsaksophak et. al., 1997). Further 
studies by Traber et. al. have shown that Cdx2 is strongly expressed at the 
crypt-villus junction and into the villus. Cdx2 is important for transcription of a 
gene that is expressed in terminally differentiated intestinal epithelial cells, 
supporting that Cdx2 stimulates differentiation and expression of intestine–
specific genes such as sucrase/isomaltase, carbonic anhydrase, and MUC2. In 
addition, Cdx2 upregulates WAF1 (Silberg et. al., 2000; Suh et. al., 1994).  
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1.4.2 Silencing or aberrant overexpression of CDX2 in 
metaplasia, carcinomas and myeloid leukemia 
CDX2 is normally expressed in the gut during development and adulthood. 
However, its expression is lost in colorectal tumors and corresponding carci-
noma cell lines (Ee et. al., 1995; Hinoi et. al., 2003; Hinoi et. al., 2001). A role 
for the loss of Cdx2 expression in colorectal carcinoma development can be in-
ferred from the frequent occurrence of adenomatous intestinal polyps in Cdx2 
heterozygous mutant mice. CDX2 overexpression seems to inhibit growth 
and/or promote differentiation of colorectal cancer cells (Mallo et. al., 1998). 
CDX2 inactivation in colon cancer results from defects in trans-acting path-
ways regulating CDX2 transcription. 
Beside the loss of function in colon cancer, aberrant and ectopic expression of 
CDX2 is associated with intestinal metaplasia (Hinoi et. al., 2003; Ishikawa et. 
al., 2004; Satoh et. al., 2002), Barrett’s epithelium (Eda et. al., 2003), gastric 
carcinoma (Silberg et. al., 2002) , but also with hematological neoplasias such 
as AML and chronic myeloid leukemia (CML) (Chase et. al., 1999; Rawat et. 
al., 2004). Normally CDX2 is not expressed in adult hematopoietic cells. Ec-
topic expression of CDX2 in AML was reported by Chase et al. in a patient 
with AML M1 with a chromosomal translocation t(12;13)(p13;q12), creating a 
novel fusion of ETV6 and CDX2 (Chase et. al., 1999). In addition, aberrant ex-
pression of CDX2 was found in a case of blast crisis of chronic myeloid 
leukemia (CML-BC) with no detectable chromosomal abnormality (Chase et. 
al., 1999). The aim of the study presented here was to assess the oncogenic po-
tential of both the ETV6/CDX2 fusion gene and the CDX2 homeobox gene as 
will be discussed later in the thesis. 
1.5 Chromosomal Translocations 
Recurring chromosomal abnormalities have been identified in a variety of can-
cers, but are most frequently associated with leukemias, lymphomas and 
sarcomas (Rabbitts, 1994; Rowley, 1999). At present, more than 500 recurring 
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cytogenetic abnormalities have been reported in hematological malignancies. 
Three main cytogenetic changes have been detected in hematological malig-
nancies: deletions, inversions and translocations. There are two principal 
consequences of chromosomal translocations: one consequence is that the 
breaks occur within a gene on each chromosome involved, creating a fusion 
gene which encodes a chimeric protein. Alternatively, a chromosomal translo-
cation can induce aberrant or ectopic expression of a proto-oncogene by the 
juxtaposition of a coding region from one gene to the promoter of another gene 
(Rabbitts, 1994). 
1.5.1 Generation of fusion genes with oncogenic proper-
ties 
There are more than 300 recurring chromosomal translocations, of which more 
than 100 have been cloned. The Philadelphia (Ph) chromosome was the first 
chromosomal aberration that was found to be specifically associated with a 
human disease (Rowley, 1999), with more than 95% of CML cases bearing this 
fusion gene. This translocation leads to the formation of the fusion gene BCR-
ABL which is a constitutively active tyrosine kinase. There are at least seven 
different chromosomal translocations associated with a myeloproliferative dis-
ease. These include the BCR/ABL, ETV6/ABL, ETV6/PDGFRB, 
HIP1/PDGFRB, H4/PDGFRB, RAB5E/PDGFRB, and ETV6/JAK2 fusions (ta-
ble 1) (Dash and Gilliland, 2001). 
 
Table 1: Translocations involving tyrosine kinases 
MPD = myeloproliferative disease 
Translocation Genes Major struc-tures Disease 
t(9;22)(q34;q11) ABL1 BCR 
TK 
GRB2/SOS bind-
ing 
CML,ALL 
t(8;13)(p11;q12) FGFR1 ZNF198/FIM/RAMP 
TK 
Cysteine rich 
MYM 
MPD 
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t(6;8)(q27;p11) FOP FGFR1 
Leucine rich 
TK MPD 
t(8;9)(p12;q33) FGFR1 CEP110 
TK 
LZ MPD 
t(5;7)(q33;q11.2) PDGFRB HIP1 
TK 
Huntingtin inter-
action 
CMML 
t(5;14)(q33;q32) PDGFRB CEV14 
TK 
LZ AML 
t(5;10)(q33;q21) PDGFRB H4/D10S170 
TK 
LZ MPD 
 
Besides tyrosine kinases, transcription factors are common targets of AML as-
sociated chromosomal translocations. In particular dysregulation of 
transcription factors, which play an important role in normal hematopoiesis, is 
a hallmark of AML. For example, there are more than a dozen chromosomal 
translocations that target subunits of the core binding factor (CBF) which is a 
heterodimeric transcription factor composed of CBFB and RUNX1 (AML1). 
CBF transactivates expression of a broad spectrum of genes that are critical for 
normal hematopoietic development (Speck et. al., 1999), as evidenced in part 
by a complete lack of definitive hematopoiesis in mice that are deficient in ei-
ther AML1 (RUNX1) or CBFB (Castilla et. al., 1996; Okuda et. al., 1996). 
Thus, chromosomal translocations that resulted in loss of function of CBF 
would be predicted to impair hematopoietic development. The three most 
common translocations involving CBF are the t(8;21) (Erickson et. al., 1992), 
inv(16) (Liu et. al., 1993), and t(12;21) (Romana et. al., 1995) that result in ex-
pression of the AML1/ETO, CBFB/MYH11 and ETV6/AML1 (Barba et. al., 
1993, Golub et. al. 1999) fusion proteins. AML associated chromosomal trans-
locations result in the persistent expression of HOX family members which are 
downregulated during normal differentiation, resulting in a block in differentia-
tion. Another gene frequently involved in leukemia–associated translocations is 
the ETV6 (TEL) gene, which has been shown to be fused to over 17 different 
partner genes in hematological malignancies. 
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1.5.2 Aberrant expression of proto-oncogenes 
In lymphoid leukemias and lymphomas, chromosomal translocations frequently 
lead to the transcriptional activation of proto-oncogenes by bringing their cod-
ing regions in the vicinity of immunoglobulin or T-cell receptor gene-
regulatory elements, thus leading to the inappropriate expression of these 
proto-oncogenes (Kuppers and Dalla-Favera, 2001). Chromosomal transloca-
tions associated with Burkitt’s lymphoma represent a typical example of this 
type of mechanism. Approximately 90% of Burkitt’s lymphoma cases harbor a 
t(8;14)(q24;q32), which juxtaposes the MYC proto-oncogene to the immu-
noglobulin heavy-chain gene enhancer and promoter (IgH) (Kuppers and 
Dalla-Favera, 2001). In addition, the variant translocations t(2;8) and t(8;22) 
described in this disease also involve MYC, which translocates into the immu-
noglobulin κ and λ light-chain loci, respectively. In these translocations, the 
coding region of MYC is not altered, suggesting that its oncogenic activity is a 
result of its mis- or overexpression, although rare somatic mutations in the cod-
ing region of MYC have also been described in Burkitt’s lymphoma (Showe et. 
al., 1985). MYC transgenic mice (TM) in which the MYC gene was expressed 
under the control of the IgH enhancer (Eμ-myc TM) developed clonal B lym-
phoid malignancies, after a long pre-lymphomatous phase characterized by the 
expansion of polyclonal pre-B cells (Langdon et. al., 1986). Aberrant expres-
sion of the BCL6 proto-oncogene caused by chromosomal translocations is also 
frequently reported in non-Hodgkin’s lymphoma. BCL6 is normally expressed 
in B and CD4+ T cells in germinal centers (GC), and plays an essential role in 
GC formation (Ye et. al., 1997, Rego and Pandolfi, 2002). The homeobox gene 
HOX11 is deregulated in the translocation t(10;14) found in 7% of human T-
cell acute lymphoblastic leukemia (T-ALL). HOX11 is not expressed in normal 
T-ALL (Hatano et. al., 1991). 
Strikingly and in contrast to the situation in lymphomagenesis or in the devel-
opment of lymphoblastic leukemias, aberrant and ectopic expression of a proto-
oncogene induced by a chromosomal translocation has so far been not de-
scribed as the key element for malignant transformation in myeloid leukemias. 
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The failure of certain fusion genes to induce leukemia on their own in animal 
models as well as the fact that more than 50% of acute myeloid leukemias do 
not have apparent cytogenetic abnormalities, point to the role of point muta-
tions in or, alternatively, the aberrant expression of proto-oncogenes in the 
development of leukemia. These observations also suggest that the aberrant ex-
pression of proto-oncogenes might be more common than is generally believed. 
The sheer number of ETV6 fusions in AML allows for the study of a diverse 
group of leukemias in which more than one of the aforementioned mechanisms 
might be operating. The t(12;13) translocation is particularly interesting in this 
regard as the expression of both the ETV6/CDX2 fusion gene as well as the ec-
topic expression of the CDX2 gene has been demonstrated. 
1.6 ETV6  
ETV6 (ETS variant gene 6) was originally called TEL, for translocation ets leu-
kemia gene. ETV6 is a member of the ets (E-26 transforming specific) family 
of transcription factors. All ets family proteins share a conserved protein do-
main of about 88 amino acids in length, the so called ets domain (see Figure 
10) (Bohlander SK 2005). The ets domain is a sequence specific DNA binding 
domain but it also mediates protein-protein interaction. The other evolutionar-
ily conserved domain is the N terminally located pointed or SAM (sterile alpha 
motif) domain in the 652 amino acids of ETV6 (Bohlander SK 2005). This 
domain is also called HLH (helix loop helix) domain. It is found in yeast pro-
teins and has been shown to be involved in homo and heterodimerization of 
transcription factors and in signal transducing proteins (e.g. of the MAPK 
pathway) (Fig.10). ETV6 contains two alternative translational start codons 
(position 1 and position 43), leading to the expression of two isoforms of 
ETV6. 
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Figure 10. ETV6 protein structure. 
1.6.1 Role of ETV6 in hematopoiesis 
ETV6 is widely expressed throughout embryonic development and in the adult. 
Embryos with a conventional knockout (KO) of the Etv6 gene die by day 11 of 
embryonic development (E11) due to vascular abnormalities. Blood formation 
in the embryo is largely unperturbed (Wang et. al., 1997). Yet, studies using 
chimeric mice from Etv6-deficient embryonic stem (ES) cells suggested a re-
quirement of Etv6 in bone marrow hematopoiesis. Inducible and lineage-
specific gene disruption of Etv6 in adult hematopoiesis in mice suggests that it 
plays two important roles in hematopoietic differentiation. First, Etv6 controls 
the survival of HSCs so that its disruption indirectly affects the majority of all 
hematopoietic cells which have limited clonal life spans and eventually will 
extinguish without constant regeneration from HSCs. Secondly, Etv6 is re-
quired late in the development of the megakaryocyte lineage, where it 
presumably acts in concert with transcriptional regulators previously implicated 
in megakaryopoiesis (Hock et. al., 2004). 
1.6.2  ETV6 fusion partners 
Translocations involving the ETV6 gene contribute to leukemogenesis through 
at least 3 different mechanisms. One mechanism is the activation of kinases. 
The second mechanism is the loss of function of critical transcription factors 
and/or the formation of aberrant transcription factors and the third mechanism 
is the induction of ectopic and aberrant expression of the proto-oncogene by the 
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chromosomal translocation. Figure 11 shows the different breakpoints in the 
ETV6 gene with regard to the different fusion partners. 
     
Figure 11. This is a schematic diagram representing the various breakpoints of ETV6 
(indicated by arrows) in the translocations involving different partner genes (indicated in 
closed boxes) 
                             
Figure 12. The wide variety of genes that fuse to ETV6 can be sub-grouped into clusters 
with regards to their functional similarity. Two main clusters have been highlighted, the 
tyrosine kinases and transcription factors, which include the sub class of homeobox transcrip-
tion factors (kindly provided by Prof. Stefan Bohlander) 
1.6.3  Protein tyrosine kinase fusion partners of ETV6 
The first identified fusion partner of ETV6 was a protein tyrosine kinase (PTK), 
the platelet-derived growth factors receptor beta (PDGFRB) (Golub et. al., 
1994). The fusion protein critical for the development of the chronic myelo-
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monocytic leukemia is the ETV6/PDGFRB fusion and not the reciprocal 
PDGFRB/ETV6 fusion. In the ETV6/PDGFRB fusion protein the N terminal 
portion of ETV6, which includes the pointed domain, is fused to the C-terminal 
two thirds of the PDGFRB protein, conserving the tyrosine kinase domain of 
PDGFRB. The fusion of the pointed domain of ETV6 in the N-terminal half 
with the tyrosine kinase domain in the C-terminal half of the fusion partner is 
characteristic of  the class of ETV6/PTK fusions and is found in the fusions of 
ETV6 with ABL1, ABL2, JAK2, NTRK3, FGFR3 and SYK (Fig. 11) (Table 2) 
(Papadopoulos et. al., 1995; Cazzaniga et. al., 1999; Knezevich et. al., 1998; 
Kuno et. al., 2001; Peeters et. al., 1997)  
Table2. Tyrosine kinase fusion partners of ETV6 
 
Translocation Fusion partner Breakpoint in 
ETV6 
Disease 
 
t(5;12)(q31;p13) 
PDGFRB 
 
 
Intron 4 
 
CMMoL 
 
t(9;12)(q34;p13) 
ABL1  
Intron 4 and 5 
 
AML, ALL 
 
t(1;12)(q25;p13) 
ABL2  
Intron 5 
 
AML-M3,-M4,T-ALL 
 
t(9;12)(p24;p13) 
JAK2  
Intron 4 or 5 
 
Pre B cell ALL,  
T-ALL 
 
t(12;15)(p13;q25) 
NTRK3  
Intron 4 or 5 
 
Congenital fibrosar-
coma, mesoblastic 
nephroma, secretory 
breast carcinoma, 
AML 
 
t(4;12)(p16;p13) 
FGFR3  
Intron 5 
 
Peripheral T-cell lym-
phoma 
 
t(9;12)(q22;p12) 
SYK  
Intron 5 
 
MDS 
1.6.4 Transcription factors and other fusion partners of 
ETV6 
The ETV6/RUNX1 (ETV6/AML1) fusion is the most common fusion gene in 
childhood acute B cell lymphoblastic leukemia (Shurtleff et. al., 1995). Re-
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porter gene assays showed that the ETV6/RUNX1 fusion protein acts as a rep-
ressor by binding to the promoter and enhancer regions of RUNX1 target 
genes. This repression function is dependent on the pointed and on the central 
domain of ETV6, which are both part of the ETV6 portion of the 
ETV6/RUNX1 fusion protein (Fenrick et. al., 1999). ETV6/ARNT and 
HLXB9/ETV6 chimeric proteins are other examples of this class of ETV6 fu-
sions found in AML and the HLXB9/ETV6 hybrid is detected in up to 20% of 
pediatric cases with AML (Beverloo et al., 2001) A potential mechanism of 
transformation for these fusions is that the ETV6/ARNT and HLXB9/ETV6 
proteins interact with the wild-type ETV6 through the pointed domain, thereby 
interfering with normal ETV6 function (Beverloo et. al., 2001).  
1.6.5 Ectopic and aberrant expression of a proto-
oncogene gene 
A number of ETV6 translocations including the ETV6-MDS1/EVI1 and the 
ETV6-CDX2 fusion only contain the transcription/translation start of ETV6 
(Peeters et al., 1997, Chase et al., 1999). In these cases ectopic expression of 
the transcription factors EVII and CDX2 was detected in addition to the expres-
sion of the fusion gene. The potential importance of the ectopic expression of a 
proto-oncogene in this class of ETV6 fusions was further underlined by obser-
vations that the ectopic expression of the proto-oncogene also occurred when 
the fusion gene itself was not translated into a protein product. For example pa-
tients with the t(4;12) positive leukemia show ectopic expression of the 
ParaHox gene GSH2. However the fusion gene CHIC2-ETV6 generated by the 
chromosomal translocation was not translated into a protein product. Further-
more, expression of IL-3 was observed in a CML case with a t(5;12), lacking 
the ETV6-ACS2 fusion protein. These results suggest that ectopic expression of 
GSH2 and IL-3 could be the key leukemogenic mechanism in these leukemias 
(Cools et. al., 2002). 
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1.7 The t(12;13)(p13;q12) translocation in myeloid leu-
kemia. 
The t(12;13)(p13;q12) translocation was discovered by Chase and coworkers in 
1999 in a rare case of AML and was shown to result in the novel fusion be-
tween ETV6 and caudal related homeobox gene CDX2 (Chase et. al., 1999). 
Interestingly, it was noted at that time that a non-rearranged CDX2 mRNA was 
expressed at high levels in this patient. Normally, CDX2 is not expressed in 
adult hematopoiesis. In addition, the aberrant expression of CDX2 was reported 
in a case of CML-BC with no cytogenetically visible abnormality (Chase et al., 
1999) (Fig. 12). This situation resembles other ETV6 translocations as de-
scribed above (1.6.5). Thus, deregulated expression of CDX2 could be a key 
event in the pathogenesis of this AML subtype.  
                
Exon 
 
Promoter 
 
Breakpoint 
                        
Figure 13. Schematic diagram to illustrate a possible mechanism for expression of an 
apparently normal full-length CDX2 transcript (a) and ETV6-CDX2 fusion transcripts b) 
and c). (Figure adopted and modified from Chase et. al., 1999)). 
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1.8 Aim of this research 
The deregulation of proto-oncogenes by chromosomal translocations is a com-
mon and frequent observation in ALL and lymphomas. In contrast, generation 
of fusion genes with transforming properties is the pathogenetic hallmark of 
AML, and so far there is no functional proof that activation of a proto-
oncogene by a balanced chromosomal translocation can be the key event for 
the development of AML. However, the observation that a significant number 
of ETV6-associated chromosomal translocation induces aberrant and ectopic 
expression of a proto-oncogene, indicates that this mechanism might play a key 
role also in myeloid leukemogenesis.  
Aim of the project was to test this hypothesis in the case of the t(12;13) posi-
tive AML and analyze whether ectopic expression of CDX2 is the key step in 
the development of AML. For this we established a mouse model of this sub-
type of leukemia aiming at providing the first functional proof of this 
mechanism for myeloid leukemogenesis. 
MATERIAL 
2 MATERIAL 
2.1  Mammalian cell lines  
293T  (human embryonic kidney cell line) 
GP+E86  (mouse fibroblast cell line) 
32D  (mouse myeloid cell line) 
NIH 3T3  (mouse fibroblast cell line) 
2.2 Plasmids: 
MIG/MIY:  murine stem cell virus derived vector. A bi-
cistronic vector with an internal ribosomal entry 
site (IRES) and an EGFP or EYFP cassette 3’ of the 
IRES) (kindly provided by Prof. Dr. R.K. 
Humphries, Vancouver, Canada) 
pCDNA6/V5-His:  mammalian expression vector used for tagging 
genes (Invitrogen, Carlsbad, CA) 
pEGFP-C1: (Clontech)  
Ecopac:  A packaging vector coding for the gag, pol, and 
env viral proteins. 
2.3 Cell culture Medium: 
DMEM high glucose (GIBCO/BRL and PAN) 
RPMI 1640 (GIBCO/BRL) 
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2.4 Chemicals and Reagents: 
Agarose    (Sigma) 
Acetic acid  (Sigma) 
ATRA         (Sigma) 
Calcium chloride   (Sigma) 
Chloroform   (Sigma) 
Dextran sulphate  (Sigma) 
DNAzol    (GIBCO/BRL)  
DNase I   (Invitrogen) 
EDTA    (Sigma) 
Ethidium bromide   (Sigma) 
Formamide  (Sigma) 
Fetal bovine serum   (PAN) 
Glycine    (Sigma) 
Giemsa    (Merck) 
Hydrochloric acid  (Merck) 
Isopropanol    (Merck) 
Methocult M 3434  (Stemcell Technologies) 
May-Grunwald’s Eosin  (Merck) 
Protamine sulfate  (Sigma-Aldrich) 
Quikchange XL site-directed Mutagenesis Kit (Stratagene) 
Sodium chloride  (Sigma) 
Sodium hydroxide  (Sigma) 
Sodium dodecyl sulphate   (Sigma) 
Skim milk  (Sigma) 
Trizma base   (Sigma) 
Trizol   (GIBCO/BRL) 
5-flurouracil  (Medac) 
ThermoScript RT-PCR  (Invitrogen) 
Megaprime DNA labeling system ( Amersham) 
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GFX PCR DNA gel band elution  ( Amersham) 
Microspin S-300 HR columns   ( Amersham) 
ECL Western blotting analysis system ( Amersham) 
Denaturation solution:   1.5M NaCl, 0.5N NaOH. 
20 X SSC:   Dissolve 3M sodium chloride and 
0.3Msodium citrate in 800 ml deionized wa-
ter and adjust pH to 7.0 and make up the 
volume to one liter. 
Pre-hybridization solution:  Dissolve 0.2g skimmed Milk and 2.0g dex-
tran sulphate in 17ml water and add 6ml 20 
X SSC, 2ml formamide, 1ml 20% SDS and 
80µl 500mM EDTA.   
Telleyesnickzky’s solution:  450ml EtOH + 25ml glacial acetic acid + 
25ml formaldehyde   
2.5  Antibodies:  
  
Name Clone company Label 
Gr-1 RB6-8C5 BD Pharmingen PE 
Mac-1 (CD11b) M1/70 BD Pharmingen APC 
Sca-1 D7 BD Pharmingen PE 
c-kit 2B8 BD Pharmingen APC 
B220 RA3-6B2 BD Pharmingen APC 
Ter119  BD Pharmingen PE 
CD4 GK1.5 BD Pharmingen PE 
CD8 53-6.7 BD Pharmingen APC 
Anti-histidine mono-
clonal antibody 
 Sigma  
Anti-CDX2 mono-
clonal antibody 
 DCS Innovative  
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2.6  Cytokines:  
mIL3  (Tebu-bio) 
mIL6  (Tebu-bio) 
M-SCF  (Tebu-bio) 
G-CSF  (R&D systems) 
2.7 Restriction Enzymes and DNA modifying En-
zymes:  
EcoRI, XhoI, HpaI, PmeI, EcoRV, T4 DNA Ligase, Calf intestine phosphatase 
all from New England Biolabs. 
2.8 Instruments: 
DNA Cross linker (GS Gene linker BIO-RAD) 
Fluorescence Activated cell sorting (BD FACSVantage SE System) 
Flow Cytometry (BD FACS Calibur System) 
Cytospin (Cytospin 2 Shandon) 
Microscope (Leitz Diavert Inverted Microscope, Ernst Leitz Wetzlar GmBH) 
2.9 Mice  
Parental strain mice were bred and maintained at the GSF animal facility. Do-
nors of primary BM cells were > 12-week-old (C57Bl/6Ly-Peb3b x C3H/HeJ) 
F1 (PebC3) mice and recipients were > 8–12 week old (C57Bl/6J x C3H/HeJ) 
F1(B6C3) mice.  
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3 METHODS 
3.1 cDNA constructs and retroviral vectors. 
cDNAs of ETV6/CDX2 (human) and murine Cdx2 (with 93% overall identity 
and 98% identity in the DNA binding homeodomain to the human protein) 
were kindly provided by D.G. Gilliland (Division of Hematology/Oncology, 
Harvard Medical School, Boston, USA) and N. Cross (Department of Hema-
tology, Hammersmith Hospital, London, UK). A poly-histidine tagged version 
of ETV6/CDX2 was constructed by ligating a PCR product of the fusion gene 
in frame to the 3’ end of the poly-histidine epitope of the pCDNA6/V5-His A 
plasmid (Invitrogen, Karlsruhe, Germany). The Cdx2 mutant lacking the first 
179 N-terminal amino acids, which are deleted in the ETV6/CDX2 fusion, was 
generated by PCR and poly-histidine tagged following standard procedures 
(ΔN-Cdx2).  For retroviral gene transfer into primary bone marrow (BM) cells, 
the different constructs were subcloned into the multiple cloning site of the 
modified MSCV 2.1 vector (Pineault et. al., 2003b) upstream of the internal 
ribosomal entry site (IRES) and the enhanced green or yellow fluorescent pro-
tein (GFP/YFP) gene. As a control the MSCV vector carrying only the IRES-
EGFP cassette was used.  
3.2 Site-Directed Mutagenesis:  
Cdx2 mutants were created, to inactivate a putative PBX1 interacting motif 
(W167A-Cdx2) which is the docking site of Hox cofactors like PBX1 and 
Meis1 (Knoepfler and Kamps, 1995) or to inactivate the DNA binding ho-
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meodomain (N51S-Cdx2) (Shanmugam et. al., 1999), using the QuikChange 
XL Site-Directed Mutagenesis Kit. PCR was done as recommended by the 
manufacturer (Stratagene, Amsterdam, Netherlands). PCR products were di-
gested with DpnI, which digests only methylated DNA, to remove template 
DNA and transformed in competent cells supplied with the kit. Desired muta-
tions were confirmed by sequencing.   
Primer sequence for N51S-Cdx2: 
Forward primer: 5'-TTTGGTTTCAGAGCCGCAGAGCCAAGGAGAG-3' 
Reverse primer: 5'-CTCTCCTTGGCTCTGCGGCTCTGAAACCAAA-3' 
Primer sequence for W167A-Cdx2: 
Forward primer: 5'-GAAACCTGTGCGAGGCGATGCGGAAGCCC-3' 
Reverse primer: 5'-GGGCTTCCGCATCGCCTCGCACAGGTTTC-3' 
A 
                    
LTR
LTR
Cdx2
ETV6/CDX2
IRES   EYFP
HDLTR
IRES   EGFP
LTR HD
Breakpoint
Activation domain
PBX Interactive
Motif
HomeodomainHD  
B 
                       
Ctrl Cdx2
E86
α – CDX2
34kD
Ctrl       ΔN- ETV6-
Del   CDX2
3T3
α - His
25kD
 
Figure 14. Schematic diagram of constructs and proof of protein expression by Western 
blotting. a) MSCV-based retroviral vectors were used to express ETV6/CDX2 and Cdx2 in 
murine bone marrow. LTR = long terminal repeats; IRES = internal ribosomal entry site. The 
figure 14b, shows the immunoblot analyses from the whole cell lysates of E86 and NIH 3T3 
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cells transfected with the different constructs and probed with the anti-human CDX2 antibody 
and anti-Histidine antibody.  
 
             
ΔN-Del
W167A
N51S
LTR
LTR
LTR
IRES   EYFP
Activation domain
PBX Interactive
Motif
IRES   EYFP
LTR HD
LTR HD
N51S
IRES   EYFP
LTR
W167A
Cdx2 – Mutants:
HomeodomainHD
N51S Mutation
W167A Mutation
 
 
Figure 15 Schematic diagram of different mutants. MSCV based retroviral vector were 
used to express Cdx2 mutants in murine Bone marrow. LTR = long terminal repeats; IRES = 
internal ribosomal entry site.  
3.3 Retrovirus Production. 
Retrovirus was produced with the constructs mentioned before by individually 
co-transfecting 15 µg of the construct DNA with equal amounts of Ecopac 
DNA into 293T cells by using the calcium chloride precipitation method of 
transfection (Pineault et. al., 2003b). Virus conditioned medium (VCM) was 
collected 48h after transfection at time intervals of eight hours for forty-eight 
hours. Production of high-titer helper-free retrovirus was achieved by transduc-
ing the ecotropic packaging cell line GP+E86 (Pineault et al., 2003b) with virus 
conditioned medium (VCM) from 293T transfected cells. Successfully trans-
duced GP+E86 cells were sorted out by FACS using GFP or YFP as a marker 4 
days after transduction using standard procedures (Pineault et. al., 2003a).  
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3.4 Retroviral infection of primary BM cells. 
Primary mouse bone marrow (BM) cells were transduced as previously de-
scribed (Pineault et. al., 2003a). Briefly, BM cells were obtained by flushing 
both femurs and tibias of donor mice treated 4 days previously with 150 mg/kg 
5-fluorouracil injected into the tail vein. 5-flourouracil eliminates cycling cells 
from the animal, thus enriching the bone marrow for primitive hematopoietic 
progenitors, which are non-cycling or quiescent in nature (Reya et. al., 2001). 
Cells were stimulated for 48 hrs in DMEM supplemented with 15% FBS, 10 
ng/ml mIL-6, 6 ng/ml mIL-3 and 100 ng/ml murine stem cell factor (SCF). For 
transduction, cells were co-cultured for 48h with irradiated (40 Gy) GP+E86 
virus producing cells in the same medium with an addition of 5 µg/ml pro-
tamine sulfate with ETV6/CDX2/GFP or Cdx2/YFP GP+E86 producers or with 
a mixture of 40 to 50% CDX2/YFP and 50 to 60% ETV6/CDX2/GFP producers 
in co-transduction experiments. Protamine sulfate prevents aggregation of viral 
particles, thus increasing efficiency of transduction.  Loosely adherent and non-
adherent BM cells were harvested from the co-culture 48h post transduction, 
BM cells were furtherer cultured in fresh medium with cytokine cocktail for 
48h to allow expression of EGFP or EYFP. Transduced BM cells were sorted 
out by florescence activated cell sorting (FACS) using EGFP or EYFP as a 
marker. 
 
In Vitro Assays 
3.5 Proliferation Assay. 
To study the proliferative potential in vitro of BM cells transduced with 
ETV6/CDX2, Cdx2, its mutants and ETV6/CDX2 + Cdx2, we performed a pro-
liferation assay by plating an equal number of successfully transduced bone 
marrow cells directly after sorting in DMEM supplemented with 15% FBS, 10 
ng/ml mIL-6, 6 ng/ml mIL-3 and 100 ng/ml mSCF (standard medium) (Tebu-
bio GmbH, Offenbach, Germany) at 370C in a humidified CO2 incubator. The 
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cells were subjected to half-media change every 7 days and their proliferation 
assessed on the same day by counting viable cells after trypan exclusion. To 
generate IL-3 dependent cell lines, successfully transduced bone marrow cells 
were cultured directly after sorting in DMEM, 15% FBS with mIL-3 alone 
(6ng/ml). A half-media change was done every 7 days.  
3.6 Colony Forming Cells Assay (CFC-assay). 
To check the differentiation and clonogenic potential of the BM cells express-
ing the various genes mentioned above, we performed a CFC assay by testing 
colony formation in methylcellulose.  The CFC–assay was performed by cul-
turing  highly purified transduced  cells (500 /dish) in 35mm-diameter Petri 
dishes directly after sorting in 1ml methylcellulose supplemented with cyto-
kines (Methocult M3434), and incubated at 370C in humidified CO2 incubator. 
Colonies were counted microscopically on 7 to 9 days after plating according 
to standard criteria (Schwaller et. al., 1998). Re-plating capacity of clonogenic 
progenitors was assayed by re-plating the primary colonies on secondary me-
thylcellulose dishes. Again colonies were counted day at 7 to 9 after the 
secondary re-plating. 
3.7 Delta CFC Assay. 
Normal bone marrow cells lose their clonogenic potential following in vitro 
culture. To analyse whether progenitors cells that expanded in the proliferation 
assay lose their clonogenic potential, we set up CFC-assays from proliferation 
assays by plating (3000 to 5000 BM cells/dish) cells in 35mm-diameter Petri 
dishes in 1 ml methylcellulose after culturing 7 days in standard medium (delta 
CFC-assay). Colonies were counted day 7 to 9 days post plating. 
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3.8 Cyto-Morphology. 
Cyto-morphological analysis of bone marrow was done by transferring 5x104 to 
1x105 bone marrow cells on glass slide by centrifugation at 500 rpm for 10 
minute using a Shandon Cytospin2 centrifuge. Slides were stained with May-
Grunwald’s eosine-methylene blue and Giemsa solution using the standard pro-
tocol supplied by Merck.    
3.9 Immunophenotyping:  
Cell differentiation was determined and lineage distribution was checked by 
immunophenotyping. 5x104 to 1x104  cells were rinsed with PBS and stained 
for 30 minutes on ice with an appropriate concentration of phycoerythrin (PE) 
conjugated antibody to Gr-1, Sca1, Ter-119, CD4, and allophycocyanin-
conjugated antibody for lineage markers Mac-1, cKit, B220 or CD8. The cells 
were then washed with PBS and stained with propidium iodide, and viable cells 
were analyzed with the FACS Calibur system. 
3.10 Differentiation assay. 
The differentiation capacity of proliferating cell populations was tested by cul-
turing 1x105 cells in DMEM, 15% FBS supplemented with G-CSF 100ng/ml or 
M-CSF 10ng/ml (R&D Systems, Wiesbaden, Germany) and all-trans retinoic 
acid (ATRA) at a final concentration of 1μM. After 5 days the morphology was 
determined by Wright-Giemsa stained cytospin preparations (Buske et. al., 
2002; Pineault et. al., 2003a). 
3.11 Delta Colony Forming Unit on Spleen (CFU-S) as-
say. 
Day-4 5-FU mobilized primary BM cells from F1(PebC3) donor mice were 
transfected with the different viruses and retrovirally-transduced cells were pu-
rified based on the expression of GFP or YFP using a FACSVantage sorter 
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(Becton Dickinson, San Jose, USA). Transduced cells were cultured for 7 days 
in standard medium. The day 0 equivalent of 2.5– 3 x 104 cells was injected 
into the tail vein of lethally irradiated F1 (B6C3) recipient mice. The recovery 
of CFU-S cells was quantified by determining the number of macroscopic 
colonies on the spleen at day 12 post injection after fixation in Telleyes-
nickzky’s solution.  
3.12 BM transplantation and assessment of mice. 
For bone marrow transplantation procedures, 8–10 week old recipient F1 
(B6C3) mice were irradiated with 850 cGy from a 137Cs γ-radiation source. 
FACS purified transduced BM cells or defined ratios of transduced and un-
transduced cells were injected into the tail vein of irradiated recipient mice. PB 
or BM cell progeny of transduced cells were tracked using GFP or YFP fluo-
rescence (Feuring-Buske et al., 2002). Lineage distribution was determined by 
flow cytometric analysis as previously described (Pineault et. al., 2003): Phy-
coerythrin-(PE) labeled Gr-1, Sca1, Ter-119, CD4 and allophycocyanin (APC) 
labeled Mac1, c-Kit, B220, CD8 antibodies were used for analysis (all Pharm-
ingen Heidelberg, Germany). For histological analyses, sections of selected 
organs were prepared and H&E stained at the Academic Pathology Laboratory, 
GSF, Munich, using standard protocols. The mice were under observation for 
early signs of leukemia. Aspiration of the blood and bone marrow was per-
formed at 8 weeks and subsequently at four week intervals and assessed for 
engraftment of the mouse with transduced cells and progression of disease. 
Early signs of leukemia included high engraftment efficiency and the presence 
of blast cells in the blood and bone marrow cytospin preparations and in blood 
smears. In the animal, the indications of initiation of disease were paleness of 
the feet, limited mobility or lethargy, short breaths or ruffled body hair. Mori-
bund mice were sacrificed and analyzed as described. 
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3.13 Analysis of sacrificed/dead experimental mice.  
Disease in the animals was determined by analyzing PB, spleen and BM of dis-
eased sacrificed mice. PB was aspirated from heart with 1 ml insulin syringes; 
Heparin was used for anticoagulation. PB was used for blood smears on glass 
slides and RBC count. WBC count and immunophenotyping was performed 
after lysing the RBC with ammonium chloride. The size of the spleen in dis-
eased mice was measured and the spleen was homogenized to single cell 
suspension in DMEM medium, for further analysis by FACS, cytospin or ex 
vivo assays. BM cells were obtained by flushing both femurs and tibias and 
subjected to WBC count, cytospin and immunophenotyping.   
3.14 Preparation for histopathology. 
The four limbs, tail and head of mice were pinned to a cork plate with needles 
after sacrificing the animals for histological analyses. Then the skin from the 
chin to the anus and also the abdominal muscles were opened in the median 
and also pinned (Fig.16). The mice were then bled by cutting one of the renal 
arteries, and the blood was sucked out with a tissue paper. Then the diaphragm 
was carefully cut away to allow the fixing liquid to get into the thorax. After 
this the whole mouse was placed into formalin over night, packed and sent to 
the histopathology, where the organs were cut and stained for analyses 
(Fig.16). 
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Figure 16. Dissected mouse before fixing in formalin 
3.15 RT-PCR  
Expression of Hoxa9 and Meis1 was assayed by RT-PCR in Sca1–/Lin+ cells 
sorted from a repopulated Cdx2 mouse or a control animal. Total RNA was iso-
lated using Trizol reagent (GIBCO BRL) and treated with DNase I (amp grade) 
to remove contaminating genomic DNA. First strand cDNA was synthesized 
from 1 μg total RNA using the thermoScript RT-PCR system (all reagents from 
Invitrogen GmbH, Karlsruhe, Germany). Equal amounts of cDNA originating 
from 50 ng starting RNA were loaded to assess transcription levels. Intron 
spanning primer pairs were selected to avoid amplification of contaminating 
genomic DNA. The annealing temperature was 58°C and 60°C for Meis1 and 
Hoxa9, respectively. The number of PCR cycles for each gene was chosen to 
stop the reaction in the linear phase of amplification (25 cycles for mβ-2 mi-
croglobulin, 35 cycles for Meis1 and Hoxa9).  
 
Primer sequence for Hoxa9: 
Forward primer: 5'-GTTGCTCTGGTTGCTCTGTG-3' 
Reverse primer. 5'-CTGTTGTGTTTGGTTGGTGAA-3' 
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Primer sequence for Meis1: 
Forward primer: 5'-ATGTGACAATTTCTGCCACCG-3' 
Reverse primer. 5'-CCTCAACGAGTGGATGCCGTG-3' 
3.16 Southern blot analysis. 
Southern blot analysis to assess proviral integration were performed by isolat-
ing DNA from bone marrow, spleen and peripheral blood of leukemic mice 
using DNAZOL reagent as recommended by the manufacturer. Southern blot 
was performed using standard protocols (Buske et al., 2001). DNA was di-
gested with EcoRI, which cuts the proviral DNA once, to release a fragment 
specific to the proviral integration site. To check the full length integration, 
DNA was digested with Nhe I, which cuts in the long terminal repeats (LTRs) 
to release the proviral genome. After digestion DNA was loaded on a 0.7% 
agarose gel with 0.5 µg/ml ethidium bromide. After electrophoresis, the DNA 
was depurinated by incubating the gel in 0.2 N HCL for 8 minute and then in 
denaturing solution for 45 minutes. After denaturation, the DNA was trans-
ferred on a zeta-probe GT membrane by capillary action in 10X transfer buffer. 
Cross linking of the DNA with the membrane was done by incubating the 
membrane at 150 mJoule in a UV GS gene linker (BioRad). The probe used 
was a 700 bp GFP fragment, which was cut out from the pEGFP-C1 plasmid 
(Clontech) and labeled with α-32P dCTP, using the Megaprime DNA labeling 
system (Amersham Biosciences). The probe was purified by using Microspin 
S-300 HR columms (Amersham Biosciences) Hybridization was done with α-
32P GFP overnight at 620C. 
3.17 Western Blot. 
Protein expression of the ETV6/CDX2, Cdx2 and Cdx2 mutants was docu-
mented by Western blotting using standard procedures (Reddy et. al., 2002). 
Total cellular protein was extracted using RIPA lysis buffer from NIH3T3 and 
E86 cells transduced with the different constructs. Whole cell lysates were 
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separated on 12% SDS-page gel and transferred to nitrocellulose membrane. 
Membranes were probed with an anti-histidine monoclonal antibody for 
ETV6/CDX2 and the ΔN-CDX2 mutant or with an anti-CDX2 human mono-
clonal antibody (kindly provided by DCS Innovative, Hamburg, Germany) for 
expression of the Cdx2, W167A-Cdx2 and N51S-Cdx2 mutants. Membranes 
were then incubated with horse radish peroxidase conjugated anti-rabbit immu-
noglobulin. Protein was visualized using an ECL plus kit, according to 
manufacturer’s recommendations.  
3.18 Statistical analysis 
Data were evaluated using the t-test for dependent or independent samples 
(Microsoft Excel). Differences with p-values <0.05 were considered statisti-
cally significant.  
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4 RESULTS  
In Vitro. 
4.1 Ectopic expression of Cdx2 induces proliferation and 
outgrowth of IL-3 dependent blast cell populations 
To analyze whether the expression of the ETV6/CDX2 fusion gene or the ec-
topic expression of the homeobox gene Cdx2 is able to transform early murine 
hematopoietic progenitors we generated MSCV-based retroviral constructs. We 
checked the proliferative potential of bone marrow (BM) cells transduced with 
ETV6/CDX2, Cdx2 and ETV6/CDX2 & Cdx2 in vitro by sorting for EGFP, 
EYFP or for cells co-expressing both fluorescent proteins, respectively. Ex-
pression of Cdx2 induced a 26.81 ±2.60 (N=7) fold rise in cell number after 2 
weeks in liquid expansion cultures (supplemented with IL-3, IL-6 and SCF) 
compared to BM cells transduced with GFP as a control (Fig. 17). Cells ex-
pressing Cdx2 were able to grow in liquid culture supplemented only with IL-3 
and showed blast cell morphology in both assay systems (Fig. 18, 17b). In con-
trast, cells expressing the ETV6/CDX2 fusion gene did not show any significant 
(0.70 ± 2.61, N=6) growth advantage compared to GFP positive cells in com-
plete medium. In addition, cells expressing the fusion gene were not able to 
grow in medium supplemented only with IL-3 (Fig. 18). BM cells co-
expressing ETV6/CDX2 and the Cdx2 showed a higher proliferation in com-
plete medium compared to GFP control cells and were able to grow in medium 
supplemented only with IL-3, comparable to the cell populations transduced 
with Cdx2 alone (Fig. 17a, 18). Furthermore, we examined the leukemic prop-
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erties of the cell population expressing Cdx2 or ETV6/CDX2 & Cdx2 by inject-
ing 1x106 transduced and 1x106 non-transduced cells per mice in lethally 
irradiated animals (N=4). All mice developed leukemia 8 weeks after trans-
plantation. 
Cytomorphological analysis of the cultured cells showed that BM cells express-
ing the fusion gene and GFP were able to differentiate to normal terminally 
differentiated macrophages and granulocytes. Of note, cells expressing Cdx2 
were blocked in differentiation at the blast cell stage (Fig. 17b).  
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Figure 17. Ectopic expression of Cdx2 increases the proliferation rate and blocks cell 
differentiation. a) BM cells expressing Cdx2 or ETV6/CDX2 + Cdx2 showed a significant 
proliferative advantage compared to GFP transduced cells (N=5) in liquid expansion medium 
whereas expression of ETV6/CDX2 did not show any growth advantage compared to GFP 
(N=5). b) Cytomorphological analysis of cultured cells infected with Cdx2 shows blast mor-
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phology indicating differentiation arrest whereas GFP and ETV6/CDX2 infected population 
were able to differentiate to normal terminally differentiated macrophages and granulocytes.   
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Figure 18. Expression of Cdx2 and ETV6/CDX2 + Cdx2 induces outgrowth of IL-3 de-
pendent blast cell populations. BM cells expressing Cdx2 or ETV6/CDX2 + Cdx2 showed 
rapid growth in liquid expansion culture supplemented only with IL-3 (N=4), cells expressing 
the fusion gene did not grow under these conditions.  
4.2 Expression of Cdx2 upregulates the primitive marker 
Sca1  
To confirm the myeloblastic nature of the cells, immunophenotyping was per-
formed of the transduced BM cells propagated two week in complete medium 
or medium supplemented only with IL-3. Cells expressing Cdx2 expressed the 
myeloid markers Mac-1 (72% ± 12, N=4), Gr-1 (48.15% ± 21, N=4)) and to a 
high percentage the primitive cell marker Sca1 (48% ± 8, N=4). In contrast, 
cells expressing ETV6/CDX2 or GFP alone differentiated to mast cells under 
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these conditions and co-expressed Sca1 and c-kit (77% ± 2 and 88% ± 5, N=4) 
as previously described for the mast cell phenotype (Fig. 19).  
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Figure 19. Cdx2 expressing cells express Sca1 and myeloid surface markers. Immuno-
phenotyping of the cells growing for 2 weeks in liquid culture supplemented with IL-3, IL-6 
and SCF. Cdx2 transduced cells expressed myeloid specific marker Gr-1, Mac-1 and were 
positive for primitive stem cell marker Sca1. Whereas >75% ETV6/CDX2 and GFP cells were 
positive for the mast cell marker c-kit+Sca1.  
4.3 Expression of Cdx2 induces blast colony formation 
and increases the number of clonogenic progenitor 
cells  
To test the differentiation potential of BM cells expressing ETV6/CDX2, Cdx2 
and ETV6/CDX2 + Cdx2 we performed the CFC assay by testing the colony 
formation on methylcellulose. Cdx2 positive cells generated a higher number of 
primary CFC in methylcellulose compared to the GFP control (76 ± 22 vs. 41 ± 
20 per 500 initially plated cells; n=5; p<0.02) (Fig. 20). Furthermore, Cdx2 
positive colonies were significantly larger containing approximately 10 times 
more cells per colony than the controls (33 x 103 vs. 3.9 x 103/colony; n=5; 
p<0.004) (Fig. 21). Cells expressing the ETV6/CDX2 fusion gene did not show 
any significant increase in colony number compared to GFP. We tested the pro-
liferative potential of the primary colony by replating primary colonies in a 
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second methylcellulose dish: Cdx2 induced a 83 fold (N=5, p<0.0023) increase 
in the total CFU count and significantly a 3184 fold increase in CFU-blast 
count compared to the empty vector (N=5, p<0.007) (Fig. 22). Expression of 
ETV6/CDX2 + Cdx2 showed a significant increase in the number of total pri-
mary CFCs and induced an increase in the total CFU-blast count in replating 
assay like Cdx2 alone (Fig. 20, 22). 
In contrast, colonies expressing the ETV6/CDX2 fusion gene did not show any 
significant increase in primary CFC. Replating primary colonies in a second 
methylcellulose dish, showed a 0.46 fold (N=5) decrease in the total CFU count 
compared to GFP (Fig. 20, 22). To check the surface marker of the colonies 
expressing different genes, we harvested the cells from 2oCFC. Immunopheno-
typing analysis showed that Cdx2 and ETV6/CDX2 + Cdx2 expressing cells 
were positive for the myeloid surface marker Gr-1 and Mac-1 (80 to 90% cells) 
and up-regulated the primitive stem cell marker Sca1 in 40 to 60% cells. Cells 
expressing ETV6/CDX2 or GFP gene only, expressed both Sca1 and c-kit, 
which indicate a mast cell phenotype. 
1°CFC
0
20
60
100
140
180
GFP ETV6/CDX2 Cdx2 ETV6/CDX2
+ Cdx2
N
o.
 O
f C
FC
/5
00
in
pu
tc
el
ls
CFU Blast
CFU Total N=5, p<0.02
 
Figure 20. Expression of Cdx2 or ETV6/CDX2 & Cdx2 increases the number of clono-
genic progenitors. In the CFC-assay, BM cells expressing Cdx2, ETV6/CDX2 & Cdx2 
showed a substantially higher number of colonies (N=5, p<0.02) compared to BM cells in-
fected with the GFP control virus alone. ETV6/CDX2 did not induce any increase in the total 
number of colonies compared to the control. 
 
 
45
RESULTS 
          
Cdx2
GFP
ETV6/CDX2+Cdx2
ETV6/CDX2  
 
Figure 21. Colonies expressing Cdx2 or ETV6/CDX2 & Cdx2 were increased in size. Mi-
croscopic picture of the colonies (50X) in the primary CFC-assay expressing Cdx2 or 
ETV6/CDX2 & Cdx2. The colonies consisted of more than 2000 cells. In comparison the av-
erage cell number per colony was 500 cells in the CFC-assay of BM cells expressing 
ETV6/CDX2 alone or GFP. 
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Figure 22. Re-plating was associated with increase in total CFU and formation of blast-
like colonies in cell expressing Cdx2. Re-plating of primary colonies expressing Cdx2 or 
ETV6/CDX2 & Cdx2 resulted in a significant increase in the total number of CFU and CFU-
blasts (N=5, p<0.0023) compared to ETV6/CDX2 and the GFP control. 
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4.4 Cdx2 expression induces an increase in the yield of Δ 
CFU-S.  
To investigate the effect of the expression of ETV6/CDX2, Cdx2 and GFP on 
more primitive hematopoietic cells, progenitor enriched BM cells were trans-
duced with the different constructs. Transduced cells were sorted out and 
injected into lethally irradiated mice after culturing them for 7 days in vitro. 
Spleen colonies of sacrificed mice were quantified macroscopically 12 days 
after injection (CFU-S assay). Cdx2 expression induced a significant, over 10 
fold increase in the yield of day12 CFU-S compared to the GFP control (n=8; 
p< 0.0001). In contrast, ETV6/CDX2 (n=6) did not show any increase in the 
yield of day 12CFU-S compared to the GFP control. Cdx2 did not only increase 
the colony numbers but also the size of the spleen colonies (Fig. 23 a,b). 
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Figure 23. Cdx2 increases the yield of day 12 CFU-S. a). Total number of day 12 CFU-S 
colonies derived per culture initiated with 1x 105 cells transduced with Cdx2, ETV6/CDX2 
and GFP as a control after 1week in liquid culture. The median is indicated. Cdx2 induced a 
significant, over 10 fold increase (N=8, p< 0.0001) in the yield of day 12 CFU-S compare to 
the GFP control. The fusion gene did not show any increase in CFU-S compared to the con-
trol. b) Spleens after fixing in Telleyesnickzky’s solution showing large spleen colonies in the 
Cdx2 experimental arm compared to the control. 
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 In Vivo 
4.5 Ectopic expression of Cdx2 causes AML in trans-
planted mice 
To analyze whether the expression of the t(12;13) associated ETV6/CDX2 fu-
sion gene or the ectopic expression of the homeobox gene Cdx2 is able to 
transform early murine hematopoietic progenitors in vivo, murine hematopoi-
etic progenitors constitutively expressing ETV6/CDX2 or Cdx2 were FACS 
sorted to high purity by GFP+ or YFP+ expression respectively, and injected 
into lethally irradiated recipient mice directly after sorting (3–3.5 x 105 and 2–
3.6 x 105 cells/mouse for Cdx2 and ETV6/CDX2, respectively).  
Mice transplanted with BM cells expressing Cdx2 became moribund after a 
median of 90 days post transplantation (n=18) (Fig. 24). Diseased mice were 
characterized by cachexia, shortness of breath and lethargy, at which time they 
were sacrificed for further analysis. Diseased Cdx2 mice were characterized by 
elevated peripheral white blood count (WBC) (3.8-fold) with up to 48 x 106 
circulating WBC/ml. Furthermore, moribund mice were anemic with a 5-fold 
decrease in peripheral erythrocyte count (p<0.001) (Table 3). All Cdx2 mice 
analyzed (n=7) suffered from spleenomegaly with an average spleen weight of 
600 mg (range 0.4–0.9 g; p<0.01 compared to control animals) (Table 3). More 
detailed hematological analyses demonstrated that animals suffered from AML 
with a high percentage of blasts in the BM (42% ± 6), PB (14% ± 3) and spleen 
(35% ± 5) (n=8; p<0.01 compared to the control animals (Table 3).  
Immunophenotypic characterization of PB, BM and spleen in diseased mice 
confirmed the predominance of myeloid Mac-1+ and Gr-1+ cells (84% ± 10 and 
73% ± 15 in the PB, 65% ± 14 and 53% ± 14 in the spleen; n=4 ) compared to 
the GFP control mice (Mac-1+ and Gr-1+ cells 47% ± 5 and 25% ± 3 in the PB, 
14% ± 9 and 10% ± 1 in the spleen; n=4) (Fig. 25 a, b, 26). Diseased mice 
showed expression of primitive stem cell marker c-kit (35% ±13 in PB and 
38% ± 11.9 in spleen) compared to GFP (0.69% ± 0.2 in PB and 1.6% ± 0.6 in 
Spleen) (Fig. 25 a, b). Furthermore, the disease was characterized by a greatly 
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reduced normal B220+ lymphoid population in the spleen and PB compared to 
controls (1.8% ± 1 versus 35% ± 8 and 1.3% ± 0.5 versus 46% ± 21 in the PB 
and in the spleen, respectively; n=4) (Fig. 25 a, b, 26).  
Table 3. Hematological parameters of experimental mice 
 
Mouse No. Retroviral survival RBC/ml WBC/ml Spleen BM Spleen PB 
Lymphoid/ 
Myeloid Ratio 
 construct days  X109 X106
Weight 
(mg) 
% of 
blast  
% of 
blast 
% of 
blast  in PB 
1 GFP 90 6.0 4.5 150 0 0 0 5 : 1 
2 GFP 90 4. 8 3.2 200 0 0 0 2 : 1 
3 GFP 90 5.0 3.6 200 0 0 0 2 : 1 
1∗ CDX2 128 1.0 3.2 400 28 21 8    0.5 : 1 
2∗ CDX2 79 2.0 37 650 40 35 12    0.4 : 1 
3∗ CDX2 52 0.7 9 600 38 30 15    0.2 : 1 
4∗ CDX2 116 0.4 48 nd ND 60 14    0.4 : 1 
5∗ CDX2 37 0.6 5 400 25 22 5    0.3 : 1 
6∗ CDX2 171 0.8 24 900 71 48 18    0.3 : 1 
7∗ CDX2 192 1. 1 10 800 60 41 30    0.5 : 1 
8∗ CDX2 84 0.4 28 400 32 24 8    0.8 : 1 
1∗ ++ 168 1.0 3.2 400 25 18 3    0.6 : 1 
2∗ ++ 230 1. 1 8 500 45 30 10    0.1 : 1 
3∗ ++ 151 0.2 8 600 58 37 16    0.4 : 1 
4∗ ++ 237 1. 5 2.4 300 25 18 5    0.6 : 1 
5∗ ++ 187 0.5 2.5 900 50 43 8    0.3 : 1 
1 ETV6/CDX2 375 6. 5 2.4 160 10 8 0   0.3  : 1 
2 ETV6/CDX2 375 5 .0 3.2 200 25 15 0    0.4 : 1 
3 ETV6/CDX2 375 5 .2 6 180 15 9 0    2 : 1 
 
* = diseased 
++ = ETV6/CDX2 + CDX2, RBC = red blood cell count, WBC = white blood cell 
count, ND = not determined 
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Figure 24. Cdx2 is highly leukemogenic in vivo, inducing an aggressive and transplant-
able AML in mice. Survival curves of the mice transplanted with BM cells expressing Cdx2 
(N=18), ETV6/CDX2 (n=9) or co-expressing Cdx2 and the fusion gene (n=13). The control 
group was injected with BM infected with the GFP empty retrovirus (n = 7). The survival 
time of 2nd recipient mice transplanted with BM from diseased primary Cdx2 or Cdx2 & 
ETV6-CDX2 recipients is indicated. Cdx2 mice died after a median of 90 days post transplan-
tation. Mice transplanted with BM cells expressing ETV6/CDX2 did not develop overt 
disease. 
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Figure 25. Cdx2 expression increases the proportion of myeloid progenitors and reduces 
that of lymphoid cells. a, b) Immunophenotyping of the PB and spleen of Cdx2 diseased 
mice showed a predominance of myeloid Gr-1+, Mac-1+ cells and >30% of this cells were 
positive for primitive stem cell surface marker c-kit+ (N=4). b) The B220+ lymphoid popula-
tion in the spleen and PB was greatly reduced compared to GFP control mice.  
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Figure 26. Flow cytometry from a representative leukemic Cdx2 mouse. PB, BM and 
spleen from Cdx2 diseased mice in comparison to a GFP control. Cells were stained for the 
myeloid markers Gr-1 and Mac-1 and the lymphoid marker B220. The proportion of positive 
cells within the GFP+ compartment is indicated. 
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4.6 Immunohistochemistry showed blast infiltration in 
multiple organs 
Histopathology report of the diseased Cdx2 mice showed a hypercellular BM. 
The normal hematopoiesis was almost completely effaced due to the presence 
of medium to large cells with a high nuclear/cytoplasmic ratio (Fig. 27 a). The 
nuclei were round with fine or blastic chromatin and one to three small nucle-
oli. The chloracetate esterase stain was negative (Fig. 27 b). The 
immunohistochemistry performed with anti-CD34 showed that approximately 
30% of the cells showed a clear, strong membranous positivity suggesting for 
accumulation of primitive cells (Fig. 27 d). Cells were negative for N-acetyl-
chloroacetate esterase, PAS and TdT, indicate that cells were positive for mye-
loid specific stain and negative for lymphoid specific (TdT) staining. 
Histologic analysis showing myeloid leukemic blasts (CD34+,TDT-) infiltrating 
in the spleen and liver are shown (Fig. 27 c, f). Histopathology of mice diag-
nosed acute myeloid leukemia. Wright-Giemsa-stained cytospins of PB, BM 
and spleen demonstated the meyloblastic nature of disease (Fig. 28).  
a
b
c
d
e
 
Figure 27. Histological analysis of diseased Cdx2 mice showed multiple organ infiltration 
of blast cell population. Histological analysis of diseased Cdx2 mice a) BM (H&E). Im-
muno-histochemistry showed that the BM is hypercellular (200X) for b) N-acetyl-
chloroacetate esterase stain was negative (400X) and d) 30% of the cells were CD34+ (640X). 
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c) Histology of the spleen showed infiltration of the blast cells in the red pulp (H&E) (25X) 
and e) Giemsa staining (640X) and f) liver with perivascular infiltration (200X) 
Cdx2 Mice           
PB BM Spleen
 
GFP mice 
 
 
 
Figure 28. Cytospins of PB, BM and spleen of Cdx2 diseased mice confirmed the myelo-
blastic phenotype compared to GFP mice. Cytospin preparations of PB, BM and spleen 
were analyzed after Giemsa staining and photographs were taken with an inverted microscope 
(Nikon) at 1000X and Spleen from GFP mice at 630X. 
 
4.7  The Cdx2-Induced AML was transplantable 
To test whether Cdx2-induced AML is transplantable, secondary mice were 
transplanted from the BM of primary diseased animals. The Cdx2–induced 
AML was transplantable and all lethally irradiated mice (n=11) died within 24 
days after transplantation (Fig. 24). The morphology and immunophenotype of 
the disease in the secondary recipients was identical to the situation in the pri-
mary recipients.   
4.8 Cdx2-induced diseased was oligoclonal 
Analysis of the clonality of the Cdx2-induced disease was performed by South-
ern blot analysis. Genomic DNA from different tissues was digested with 
EcoRI, which cuts once in the proviral genome. GFP was used as a probe. 
Southern blot analysis demonstrated different intensities and patterns of provi-
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ral signals in the different hematopoietic organs consistent with an oligoclonal 
nature of the disease (Fig. 28 a). Full-length integration of Cdx2 was confirmed 
by digesting genomic DNA with NheI, which releases the proviral genome 
from LTR to LTR (Fig. 28 b). 
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Figure 28. Southern blot showed oligoclonality of the disease: a) Southern blot analyses of 
genomic DNA from BM, PB and spleen of representative leukemic Cdx2 mice. Genomic 
DNA was digested with EcoR1, which cuts once in the provirus, to determine the number of 
provirus integrants. Signals with lower intensity, indicating the presence of different leukemic 
clones, are indicated. b) Full-length provirus integration was documented by digestion with 
NheI, which cuts only in the LTRs of the provirus. 
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4.9 Ex Vivo analyses 
Cdx2-transplanted mice were characterized by a 19-fold increase in frequency 
of clonogenic cells in the PB and an over 100-fold increase in the spleen com-
pared to the control as quantified by ex vivo CFC assays (248 versus 13 
clonogenic cells per 1x106 cells/ml in the PB and 1400 clonogenic versus 13 
cells per 1x106 cells/ml in the spleen) (n=3). 28% (± 3) of these clonogenic 
progenitors were not able to terminally differentiate and formed blast colonies 
in methylcellulose with high serial replating capacity  
4.10 ETV6/CDX2 causes myeloproliferation but does 
not induce terminal disease 
In striking contrast, mice transplanted with ETV6/CDX2 expressing cells did 
not succumb to terminal disease (n=9) (Fig. 29 a). However, when the PB of 
healthy ETV6/CDX2 mice (n=4) was analyzed 40 weeks after transplantation, 
immunophenotyping analysis showed a high percentage of myeloid Gr-1+/Mac-
1+ cells in the GFP compartment (Fig. 29a). In order to analyze whether the 
ETV6/CDX2 fusion caused subtle perturbations in hematopoietic development, 
healthy animals (n=3) were sacrificed 44 weeks after transplantation. Interest-
ingly, two of the three animals showed an expansion of the mature neutrophil 
compartment in the PB with an inversion of the lymphoid/myeloid ratio (Table 
3). In the GFP+ positive compartment 87% and 68% were Mac-1+/Gr-1+ cells. 
Furthermore, the spleens from all mice were infiltrated with terminally differ-
entiated myeloid cells (86% ± 0.9 Gr-1+/Mac-1+ cells) (Fig. 29b). However, 
none of the animals suffered from anemia, splenomegaly or the emergence of a 
blast population in the PB (Table 5). Thus, ETV6/CDX2 was able to induce a 
mild myeloproliferation without causing disease after a long latency time of 11 
months after transplantation, but failed to induce leukemic transformation.  
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Figure 29. ETV6/CDX2 induces myeloproliferation without causing disease in trans-
planted mice: a) ETV6/CDX2 engrafted mice show an expansion of the myeloid Gr-1+/Mac-
1+ cells in the GFP-positive compartment of PB 40 weeks after transplantation (n=4). b) 
Spleens of the engrafted ETV6/CDX2 sacrificed mice were infiltrated with myeloid cells (86% 
± 1 Gr-1+/Mac-1+ cells, n=3). 
4.11 Co-expression of ETV6/CDX2 and Cdx2 does not 
accelerate or change the Cdx2 induced phenotype 
In addition, 13 mice were transplanted with a mixture of ETV6/CDX2, Cdx2, 
and ETV6/CDX2 + Cdx2 co–expressing cells, containing between 1.9 - 4.5 x 
104 Cdx2 & ETV6/CDX2 cells and less than 4000 Cdx2 cells per mouse. The 
addition of ETV6/CDX2 + Cdx2 co-expressing cells did not accelerate the 
course or change the phenotype of the disease compared to only Cdx2 express-
ing cells (Fig. 24). All animals succumbed to AML and the leukemic 
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population consisted of ETV6/CDX2 + Cdx2 co-expressing or Cdx2 expressing 
cells in all mice analyzed (n=4) (Fig. 30 a, b). These data indicate that aberrant 
expression of the wild-type Cdx2 gene is crucial for malignant transformation 
in this model. 
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Figure 30. Co-expression of ETV6/CDX2 + Cdx2 causes AML in mice: a) Co-expression 
of ETV6/CDX2 +Cdx2 was confirmed by flow cytometry analysis of the BM cells of a leuke-
mic mice using YFP/GFP as a marker. b) Giemsa staining of the cytospin of the BM cells of 
ETV6/CDX2 +Cdx2 mice showed the myeloblastic nature of the disease.  
4.12 The transforming potential of Cdx2 is dependent 
on the N-terminal transactivation domain and the 
intact homeodomain  
In an effort to characterize the contribution of different motifs of Cdx2 to the 
transforming capacity of the gene, three different mutants were designed: a 
homeodomain mutant of Cdx2 (N51S-Cdx2), which results in loss of the DNA 
binding capacity, a Cdx2 mutant with an inactivating mutation in the putative 
PBX1 interacting motif (W167A-Cdx2) and a mutant lacking the N-terminal 
transactivation portion of Cdx2, which is also not present in the ETV6/CDX2 
fusion (ΔN-Cdx2). Protein expression of the mutants was confirmed by West-
ern blot analysis (Fig. 31). Expression of wild-type Cdx2 and W167A-Cdx2 
rapidly induced the outgrowth of IL-3 dependent cell lines in liquid cultures. 
The ΔN-Cdx2 or the N51S-Cdx2 mutants were not able to form cell lines in vi-
tro.  
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When the impact of the different constructs were tested on colony formation, 
W167A-Cdx2 positive cells generated a higher number of CFU total and blast 
colonies in secondary CFC in comparison to the GFP control (10 fold and 40 
fold per 500 initially plated cells, respectively; n=3; p<0.02) (Fig. 32 a, b). 
W167A-Cdx2 positive colonies were of the same size as Cdx2 colonies. In 
contrast, the expression of the N51S-Cdx2 and the ∆N-Cdx2 mutants did not 
show a significant increase in colony number or size of the colonies compared 
to GFP and did not induce growth of blast colonies (Fig. 31 a, b).  
To investigate the effect of the different mutants on more primitive hematopoi-
etic cells, progenitor enriched BM infected with the different viruses was 
injected into lethally irradiated mice after 7 days of in vitro culture and spleen 
colony formation was quantified 12 days after injection in sacrificed mice 
(CFU-S assay). The expression of Cdx2 as well as the W167A-Cdx2 mutant 
induced a significant, over 10 fold increase in the yield of d12 CFU-S com-
pared to the GFP control (n=8; p< 0.0001) (Fig. 33). In contrast, deletion of the 
N-terminal portion of Cdx2 (n=5) or inactivation of the homeodomain (n=5) 
resulted in a complete loss of the Cdx2 activity (Fig. 33).  
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Figure 31. Protein expression of the Cdx2 mutants: Immunoblot analysis from whole cell 
lysates NIH 3T3 cells transfected with the different mutants, probed with anti- human CDX2 
antibody. 
 
 
58
RESULTS 
a) 
                    
CFU-GM
CFU-blast
CFU total
000
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
GFP Cdx2 W167A N51S Δ N-Del
10 CFC, N=3
N
o.
 O
f C
FC
/5
00
in
pu
tc
el
ls
 
 
b) 
                      
0
20
40
60
80
100
120
140
160
180
GFP Cdx2 W167A N51S Δ N-Del
CFU-G/GM
CFU-blast
CFU total
20 CFC, N=3
X1
04
N
o.
 O
f 2
nd
C
FC
/5
00
 
in
pu
tc
el
ls
in
 1
°C
FC
 
Figure 32. CFC assay showed  that homeodomain dead mutant and  mutant with a dele-
tion of the transactivation domain lose their clonogenic potential: a) Cdx2 and W167A-
Cdx2 showed a substantial increase in the number of CFU-blast in primary CFC (N=3) com-
pared to the GFP control. b) In the re-plating assays N51S-Cdx2 and ΔN-Cdx2 failed to 
increase the number of secondary colonies compared to Cdx2 wild-type.  
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Figure 33. Deletion of the transactivation domain and inactivation of the homeodomain 
results in loss of activity in the CFU-S assay compared to wild-type Cdx2. Total number 
of day 12 CFU-S colonies derived per culture initiated with 1x 105 cells transduced with dif-
ferent vectors. The median is indicated. Cdx2 and W167A-Cdx2 induced a significant, over 
10 fold increase (N=8, p< 0.0001) in the yield of day 12 CFU-S compared to the GFP control. 
N51S-Cdx2 and ΔN-Cdx2 did not show any increase in the yield of day 12 CFU-S compared 
to the GFP control.  
4.13 The expression of Hoxa9 and Meis1 is not up-
regulated by ectopic expression of Cdx2  
As Cdx2 is an upstream regulator of Hox genes, we asked whether Cdx2 would 
perturb expression of leukemogenic homeobox genes such as Hoxa9 or Meis1. 
First, expression of and Meis1 determined in the 32D cell line, transduced with 
the, the ETV6/CDX2 or the GFP-only virus, by RT–PCR. Compared to the con-
trol Cdx2 did not upregulate expression of Hoxa9 or Meis1. In addition, Scal-
/Lin+ differentiated cells were recovered and highly purified from a Cdx2 
mouse and a control animal, a cell population with normally has no detectable 
expression of Hoxa9 and Meis1 (Pineault et. al., 2002): specific amplification 
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products were not detectable by RT-PCR after 25 cycles in both experimental 
arms. Amplification products could be detected after 35 cycles but without 
considerable differences in the intensity between Cdx2 and the control (Fig. 
34). Thus, ectopic expression of Cdx2 was not associated with upregulation of 
Meis1 or Hoxa9 in this model system.  
 
 
Hoxa9Meis1 β2-microglobulin
Sca-/lin+ BM
C  Cdx C   Cdx C   Cdx C Cdx C Cdx
35              35               25  30 35 cycles  
Figure 34. Ectopic expression of Cdx2 in BM cells did not upregulate Hox genes: Expres-
sion of Meis1 and Hoxa9 analyzed by RT–PCR in Scal-/Lin+ BM cells isolated from a 
leukemic Cdx2 mouse or a control mouse. The number of PCR cycles for each gene was cho-
sen to be in the linear phase of the amplification (25 cycles for mβ-2 microglobulin, 35 cycles 
for Meis1 and Hoxa9). C = control; Cdx = Cdx2 
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5 DISCUSSION 
In general, chromosomal translocations can contribute to malignant transforma-
tion by two distinct mechanisms: first they can generate fusion genes with 
oncogenic potential. Secondly, they can induce aberrant or ectopic expressing 
of a proto-oncogene, thereby leading to malignant transformation. Both 
mechanisms are found in lymphoid neoplasia, with proto-oncogene activation 
being more frequently found in lymphomagenesis and in ALL. 
The formation of fusion genes with oncogenic properties by balanced chromo-
somal rearrangements is considered to be the crucial step of leukemic 
transformation in patients with AML, and so far there is no proof that activa-
tion of a proto-oncogene by a balanced chromosomal translocation can be the 
key event for the development of AML (Cools et. al., 2002; Look, 1997). How-
ever, recent data have suggested that the activation of proto-oncogenes might 
be much more widespread in myeloid leukemogenesis than previously thought, 
because there are many AML cases, which do not express a functional fusion 
protein despite the occurrence of a balanced chromosomal translocation (Cools 
et al., 2002). Furthermore, many fusion proteins expressed in AML have 
clearly no leukemogenic potential in experimental in vivo models (Castilla et. 
al., 1996; Mulloy et. al., 2002; Pineault et. al., 2003), suggesting that additional 
or other functional alterations are the relevant pathogenetic events in these 
AML cases.  
By using a murine BM transplantation model we now provide direct evidence 
that the induction of ectopic expression of the proto-oncogene CDX2, and not 
the creation of the fusion gene ETV6/CDX2, is the key transforming event in 
t(12;13)(p13;q12) positive AML. In addition, these data present the first direct 
evidence that the homeobox gene and Hox gene upstream regulator Cdx2, 
which so far has been linked to intestinal metaplasia and colon cancer (Silberg 
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et. al., 2002), is highly leukemogenic when ectopically expressed in hemato-
poietic progenitor cells.  
Our data clearly show that Cdx2 transforms murine bone marrow cells in vitro 
and in vivo. As shown in the proliferation assays, Cdx2-transduced cells dis-
played a high rate of proliferation and were able to grow in medium 
supplemented only with IL-3 in vitro. Furthermore, these indefinitely growing 
cell populations displayed a myeloblastic phenotype and were able to cause 
leukemia when transplanted into lethally irradiated syngenic mice. This data 
indicated that ectopic expression of the Cdx2 homeobox gene blocks differen-
tiation of bone marrow cells. These data were supported by the observation that 
Cdx2 enhanced the in vitro clonogenic potential of BM cells and supported the 
outgrowth of blast colonies in the CFC-assay, indicating that Cdx2 increased 
the proliferation and blocked differentiation of these progenitor cells in methyl-
cellulose. This effect was also confirmed when more primitive progenitor cells 
were analyzed in the CFU-S assay, in which Cdx2 expression significantly en-
hanced the number of spleen colony forming units.  
The perturbation of the normal hematopoietic development by Cdx2 might be 
linked to critical alterations in downstream Hox genes, which are central regu-
lators of normal early hematopoietic development in the adult with a distinct 
expression profile in human and murine early progenitor cells (Buske and 
Humphries, 2000; Pineault et. al., 2002; Sauvageau et. al., 1994). Gene expres-
sion profiling of acute leukemias using DNA microarray technology linked 
aberrant expression of Hox genes such as HOXA9, HOXA10 and of the non-
clustered homeobox gene MEIS1 to leukemogenesis (Debernardi et. al., 2003; 
Ferrando et. al., 2003; Golub. et al., 1999a; Yeoh et al., 2002). Retrovirally en-
forced expression of these genes induced severe perturbations of normal 
hematopoietic development in human and murine experimental models (Buske 
et. al., 2001; Thorsteinsdottir et. al., 2001). The perturbance of the expression 
of several Hox genes might be one of the reasons for the strong oncogenic po-
tential of Cdx2 (Lorentz et. al., 1997b; van den Akker et. al., 2002). However, 
RT–PCR analyses in the 32D cell line model and in Sca1-/lin+ BM population 
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of a mouse repopulated with Cdx2 expressing cells did not show up-regulation 
of Meis1 or Hoxa9 by Cdx2. However this does not exclude that perturbation 
of other Hox genes might play a role in the transformation process initiated by 
ectopic Cdx2 expression.  
Of note, perturbed expression of HOX genes such as HOXA9 or HOXA10 in 
hematopoietic progenitor cells is not able to induce genuine AML in trans-
planted mice after a short latency time, but requires co-operation with the Hox 
co-factor MEIS1. In striking contrast, constitutive expression of Cdx2 rapidly 
caused leukemia in recipient mice on its own. Moreover, mutating the PBX1 
interacting motif (PIM) in Cdx2 was found to be insufficient to suppress the 
leukemogenic potential of the gene. This implies that Cdx2 differs from the 
other Hox genes in the requirement of the cofactors MEIS1 and PBX1 for its 
leukemogenic activity. The underlying cause for the difference in the leuke-
mogenic activity between Cdx2 and HOXA9 or HOXA10 is not known. But in 
contrast to HOXA9 and HOXA10, which are normally expressed at high levels 
in progenitor cells, CDX2 is not expressed in hematopoietic cells (Chase et al., 
1999). Thus, ectopic expression of CDX2 might result in the activation of de 
novo downstream pathways, which are normally silent in early blood develop-
ment.  
Despite the differences in the oncogenic potential, many of the in vitro and in 
vivo hematopoietic effects induced by Cdx2 are highly reminiscent of the ef-
fects of retrovirally overexpressed HOX genes as well as of leukemia–specific 
fusion genes such as NUP98-HOXD13 with regard to the impact on short-term 
repopulating CFU-S or clonogenic progenitors (Pineault et. al., 2003a; Sau-
vageau et. al., 1997; Thorsteinsdottir et. al., 2001). The striking similarities of 
the phenotypes induced by the over-expression of homeobox genes of the HOX 
cluster and of Cdx2, as a member of the ParaHOX complex (Brooke et al., 
1998), point to a high level of functional redundancy among homeobox pro-
teins in hematopoiesis. 
The hematopoietic activity of Cdx2 was strictly dependent on an intact ho-
meodomain, implicating that DNA binding of Cdx2 is essential for its 
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transforming activity. Furthermore, deletion of the Cdx2 N-terminal portion 
resulted in a complete loss of the activity in our assays. Of note, it was demon-
strated that the N-terminal part of Cdx2 is necessary for transcriptional 
activation of HOX genes, supporting the concept that activation of downstream 
HOX genes is a potential key mechanism of Cdx2 induced transformation 
(Taylor et. al., 1997). Furthermore, it was demonstrated that the transcriptional 
activity of CDX proteins depends on the interaction of the p38 mitogen-
activated protein kinase with the N-terminal transactivation domain of Cdx2 
(Houde et. al., 2001). Serine-60 in the N-terminal domain has been shown to be 
phosphorylated by MAPK via ERK1/2 and the phosphorylated form of Cdx2 
loses the transactivation capacity in intestinal epithelial cells. As a conse-
quence, N-terminal deletion would diminish the transactivation capacity of 
Cdx2, thus abolishing its transforming capability. Importantly, the ETV6/CDX2 
fusion gene lacks the N-terminal portion of CDX2, presumably hampering its 
capability to transactivate target genes. This would explain the obvious dis-
crepancy in the oncogenic potential between Cdx2 and the ETV6/CDX2 fusion 
gene. This is supported by the presented data, which demonstrate a complete 
loss of activity, when this N-terminal portion of Cdx2, which is not present in 
the ETV6/CDX2 fusion gene, is deleted in the ΔN-CDX2 mutant. Notably, mice 
transplanted with BM cells expressing the chimeric gene developed a mild 
myeloproliferation after a long latency time but without any clinical symptoms. 
This indicates that despite the loss of the N-terminal portion, the fusion gene is 
able to perturb hematopoietic development, although to a significantly lesser 
extent than full-length Cdx2. However, it cannot be excluded from our experi-
ments that the first 54 amino acids of the ETV6 protein fused to CDX2 are 
responsible or at least contribute to the observed weak disturbances of hemato-
poiesis. However, to date there are no data that have shown a distinct function 
for these first 54 aa of ETV6. Taken together, our data propose a model, in 
which the chromosomal translocation t(12;13)(p13;q12) causes AML by acti-
vating the wild-type proto-oncogene CDX2. The mechanism of activation is not 
precisely known, but it was demonstrated that the chromosome 13 breakpoint 
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lies upstream of the CDX2 gene. Therefore, one possible mechanism of CDX2 
activation could be that the full-length CDX2 is translocated downstream to one 
of the two alternative ETV6 promoters, located between exon 2 and exon 3 of 
ETV6 (Chase et. al., 1999). Intriguingly, recent data demonstrated the ectopic 
expression of the homeobox gene GSH2 and of IL3 in patients with AML and 
the translocations t(4;12)(q11-12;p13) and t(5;12)(q31;p13), respectively. Both 
translocations involve the ETV6 gene, but do not create any functional fusion 
genes (Cools et. al., 2002). This suggests that activation of proto-oncogenes 
might be a common phenomenon in ETV6–associated leukemias. AML cases 
which do not express any functional fusion protein despite the occurrence of a 
balanced chromosomal translocation have also been reported. Furthermore, 
many fusion proteins expressed in AML fail to demonstrate leukemogenic po-
tential in experimental in vivo models (Cools et al, 2002; Schwaller et. al. 1998; 
Mulloy et. al. 2002; Peeters et. al.1997b). Taking these findings into considera-
tion it is tempting to speculate that activation of proto-oncogenes by 
chromosomal rearrangements might be a more widespread mechanism in mye-
loid leukemogenesis than previously thought. This is supported by observations 
in AML cases not affecting ETV6, in which expression of the putative proto-
oncogene EVI1 is upregulated by juxtaposition of the gene to the enhancer se-
quences of the ribophorin-I gene in patients with AML and 3q21 alterations 
(Nucifora, 1997). Our data now provide compelling evidence, that myeloid 
leukemogenesis can be initiated by this mechanism and stresses the relevance 
of proto-oncogene activation for the development of AML. 
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6 SUMMARY 
In conclusion, the thesis demonstrates for the first time that activation of a 
proto-oncogene by a chromosomal translocation can be the key step in myeloid 
leukemogenesis, even if a fusion gene is generated and expressed in parallel. 
This mechanism of AML leukemogenesis was proven in a murine model of 
t(12;13)(p13;q12) AML, showing that myeloid leukemogenesis is induced by 
the ectopic expression of Cdx2 and not by the ETV6/CDX2 chimeric gene. 
Mice transplanted with bone marrow cells retrovirally engineered to express 
Cdx2 rapidly succumbed to fatal and transplantable AML. In contrast, mice 
which were transplanted with BM cells expressing the fusion gene alone did 
not develop AML. The transforming activity of Cdx2 was dependent on an in-
tact homeodomain and the N-terminal transactivation domain. Although mice 
transplanted with ETV6/CDX2 expressing BM cells did not develop overt dis-
ease, these animals suffered from a mild myeloproliferation. Experiments 
testing the effect of simultaneous expression of the Cdx2 and the fusion gene 
showed no acceleration or change in phenotype of the disease compared to ex-
pression of Cdx2 alone, again demonstrating that the ectopic expression of 
Cdx2 was the key event in this leukemia model. These findings link proto-
oncogene activation to myeloid leukemogenesis, an oncogenic mechanism so 
far associated mainly with lymphoid leukemias and lymphomas. Our model 
constitutes the first functional proof that activation of a proto-oncogene by a 
chromosomal translocation is the key leukemogenic event in AML. As many 
fusion proteins expressed in AML have clearly no leukemogenic potential in 
experimental in vivo models, this mechanism might be more important for the 
development of AML than previously thought and should be included in the 
pathogenetic models of this disease.  
ZUSAMMENFASSUNG 
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7 ZUSAMMENFASSUNG 
Schließlich zeigt diese Doktorarbeit zum ersten Mal, dass die Aktivierung eines 
Proto-Onkogens durch eine chromosomale Translokation der Schlüssel zur 
myeloischen Leukämogenese sein kann, selbst dann, wenn parallel dazu ein 
Fusionsgen generiert und exprimiert wird. Dieser Mechanismus für die 
Entstehung einer AML wurde in einem t(12;13)(p13;q12)AML-Mausmodell 
nachgewiesen, wobei gezeigt wurde, dass die myeloische Leukämogenese von 
der ektopischen Cdx2-Expression induziert wird, und nicht von dem 
ETV6/CDX2–Fusionsgen. Mäuse, die mit Knochenmarkzellen transplantiert 
wurden, welche durch retroviralen Gentranfer Cdx2 überexprimierten, 
verstarben innerhalb kürzester Zeit an einer tödlichen und transplantierbaren 
AML. Im Gegensatz dazu entwickelten Mäuse, die mit Knochenmarkzellen 
transplantiert wurden, welche nur das Fusionsgen allein exprimierten, keine 
AML. Die Transformations-Aktivität von Cdx2 war von einer intakten 
Homeodomäne und der N-terminalen Transaktivations-Domäne abhängig. 
Obwohl die Mäuse, die mit Knochenmarkzellen transplantiert wurden, die 
ETV6/CDX2 exprimieren, nicht offensichtlich krank wurden, litten diese Tiere 
doch an einer leichten Myeloproliferation. Experimente, die den Effekt der 
gleichzeitigen Expression von Cdx2 und dem Fusionsgen untersuchten, zeigten 
keinerlei Beschleunigung oder Veränderung im Phänotyp der Erkrankung 
verglichen mit der Expression von Cdx2 alleine. Wieder wurde gezeigt, dass 
die ektopische Expression von Cdx2 eine  Schlüsselrolle in diesem Leukämie-
Modell untermauerte. Diese Ergebnisse zeigen die Bedeutung von Proto-
Onkogen-Aktivierung in der myeloischer Leukämogenese. Dieser 
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Mechanismus wurde bisher vor allem mit lymphoiden Leukämien und 
Lymphomen in verbindung gebracht. Unser Modell stellt den ersten Beweis 
dafür dar, dass die Aktivierung eines Proto-Onkogens durch eine 
chromosomale Translokation der Hauptgrund für die Entstehung einer AML 
ist. Da manche Fusionsproteine, die bei einer AML exprimiert werden, 
keinerlei leukämieauslösendes Potential bei Experimenten mit in vivo-
Modellen besitzen, dürfte dieser Mechanismus eine weitaus wichtigere Rolle 
bei der Entwicklung einer AML spielen als bisher angenommen. Deshalb sollte 
er auch in das pathogenetische Modell dieser Erkrankung aufgenommen 
werden. 
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Creation of fusion genes by balanced chromosomal translocations is
one of the hallmarks of acute myeloid leukemia (AML) and is consid-
ered one of the key leukemogenic events in this disease. In
t(12;13)(p13;q12) AML, ectopic expression of the homeobox gene
CDX2 was detected in addition to expression of the ETV6-CDX2 fusion
gene, generated by the chromosomal translocation. Here we show in
a murine model of t(12;13)(p13;q12) AML that myeloid leukemogen-
esis is induced by the ectopic expression of CDX2 and not by the
ETV6-CDX2 chimeric gene. Mice transplanted with bone marrow cells
retrovirally engineered to express Cdx2 rapidly succumbed to fatal
and transplantable AML. The transforming capacity of Cdx2 de-
pended on an intact homeodomain and the N-terminal transactiva-
tion domain. Transplantation of bone marrow cells expressing ETV6-
CDX2 failed to induce leukemia. Furthermore, coexpression of ETV6-
CDX2 and Cdx2 in bone marrow cells did not accelerate the course of
disease in transplanted mice compared to Cdx2 alone. These data
demonstrate that activation of a protooncogene by a balanced
chromosomal translocation can be the pivotal leukemogenic event in
AML, characterized by the expression of a leukemia-specific fusion
gene. Furthermore, these findings link protooncogene activation to
myeloid leukemogenesis, an oncogenic mechanism so far associated
mainly with lymphoid leukemias and lymphomas.
The molecular dissection of balanced chromosomal translo-cations in patients with acute leukemia has greatly advanced
our knowledge of the pathogenesis of this disease, demonstrating
that chromosomal translocations often affect genes that regulate
hematopoiesis. Chromosomal translocations involve mainly two
mechanisms that lead to malignant transformation: deregulation
of the expression of a protooncogene by juxtaposition of a potent
enhancer or promoter elements or creation of a fusion gene
(1–3). Although both mechanisms are found in lymphoid leu-
kemia or lymphoma, formation of a fusion gene predominates in
acute myeloid leukemia (AML). In fact, to date, there are no
experimentally confirmed instances in which the transcriptional
deregulation of a protooncogene is the key leukemogenic event
in a fusion gene-positive AML.
The oncogenic potential of fusion genes has been well docu-
mented experimentally. However, emerging data, mostly from
murine in vivo models, have demonstrated that many of these fusion
genes are not able to induce leukemia on their own. This observa-
tion suggests an important role for other genetic alterations that
cooperate with fusion genes in patients with AML (4–6). The
intriguing differences in the oncogenic potential of fusion genes are
well documented for the large family of chimeric genes involving the
ets transcription factor ETV6, located at 12p13. ETV6 is one of the
genes most frequently involved in chromosomal translocations.
Chromosomal translocations affecting the ETV6 locus have been
reported with 40 different partners (7). Fusion partners of ETV6
can be phosphotyrosine kinases (PTK) or transcription factors and
genes of unknown function, dividing ETV6 fusion genes into two
distinct groups. Fusions of ETV6 with PTKs such as PDGFRB,
JAK2, ABL1, ABL2, or NTRK3 create highly leukemogenic proteins
in murine experimental models (8–12). In the group of ETV6-
transcription factor fusions, the N-terminal portion of ETV6 is fused
to the partner gene in most cases, retaining (e.g., ETV6-AML1) or
losing the pointed domain (e.g., ETV6-CDX2, ETV6-MDS1EVII)
(13–15). Although data about the leukemogenic potential of this
group of fusion genes are still limited, extensive analyses of the most
frequent ETV6 chimeric transcription factor, ETV6-AML1, failed to
show any major transforming activity in a transgenic or bone
marrow (BM) transplantation mouse model (16, 17). Based on
these data, expression of an ETV6-transcription factor fusion might
not be sufficient to induce disease. Indeed, recent evidence cor-
roborates that ETV6 acts as a tumor suppressor gene and that, in
almost all cases of ETV6AML1-positive acute lymphoblastic leu-
kemias, there is a deletion or loss of expression of the nonrear-
ranged ETV6 allele (18, 19). Furthermore, several chromosomal
translocations involving the ETV6 locus associated with myeloid
malignancies such as t(4;12), t(5;12), or t(12;17) do not form any
functional fusion gene at all, pointing to a key variant oncogenic
mechanism in these cases (20, 21). In this regard, the
t(12;13)(p13;q12) associated with the ETV6-CDX2 fusion gene in
human AML is of notable interest. The translocation breakpoint
leaves the CDX2 gene intact, and expression of both the fusion gene
and full-length CDX2, normally restricted to intestinal epithelial
cells, was observed in leukemic cells, thus raising the possibility that
ectopic expression of CDX2 is the key pathogenic event (14).
To clarify this particular issue and to gain insight into alter-
native mechanisms of transformation in patients with AML and
ETV6 rearrangements, we established a mouse model for
t(12;13)(p13;q12) human AML. We demonstrate that ectopic
expression of Cdx2 is the key transforming event that induces
fatal AML in transplanted mice. In contrast, expression of the
ETV6-CDX2 fusion protein is unable to induce leukemia.
Furthermore, we show that the transforming potential of Cdx2
depends on the integrity of its DNA-binding domain and the
N-terminal domain of Cdx2. Our data point to a previously
uncharacterized mechanism of leukemogenesis in patients with
AML, in which a balanced chromosomal translocation contrib-
utes to malignant transformation by activating the expression of
a protooncogene, a mechanism so far associated mainly with
lymphoid leukemias or lymphomas (3).
Materials and Methods
cDNA Constructs and Retroviral Vectors. cDNAs of ETV6-CDX2 and
Cdx2 (93% overall and 98% identity in the homeodomain between
This paper was submitted directly (Track II) to the PNAS office.
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the human and murine proteins) were kindly provided by D. G.
Gilliland (Division of HematologyOncology, Harvard Medical
School, Boston) and N. Cross (Department of Haematology,
Hammersmith Hospital, London). A histidine-tagged version of
ETV6-CDX2 was constructed by ligating a PCR product of the
fusion gene in frame to the 3 end of the histidine epitope of the
pCDNA6V5-His A plasmid (Invitrogen), Cdx2 mutants were
created that were previously shown to inactivate a putative PBX1
interacting motif (W167A-Cdx2) (22) or to inactivate the DNA-
binding homeodomain (N51S-Cdx2) (23) by using the QuikChange
XL Site-Directed Mutagenesis Kit (Stratagene). The Cdx2 mutant
lacking the first 179 N-terminal amino acids, which are deleted in
the ETV6-CDX2 fusion, was generated and histidine tagged by PCR
following standard procedures (N-Cdx2) (4). For retroviral gene
transfer into primary BM cells, the different constructs were
subcloned into the multiple cloning site of the modified murine
stem cell virus (MSCV) 2.1 vector (4) upstream of the internal
ribosomal entry site (IRES) and the enhanced GFP or yellow
fluorescent protein (YFP) gene. As a control, the MSCV vector
carrying only the IRES-enhanced GFP cassette was used.
Production of high-titer helper-free retrovirus was carried out
following standard procedures by using the ecotropic packaging cell
line GPE86 (4). The number of provirus integrants was deter-
mined by EcoRI digestion and full length integration by NheI
digestion, followed by Southern blot analysis using standard tech-
niques (24). Protein expression of the ETV6-CDX2, Cdx2, and Cdx2
mutant plasmids was documented by Western blotting using stan-
dard procedures. Membranes were probed with an antihistidine
monoclonal antibody (Sigma) for ETV6-CDX2 and the N-Cdx2
mutant or with an anti-CDX2 monoclonal antibody (kindly pro-
vided by DCS Innovative, Hamburg, Germany) for expression of
the Cdx2, W167A-Cdx2, and N51S-Cdx2 mutants (25) (Fig. 1).
In Vitro Assays. Cell proliferation was assessed in DMEM supple-
mented with 15% FBS10 ng/ml mIL-66 ng/ml mIL-3100 ng/ml
murine stem cell factor (standard medium) (Tebu-bio, Offenbach,
Germany). Differentiation of clonogenic progenitors was analyzed
by plating cells in methylcellulose supplemented with cytokines
(Methocult M3434, StemCell Technologies, Vancouver). IL-3-
dependent cell populations expressing Cdx2 or coexpressing ETV6-
CDX2 and Cdx2 were established in vitro directly after sorting in
DMEM15% FBS with IL-3 alone (6 ng/ml). The differentiation
capacity of cultured cells was tested in DMEM15% FBS supple-
mented with granulocyte colony-stimulating factor 100 ng/ml or
macrophage colony-stimulating factor 10 ng/ml (R & D Systems)
and all-trans retinoic acid at 1 M final concentration. After 5 days,
the morphology was determined by Wright–Giemsa-stained cyto-
spin preparations (4, 25).
Mice and Retroviral Infection of Primary BMC. Parental strain mice
were bred and maintained at the GSF animal facility. Donors of
primary BM cells were 12-wk-old (C57BL6Ly-Pep3b  C3H
HeJ) F1 (PepC3) mice, and recipients were 8- to 12-wk-old
(C57BL6J  C3HHeJ) F1(B6C3) mice. Primary mouse BM cells
were transduced as described (4). For transduction, cells were
cocultured with irradiated (40 Gy) ETV6-CDX2GFP or Cdx2
YFP GPE86 producers or with a mixture of 40–50% Cdx2YFP
and 50–60% ETV6-CDX2GFP producers in cotransduction
experiments.
Colony-Forming Unit–Spleen (CFU-S) Assay. Primary BM cells from
F1(PepC3) donor mice treated 4 days previously with 5-fluorouracil
were transfected with the different viruses, and retrovirally trans-
duced cells were highly purified based on expression of GFP or YFP
by using a FACSVantage (Becton Dickinson). Transduced cells
were cultured 7 days in standard medium. The day 0 equivalent of
2.5–3  104 cells was injected into lethally irradiated F1(B6C3)
recipient mice. The recovery of CFU-S cells was quantified by
determining the number of macroscopic colonies on the spleen at
day 12 postinjection after fixation in Telleyesnickzky’s solution.
BM Transplantation and Assessment of Mice. Recipient F1(B6C3)
mice (8–10 wk old) were irradiated with 850 cGy from a 137Cs
-radiation source. FACS-purified transduced BM cells, or a de-
fined ratio of transduced and untransduced cells was injected into
the tail vein of irradiated recipient mice. Peripheral blood (PB) or
BM cell progeny of transduced cells were tracked by using the GFP
or YFP fluorescence (26). The lineage distribution was determined
by FACS analysis as described (4): phycoerythrin-labeled Gr-1,
ScaI, Ter-119, CD4, and allophycocyanin-labeled Mac1, cKit, B220,
or CD8 antibodies were used for analysis (all PharMingen). For
histological analyses, sections of selected organs were prepared and
hematoxylineosin-stained by using standard protocols.
RT-PCR. Expression of Hoxa9 and Meis1 was assayed by RT-PCR in
Sca-1–Lin cells sorted from a mouse repopulated with Cdx2
expressing BM cells or a control animal. Total RNA was isolated
by using Trizol reagent (GIBCOBRL) and treated with DNase I
(amp grade) to remove contaminating genomic DNA. First-strand
cDNA was synthesized from 1 g of total RNA by using the
thermoScript RT-PCR system (all reagents from Invitrogen).
Equal amounts of cDNA originating from 50 ng of starting RNA
were loaded to assess transcription levels. Intron-spanning primer
pairs were selected to avoid amplification of contaminating
genomic DNA. The annealing temperatures were 58°C and 60°C for
Meis1 and Hoxa9, respectively. The number of PCR cycles for each
gene was chosen to stop the reaction in the linear phase of
amplification (25 cycles for m-2 microglobulin, 35 cycles for Meis1
and Hoxa9).
Statistical Analysis. Data were evaluated by using the t test for
dependent or independent samples (Microsoft EXCEL). Differences
with P values  0.05 were considered statistically significant.
Fig. 1. (a) Retroviral vectors used to expressETV6-CDX2,Cdx2, and the different
Cdx2 mutants in murine BM. IRES, internal ribosomal entry site. (b) Western blot
analysisofcellularextracts fromNIH3T3orE86cells transfectedwiththedifferent
constructs. The molecular mass is indicated.
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Results
Ectopic Expression of Cdx2 Causes AML in Transplanted Mice. To
analyze whether expression of the t(12;13)-associated ETV6-CDX2
fusion gene andor the ectopic expression of the homeobox gene
Cdx2 is able to transform early murine hematopoietic progenitors
in vivo, we generated MSCV-based retroviral constructs and doc-
umented full-length protein expression by Western blotting (Fig. 1).
Murine hematopoietic progenitors constitutively expressing ETV6-
CDX2 or Cdx2 were highly purified by FACS based on GFP or
YFP expression, respectively, and injected into lethally irradiated
recipient mice directly after sorting (3–3.5  105 and 2–3.6  105
cells per mouse for Cdx2 and ETV6-CDX2, respectively).
Mice transplanted with BM cells expressing Cdx2 became mor-
ibund after a median of 90 days posttransplantation (n  18) (Fig.
2). Diseased mice were characterized by cachexia, shortness of
breath, and lethargy when they were killed for further analysis. In
striking contrast, mice transplanted with ETV6-CDX2-expressing
cells did not succumb to terminal disease (n  9) (Fig. 2). Diseased
Cdx2 mice were characterized by elevated peripheral white blood
count (WBC) (3.8-fold) with up to 48  106 circulating WBC per
milliliter. Furthermore, moribund mice were anemic, with a 5-fold
decrease in peripheral erythrocyte count (P  0.001) (Table 1). All
Cdx2 mice analyzed (n  7) suffered from splenomegaly, with an
average spleen weight of 0.6 g (range 0.4–0.9; P  0.01 compared
to control animals) (Table 1). More detailed hematological analyses
demonstrated that animals suffered from AML with a high per-
centage of blasts in the BM (42%  6), PB (14%  3), and spleen
(35%  5) (n  8; P  0.01 compared to the control animal) (Table
1). Furthermore, leukemic mice showed multiple organ infiltration
with blast cells. Thirty percent of the blasts expressed CD34 but
were negative for N-acetyl-chloroacetate esterase, periodic acid
Schiff reagent, and terminal deoxynucleotidyltransferase, as shown
by immunohistochemistry, consistent with an undifferentiated my-
eloblastic phenotype of the disease (Fig. 3). Immunophenotypic
Fig. 2. Survival curve of mice transplanted with BM cells expressing Cdx2 (n 
18), ETV6-CDX2 (n  9), or coexpressing Cdx2 and the fusion gene (n  13). The
control group was injected with BM infected with the GFP empty retrovirus (n 
7). The survival time of secondary recipient mice, transplanted with BM from
diseased primary Cdx2 or ETV6-CDX2 and Cdx2 recipients, is indicated.
Table 1. Hematological parameters of experimental mice
Mouse no.
Retroviral
construct
Day of
death
RBC per ml
109
WBC per ml
106
Spleen weight,
mg
BM
% blasts
Spleen
% blasts
PB %
blasts
Lymphoidmyeloid
ratio in PB
1 GFP 90 6 4.5 150 0 0 0 5:1
2 GFP 90 4.8 3.2 200 0 0 0 2:1
3 GFP 90 5.0 3.6 200 0 0 0 2:1
1* Cdx2 128 1.0 3.2 400 28 21 8 0.5:1
2* Cdx2 79 2.0 37 650 40 35 12 0.4:1
3* Cdx2 52 0.7 9 600 38 30 15 0.2:1
4* Cdx2 116 0.4 48 nd ND 60 14 0.4:1
5* Cdx2 37 0.6 5 400 25 22 5 0.3:1
6* Cdx2 171 0.8 24 900 71 48 18 0.3:1
7* Cdx2 192 1.1 10 800 60 41 30 0.5:1
8* Cdx2 84 0.4 28 400 32 24 8 0.8:1
1*  168 1.0 3.2 400 25 18 3 0.6:1
2*  230 1.1 8 500 45 30 10 0.1:1
3*  151 0.2 8 600 58 37 16 0.4:1
4*  237 1.5 24 300 25 18 5 0.6:1
5*  187 0.5 25 900 50 43 8 0.3:1
1 ETV6-CDX2 375 6.5 2.4 160 10 8 0 0.3:1
2 ETV6-CDX2 375 5 3.2 200 25 15 0 0.4:1
3 ETV6-CDX2 375 5.2 6 180 15 9 0 2:1
*, diseased; , ETV6-CDX2 and Cdx2; RBC, red blood cell count; WBC, white blood cell count; ND, not determined.
Fig. 3. Histological analysis of diseased Cdx2 mice. (a) BM [hematoxylineosin
(H&E)]. Immunohistochemistry of the BM (200) for N-acetyl-chloroacetate es-
terase (400) (b) and CD34 expression (640) (c). Histology of the spleen H&E
(25) (d) and Giemsa staining (640) (e) and liver with perivascular infiltration
(200) (f ). Cytospin preparations from PB (g), BM (h), and spleen (i) (all 1,000).
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characterization of PB, BM, and spleen in diseased mice confirmed
the predominance of myeloid Mac1 and Gr-1 cells (84%  10
and 73%  15 in the PB, 65%  14 and 53%  14 in the spleen,
respectively; n  4) compared to the GFP control mice (Mac1 and
Gr-1 cells 47%  5 and 25%  3 in the PB, 14%  9 and 10%
 1 in the spleen, respectively; n  4). Furthermore, diseased mice
were characterized by a greatly reduced normal B220 lymphoid
population in the spleen and PB compared to controls (1.8%  1
vs. 35%  8 and 1.3%  0.5 vs. 46%  21 in the PB and in the
spleen, respectively; n  4) (Fig. 4a). Mice transplanted with
Cdx2-expressing BM cells were characterized by a 19-fold increased
frequency of clonogenic cells in the PB and a 100-fold increase in
the spleen compared to the control as quantified by ex vivo CFC
assays (248 vs. 13 clonogenic cells per 1  106 cellsml in the PB and
1,400 clonogenic cells vs. 13 per 1  106 cellsml in the spleen,
respectively) (n  3). Twenty-eight percent (3) of these clono-
genic progenitors were not able to terminally differentiate and
formed blast colonies in methylcellulose with high serial replating
capacity (data not shown).
The Cdx2-induced AML was transplantable and all lethally
irradiated mice (n  11) injected with BM cells of diseased Cdx2
animals died within 24 days posttransplantation (Fig. 2). Analysis of
the clonality of the disease by Southern blot analysis demonstrated
different intensities and patterns of proviral signals in the different
hematopoietic organs consistent with an oligoclonal nature of the
disease (Fig. 4b).
To analyze whether the ETV6-CDX2 fusion caused subtle per-
turbations in hematopoietic development, healthy animals (n  3)
were killed 44 wk after transplantation with ETV6-CDX2-
expressing BM cells. Interestingly, two of three animals showed an
expansion of the mature neutrophil compartment in the PB with an
inversion of the lymphoidmyeloid ratio (Table 1) and 87% and
68% Mac1Gr1 cells in the GFP-positive compartment. Fur-
thermore, spleens from all mice were infiltrated with terminally
differentiated myeloid cells (86%  0.9 Gr1Mac1 cells). How-
ever, none of the animals suffered from anemia, splenomegaly, or
the emergence of a blast population in the PB (Table 1). Thus,
ETV6-CDX2 was able to induce a myeloproliferation without
causing disease but failed to induce leukemic transformation.
In addition, 13 mice were transplanted with a mixture of ETV6-
CDX2, Cdx2, and Cdx2 and ETV6-CDX2 coexpressing cells, con-
taining between 1.9–4.5  104 Cdx2 and ETV6-CDX2 cells and
4,000 Cdx2 cells per mouse. The addition of Cdx2 and ETV6-
CDX2 coexpressing cells did not accelerate the course or change the
phenotype of the disease compared to only Cdx2-expressing cells.
All animals succumbed to AML, and the leukemic population
consisted of Cdx2- and ETV6-CDX2-coexpressing or Cdx2-
expressing cells in all mice analyzed (n  4) (Fig. 2). These data
indicate that aberrant expression of the wild-type Cdx2 gene is
crucial for malignant transformation in this model.
The Transforming Potential of Cdx2 Depends on the N-Terminal
Transactivation Domain and the Intact Homeodomain. In an effort to
characterize the contribution of different motifs of Cdx2 to the
transforming capacity of the gene, three different mutants were
designed: a mutant inactivating the homeodomain (N51S-Cdx2), a
Cdx2 mutant with an inactivating mutation in the putative PBX1-
interacting motif (W167A-Cdx2), and a mutant lacking the N-
terminal portion of Cdx2, which is not present in the ETV6-CDX2
fusion (N-Cdx2). Protein expression of the mutants was con-
firmed by Western blot analysis (Fig. 1b). Expression of wild-type
Cdx2 and W167A-Cdx2 in primary bone marrow cells rapidly
induced the outgrowth of IL-3-dependent cell populations in liquid
cultures. The cells showed blast morphology, were GrMac1-
positive, and had lost their differentiation capacity when incubated
with macrophage colony-stimulating factor, granulocyte colony-
stimulating factor, or all-trans retinoic acid (data not shown).
Furthermore, mice transplanted with 1  106 of these cells devel-
oped leukemia 8 wk posttransplant in contrast to mice injected with
nontransduced or GFP-expressing control cells. Cells expressing
Fig. 4. (a) Flow cytometry from a representa-
tive leukemic Cdx2 mouse from PB, BM, and
spleen in comparison to a GFP control animal.
Cells were stained for the myeloid markers Gr1
and Mac1 and the lymphoid marker B220. The
proportion of positive cells within the GFP com-
partment is indicated. (b) Southern blot analyses
of genomic DNA from BM, PB, and spleens of
representative leukemic Cdx2 mice. Genomic
DNA was digested with EcoRI, which cuts once in
the provirus, to determine the number of provi-
rus integrants. Signals with different intensity,
indicating the presence of different leukemic
clones, are indicated. Full-length provirus inte-
gration was documented by digestion with NheI,
which cuts only in the LTRs of the provirus.
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ETV6-CDX2, the N-Cdx2, or the N51S mutant as well as the
control cells were not able to form blast cell populations in vitro.
When colony formation was tested, Cdx2-positive cells generated a
higher number of primary CFC in methylcellulose compared to
GFP (76  22 vs. 41  20 per 500 initially plated cells, respectively;
n  5; P  0.02). Furthermore, Cdx2-positive colonies contained
	10 times more cells per colony than the controls (33  103 vs.
3.9  103 per colony, respectively; n  5; P  0.004). The expression
of the other constructs did not change the size or number of
colonies compared to the control. To investigate the effect of the
different mutants on primitive hematopoietic cells, cells infected
with the different viruses were injected into lethally irradiated mice
after 7 days of in vitro culture, and spleen colony formation was
quantified 12 days after injection in killed mice (CFU-S assay).
Cdx2 expression as well as expression of the W167A-Cdx2 mutant
induced a significant 10-fold increase in the yield of day 12 CFU-S
compared to the GFP control (n  8; P  0.0001). In contrast,
deletion of the N-terminal portion of Cdx2 (n  5) or inactivation
of the homeodomain (n  5) resulted in complete loss of the Cdx2
activity in these assays. ETV6-CDX2 (n  6) did not show any
increase in CFU-S compared to the GFP control (Fig. 5a).
The Expression of Hoxa9 and Meis1 Is Not Increased by Ectopic
Expression of Cdx2. Given the role of Cdx2 as an upstream regulator
of Hox gene expression, we asked whether Cdx2 would perturb
expression of leukemogenic homeobox genes such as Hoxa9 or
Meis1. First, expression of Hoxa9 and Meis1 was determined by
RT–PCR in the 32D cell line transduced with the Cdx2, the
ETV6-CDX2, or the GFP virus. Compared to the control, Cdx2 did
not increase expression of Hoxa9 or Meis1 (data not shown). In
addition, Sca
lin-differentiated cells were recovered and highly
purified from a mouse transplanted with Cdx2-expressing BM cells
and a control animal, a cell population with normally no detectable
expression of Hoxa9 and Meis1 (27): specific amplification products
were not detectable by RT-PCR after 25 cycles in both experimen-
tal arms. Amplification products could be detected after 35 cycle
but without considerable differences in the intensity between
Cdx2-transduced and control cells (Fig. 5b). Thus, ectopic expres-
sion of Cdx2 was not associated with up-regulation of Meis1 or
Hoxa9 in this model system.
Discussion
The formation of fusion genes with oncogenic properties by
balanced chromosomal rearrangements is considered one of the
crucial steps for leukemic transformation in patients with AML.
By using the murine BM transplantation model, we now provide
direct evidence that the ectopic expression of the protooncogene
Cdx2 and not the expression of the fusion gene ETV6-CDX2 is
the key transforming event in t(12;13)(p13;q12)-positive AML.
Activation of protooncogenes by balanced chromosomal trans-
locations is a well-known oncogenic mechanism in lymphoid
leukemias or lymphomas but has, to our knowledge, not been
functionally demonstrated for AML and translocations involving
ETV6 (3). In addition, these data present evidence that the
homeobox gene and Hox gene upstream regulator Cdx2, which
so far has been linked to intestinal metaplasia and colon cancer
(28), is highly leukemogenic when aberrantly expressed in he-
matopoietic progenitor cells.
Cdx2 belongs to the large group of homeobox genes, which were
originally described as master regulators of embryonic body devel-
opment. The Cdx genes and their homologues caudal in Drosophila
and Xcad in Xenopus belong to the ParaHox cluster, which is
considered an ancient paralog of the Hox gene cluster (29).
Although the Cdx genes show similarities to the 5-located
Abdominal-B like genes of the Hox gene cluster, they possess a Pbx
recognition motif, a characteristic of 3-located Hox genes (30). Cdx
genes play a key role in the homeobox regulatory network, acting
as upstream regulators of several Hox genes (30, 31). Thus, per-
turbation of Cdx2 might be linked to critical alterations in down-
stream Hox genes that are central regulators of normal early
hematopoietic development in the adult with a distinct expression
profile in human and murine early progenitor cells (27, 32, 33).
Gene expression profiling of acute leukemias using DNA microar-
ray technology linked aberrant expression of Hox genes such as
HOXA9, HOXA10, and of the nonclustered homeobox gene MEIS1
to leukemogenesis (34–37). Retrovirally enforced expression of
these genes induced severe perturbations of normal hematopoietic
development in human and murine experimental models (24, 38).
Altered expression of several Hox genes might be one of the reasons
for the strong oncogenic potential of Cdx2 (30, 39–42). However,
RT–PCR analyses in the 32D cell line model and in Sca
lin BM
population of a Cdx2 repopulated mouse did not indicate gross
up-regulation of Meis1 and Hoxa9 by Cdx2. However, this does not
exclude that perturbation of other Hox genes might play a role in
the transformation process initiated by ectopic Cdx2 expression.
Of note, perturbed expression of Hox genes such as HOXA9 or
HOXA10 in hematopoietic progenitor cells is not able to induce
frank AML in transplanted mice after a short latency time but
requires collaboration with the Hox co-factor MEIS1. In striking
contrast, constitutive expression of Cdx2 rapidly caused leukemia in
recipient mice. The underlying cause for the difference in the
leukemogenic activity between Cdx2 and HOXA9 or HOXA10 is
not known. But, in contrast to HOXA9 and HOXA10, which are
normally expressed at high levels in progenitor cells, CDX2 is not
expressed in hematopoietic cells (14). Thus, ectopic expression of
CDX2 in leukemia patients might result in the activation of de novo
downstream pathways, which are normally silent in early blood
development.
Despite the differences in the oncogenic potential, many of the
in vitro and in vivo hematopoietic effects induced by Cdx2 are highly
reminiscent of the effects of retrovirally overexpressed hematopoi-
etic HOX genes as well as leukemia-specific fusion genes such as
NUP98-HOXD13 with regard to the impact on short-term repop-
ulating CFU-S or clonogenic progenitors (4, 38, 43). The striking
similarities of the phenotypes induced by the over-expression of
Fig. 5. (a) Total number of d12 CFU-S colonies derived per culture initiated with
1  105 cells transduced with the different viruses after 1 wk in liquid culture. The
median is indicated. (b) Expression of Meis1 and Hoxa9 analyzed by RT-PCR in
Sca
lin BM cells isolated from a Cdx2 mouse or a control mouse. The number of
PCR cycles for each gene was chosen to stop the reaction in the linear phase of the
amplification (25 cycles for m-2 microglobulin, 35 cycles for Meis1 and Hoxa9).
C, control; Cdx, Cdx2.
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homeobox genes of the Hox cluster and of Cdx2 as a member of the
ParaHox complex (29) point to a high level of functional redun-
dancy among homeobox proteins in hematopoiesis.
The hematopoietic activity of Cdx2 strictly depended on its intact
homeodomain, implicating that DNA binding of Cdx2 is essential
for its transforming activity. Furthermore, deletion of the Cdx2
N-terminal portion resulted in a complete loss of activity in our
assays. Of note, it was demonstrated that the N-terminal part of
Cdx2 is necessary for transcriptional activation of Hox genes,
supporting the concept that activation of downstream Hox genes is
a potential key mechanism of Cdx2-induced transformation (44).
Furthermore, it was demonstrated that the transcriptional activity
of CDX proteins depends on the interaction of the p38 mitogen-
activated protein kinase and the N-terminal transactivation domain
of Cdx2 (45). As a consequence, N-terminal deletion would dimin-
ish the transactivation capacity of CDX2. Importantly, the ETV6-
CDX2 fusion gene lacks the N-terminal portion of CDX2, presum-
ably hampering its capability to transactivate target genes. This
would explain the obvious discrepancy in the oncogenic potential
between Cdx2 and the ETV6-CDX2 fusion gene; this is supported
by our data, which demonstrate a complete loss of activity when this
N-terminal portion of Cdx2, which is not present in the ETV6-CDX2
fusion gene, is deleted in the N-Cdx2 mutant. Notably, mice
transplanted with BM cells expressing the chimeric gene developed
myeloproliferation after a long latency time but without any clinical
symptoms. These data indicate that, despite the loss of the N-
terminal portion, the fusion gene is able to perturb hematopoietic
development, although to a significantly lesser extent than full-
length Cdx2. However, it cannot be excluded from our experiments
that the first 54 amino acids of ETV6, which are fused to CDX2, are
responsible for or at least contribute to the observed disturbances
of hematopoiesis. Taken together, our data propose a model in
which the chromosomal translocation t(12;13)(p13;q12) causes
AML by inducing the ectopic expression of CDX2. The mechanism
of transcriptional induction is not precisely known, but it was
demonstrated that the chromosome 13 breakpoint lies upstream of
the CDX2 gene. Therefore, one possible explanation for the ectopic
expression of CDX2 could be that the translocated protooncogene
might now be under the control of one of the two alternative ETV6
enhancerpromoters, located between exons 2 and 3 of ETV6 (14).
Intriguingly, it was recently shown that the homeobox gene GSH2
and IL-3 are ectopically expressed in patients with AML and the
translocations t(4;12)(q11–12;p13) and t(5;12)(q31;p13), respec-
tively. Both translocations involve ETV6 but do not create any
functional fusion genes (20). This observation suggests that activa-
tion of protooncogenes is a more common phenomenon in ETV6-
associated leukemias than previously thought. Taking into consid-
eration that several AML-associated fusion genes are not
leukemogenic on their own, it is tempting to speculate that activa-
tion of protooncogenes by chromosomal rearrangements might be
quite a widespread mechanism in myeloid leukemogenesis. This
hypothesis is supported by observations in AML cases not affecting
ETV6, in which expression of the putative protooncogene EVI1 is
activated by juxtaposition to the enhancer sequences of the ribo-
phorin-I gene in patients with AML and 3q21 alterations (46). Our
data provide compelling evidence that myeloid leukemogenesis can
be initiated by this mechanism and emphasize the relevance of
protooncogene activation for the development of AML.
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The	molecular	characterization	of	leukemia	has	demonstrated	that	genetic	alterations	in	the	leukemic	clone	
frequently	fall	into	2	classes,	those	affecting	transcription	factors	(e.g.,	AML1-ETO)	and	mutations	affecting	
genes	involved	in	signal	transduction	(e.g.,	activating	mutations	of	FLT3	and	KIT).	This	finding	has	favored	
a	model	of	leukemogenesis	in	which	the	collaboration	of	these	2	classes	of	genetic	alterations	is	necessary	for	
the	malignant	transformation	of	hematopoietic	progenitor	cells.	The	model	is	supported	by	experimental	
data	indicating	that	AML1-ETO and	FLT3	length	mutation	(FLT3-LM),	2	of	the	most	frequent	genetic	altera-
tions	in	AML,	are	both	insufficient	on	their	own	to	cause	leukemia	in	animal	models.	Here	we	report	that	
AML1-ETO	collaborates	with	FLT3-LM	in	inducing	acute	leukemia	in	a	murine	BM	transplantation	model.	
Moreover,	in	a	series	of	135	patients	with	AML1-ETO–positive	AML,	the	most	frequently	identified	class	of	
additional	mutations	affected	genes	involved	in	signal	transduction	pathways	including	FLT3-LM	or	muta-
tions	of	KIT and	NRAS.	These	data	support	the	concept	of	oncogenic	cooperation	between	AML1-ETO	and	a	
class	of	activating	mutations,	recurrently	found	in	patients	with	t(8;21),	and	provide	a	rationale	for	therapies	
targeting	signal	transduction	pathways	in	AML1-ETO–positive	leukemias.
Introduction
The cloning of recurring chromosomal translocations and, increas-
ingly, the molecular characterization of point mutations in patients 
with acute leukemia have substantially contributed to the under-
standing of the pathogenesis of this disease. In acute myeloid leu-
kemia (AML), chromosomal translocations most frequently target 
transcription factors involved in the regulation of normal hema-
topoietic differentiation, whereas point mutations often affect 
genes involved in signal transduction pathways associated with cell 
proliferation (1–3). The systematic analyses of genetic alterations 
in patients with AML have demonstrated that genetic lesions of 
more than 1 transcriptional regulator, such as AML1-ETO (RUNX1-
MTG8), HOX fusion genes, or PML-RARA, rarely occur in the leuke-
mic clone. Similarly, patients with concurrent mutations of FLT3, 
KIT, or NRAS are rare. However, there are numerous examples in 
which fusion genes are identified together with activating muta-
tions of receptor tyrosine kinases, exemplified by PML-RARA and 
the FLT3 length mutation (FLT3-LM), which occur together in up 
to 35% of all patients with t(15;17)–positive AML (4).
These observations have favored a model of pathogenesis of acute 
leukemia in which the 2 groups of genetic alterations, 1 affecting 
transcriptional regulation and hematopoietic differentiation, the 
other altering signal transduction cascades associated with cell pro-
liferation, collaborate in inducing acute leukemia (5). This concept 
is supported by experimental data demonstrating that AML1-ETO, 
one of the most frequent fusion genes in AML, is not able, on its 
own, to induce leukemia in experimental in vivo models but requires 
additional mutations in yet unknown genes for induction of hema-
tological disease. In a conditional AML1-ETO murine model, for 
example, only mice treated additionally with N-ethylnitrosourea 
(ENU) developed AML as well as T cell lymphoblastic lymphoma, 
whereas untreated AML1-ETO mice showed only minimal hemato-
poietic abnormalities (6). Similar observations were reported from 
an hMRP8–AML1-ETO transgenic mouse model, which developed 
AML as well as T–acute lymphoblastic leukemia/lymphoma (T-ALL/
lymphoma) only after ENU mutagenesis (7), and from a murine BM 
transplantation model inducing constitutive expression of AML1-
ETO in hematopoietic progenitor cells by retroviral gene transfer 
(8). In a recent report, mice targeted to express AML1-ETO in the 
HSC compartment developed a nonlethal long-latency myeloprolif-
erative syndrome but failed to develop acute leukemia (9).
To test the hypothesis of oncogenic cooperation between differ-
ent classes of mutations, we analyzed a series of 135 patients with 
AML1-ETO–positive AML for the occurrence of activating muta-
tions involving signal transduction pathways (FLT3-LM, FLT3D835, 
KITD816, NRAS codon 12/13/61). Because almost one-third of all 
AML1-ETO–positive patients had such activating mutations, we 
asked whether AML1-ETO would be able to collaborate with 1 of 
Nonstandard	abbreviations	used: ALL, acute lymphoblastic leukemia; AML, acute 
myeloid leukemia; B6C3, C57BL/6J × C3H/HeJ (mice); CBF, core-binding factor;  
CFU-S, colony-forming spleen unit(s); cy, cytoplasmic; ENU, N-ethylnitrosourea; 
FLT3-LM, FLT3 length mutation; GSF, National Research Center for Environment 
and Health; IRES, internal ribosomal entry site; KD, kinase dead; LTR, long-terminal 
repeat; MSCV, murine stem cell virus; PepC3, C57BL/6Ly-Pep3b × C3H/HeJ (mice); 
VCM, virus-containing medium; YFP, yellow fluorescent protein.
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these alterations to induce leukemia. Here we demonstrated that 
retrovirally engineered coexpression of AML1-ETO and FLT3-LM 
potently synergizes to trigger the development of aggressive leu-
kemia in a murine transplantation model.
This model will allow valuable insights into the pathogenesis 
of core-binding factor (CBF) leukemias and demonstrates, for 
the first time to our knowledge, the functional collaboration of 
AML1-ETO with a class of activating mutations frequently found 
in patients with t(8;21)–positive leukemia.
Results
AML1-ETO occurs frequently together with activating mutations involving 
signal transduction pathways in patients with AML. In order to charac-
terize genetic alterations that occur together with the AML1-ETO 
fusion gene in AML, 135 patients with AML1-ETO (93 male, 42 
female; median age 50.9, range 15.8–89.1) were screened for activat-
ing mutations in the receptor tyrosine kinases FLT3 and KIT as well 
as in NRAS (KITD816, NRAS codon 12/13/61). Patients included 118 
with newly diagnosed AML, 4 in first relapse, and 13 classified as 
having therapy-related AML. Activating mutations were detected in 
38 patients (28.1%) and included mutations in the receptor tyrosine 
kinase FLT3 or KIT (25 patients in total) or in NRAS (13 patients). In 
contrast, no MLL-PTD (partial tandem duplication) mutations were 
detected in 87 samples subjected to this analysis (Table 1). These 
data demonstrate that genetic alterations occurring with the AML1-
ETO fusion gene frequently affect signal transduction pathways.
AML1-ETO cooperates with FLT3-LM in inducing acute leukemia in trans-
planted mice. To test the functional significance of the association of 
AML1-ETO with mutations involving critical signal transduction 
cascades, we used the murine BM transplantation model. Murine 
stem cell virus–based (MSCV-based) retroviral constructs carrying 
the AML1-ETO cDNA upstream of an internal ribosomal entry site–
green fluorescent protein (IRES-GFP) cassette or the FLT3-LM cDNA 
upstream of an IRES–yellow fluorescent protein (IRES-YFP) cassette 
were generated to transduce and track hematopoietic cells expressing 
AML1-ETO (GFP+), FLT3-LM (YFP+), or both AML1-ETO and FLT3-
LM (GFP+/YFP+) in vitro and in vivo (Figure 1). In order to investigate 
the impact of expression of AML1-ETO or FLT3-LM individually on 
primary primitive hematopoietic progenitor cells, we performed the 
colony-forming spleen assay (CFU-S). BM cells transduced with the 
AML1-ETO/GFP or FLT3-LM/YFP vector or both vectors were highly 
purified 96 hours after the start of infection by FACS. Their ability 
to form spleen colonies (day 0 equivalent) was measured by trans-
plantation of transduced cells after purification into lethally irradi-
ated recipient mice and quantification of spleen colony formation 
12 days after injection. Constitutive expression of FLT3-LM did not 
increase the CFU-S content compared with the GFP control. In con-
trast, AML1-ETO increased the CFU-S content 3.1-fold compared 
with the control (P < 0.002). Strikingly, coexpression of FLT3-LM 
together with AML1-ETO increased CFU-S numbers a further 2.1-
fold for a net increase of 6.5-fold CFU-S compared with the control 
(P < 0.013), thus demonstrating functional collaboration of these 2 
genetic alterations in enhancing the CFU-S frequency (Figure 2A). In 
an effort to characterize the domains responsible for the collabora-
tion of the 2 aberrations, an FLT3-LM and an AML1-ETO mutant 
were generated: the FLT3-LM mutant with loss of its kinase activ-
ity (kinase dead [KD]) (FLT3-LM-KD) and the AML1-ETO mutant 
with an L148D point mutation in the Runx1 domain of AML1-ETO 
(AML1-ETO-L148D), previously reported to lack DNA-binding 
activity. Expression of the constructs was tested by Western blot and 
FACS analysis, and FLT3-LM-KD was also tested for autophosphory-
lation as a surrogate marker for kinase activity and for its capacity 
to induce IL-3–independent growth in Ba/F3 cells (Figure 1, B, D, F, 
and G). Of note, AML1-ETO-L148D was not able to collaborate with 
FLT3-LM. Furthermore, the collaboration between AML1-ETO and 
FLT3-LM was dependent on the kinase activity of FLT3, as FLT3-
LM-KD did not collaborate with the fusion gene (Figure 2A). Inhibi-
tion of the kinase activity of FLT3-LM by the protein tyrosine kinase 
(PTK) inhibitor PKC412 was tested in a ∆CFU-S assay after 48 hours 
of incubation with the inhibitor. The compound induced a 62% 
reduction of the day 0 equivalent of the CFU-S frequency (42 versus 
16 per 1 × 105 initiating BM cells) of cells cotransfected with FLT3-LM 
and AML1-ETO compared with the untreated control, whereas the 
CFU-S frequency of cells infected with the GFP control vector was 
unchanged by the inhibitor (Figure 2B).
To further assess the potential collaboration of AML1-ETO with 
FLT3-LM, we carried out  long-term BM transplantation stud-
ies using BM transduced with AML1-ETO or FLT3-LM alone or 
with both together. Over an observation period extending to 20.6 
months, no disease developed in recipients of BM singly transduced 
with AML1-ETO (3 × 105 to 4 × 105 highly purified GFP+ cells; n = 9) 
or FLT3-LM (7 × 104 to 2 × 105 highly purified YFP+ cells together 
with 3 × 105 to 1 × 106 nontransduced helper cells; n = 9). To obtain 
mice engrafted with AML1-ETO/FLT3-LM–coexpressing BM cells, 
mice were injected with a mixture of GFP+/YFP+ cells (range 1 × 103 
to 5.5 × 104 cells) and nontransduced normal BM cells  (range 
2.3 × 105 to 1.9 × 106). All recipients of doubly transduced BM (n = 11 
from 5 independent experiments) succumbed to an aggressive acute 
leukemia after a median latency time of 233 days post-transplan-
tation (Figure 3). These mice were engrafted with GFP/YFP–coex-
pressing cells that were positive for AML1-ETO and FLT3-LM tran-
scripts in the RT-PCR analysis (Figure 1C). At diagnosis the mice 
were moribund, cachectic, and short of breath and suffered from 
splenomegaly (median spleen weight 441 mg) (Table 2). Peripheral 
blood and BM contained a high proportion of blasts, and peripheral 
blood wbc counts were highly elevated in 5 of 11 animals (range 
2 × 106 to 430 × 106 cells/ml) compared with the GFP control (range 
3.5 × 106 to 9 × 106) (Table 2), consistent with a diagnosis of acute 
leukemia. Additionally, mice were anemic, with a 45% reduction in 
erythrocyte counts compared with the mean count in the control.
Coexpression of AML1-ETO and FLT3-LM causes both acute myeloblas-
tic and lymphoblastic leukemia. In 7 animals the morphology of the 
blasts was myeloblastic (Figure 4A), whereas 4 animals were char-
acterized by a lymphoblastic cell population (Figure 4, B and C, 
and Table 2). In 2 of the 7 animals with AML (mice nos. 16 and 24) 
the blast population was accompanied by a dominant mast cell 
Table 1
Genetic alterations in patients with AML1-ETO rearrangement
	 No.	of	patients	 No.	of	patients		
	 analyzed	 with	mutation		
	 	 detected
FLT3-LM 135 11 (8.1%)
FLT3D835 135 3 (2.2%)
KITD816 135 11 (8.1%)
NRAS codon 12/13/61 135 13 (9.6%)
FLT3, KIT, or NRAS mutation 135 38 (28.1%)
MLL-PTD 87 0
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population with fine metachromatic granulation in the panop-
tic staining (Figure 4A). The BM and spleen were infiltrated with 
up to 80% and 80% blasts, respectively, in the mice with AML and 
up to 85% and 95%, respectively, in the mice suffering from ALL 
(Table 2 and Figures 4 and 5).
In order to determine more precisely the immunophenotype of the 
leukemic population, flow cytometric analyses from BM cells were 
performed. Seven animals suffered from AML with a Gr-1/Mac-1– 
positive cell population in the transduced compartment, which 
coexpressed Sca-1 (45.2%, range 19–73%). Of note, in 4 of the 7 ani-
mals with AML, coexpression of CD4 was detected in 21%, 27%, 31%, 
and 32% of BM cells (animals nos. 15, 16, 22, and 23, respectively; 
Table 2). Three mice suffered from B-lymphoblastic leukemia, with 
90.4% of the transduced cells expressing B220 (range 85–97%) and 
lacking expression of myeloid antigens (Gr-1–positive 1.5%, range 
0.4–2.3%; Mac-1–positive 1.7%, range 1.4–1.9%). One animal devel-
oped T cell leukemia, with coexpression of CD4 and CD8 (99% 
CD8+, 86% CD4+ in the transduced compartment) and expression 
of Sca-1 in 76% of all cells (Figure 4C). Histological tissue sections 
and immunohistochemistry were performed in 2 diseased mice with 
AML, including 1 of the animals with an increase in mast cells in 
the peripheral blood (mouse no. 16). Both animals showed multiple-
organ infiltration into hematopoietic and nonhematopoietic organs 
with effacement of the normal follicular architecture of the spleen 
(Figure 5, D and E [right side]) and an infiltration with leukemic blasts 
in the liver and spleen (Figure 5, A–D and F). Immunohistochemistry 
Figure 1
Schematic diagram and analysis of expression of different constructs. (A) Retroviral constructs for expression of AML1-ETO and of the AML1-ETO-
L148D (31, 47), FLT3-LM, and FLT3-LM-KD mutant proteins. The GFP vector served as a control. AE, AML1-ETO; LTR, long-terminal repeat; RHD, 
runt homology domain; TAF110, TATA-binding protein–associated factor 110; HHR, hydrophobic heptad repeat; ZNF, zinkfinger; TM, transmem-
brane; JM, juxtamembrane; PTK, protein tyrosine kinase; KI, kinase insert. (B, C, and E) Western blot analysis of cellular extracts from GP+ E86 
and NIH 3T3 cells transfected with the different constructs (the molecular mass is indicated). Kasumi cells served as a positive control. (D) a-pTyr 
plot demonstrating phosphorylation of FLT3-LM and FLT3-WT but not of FLT3-LM-KD. (F) FACS analysis of Ba/F3 cells transduced with the FLT3 
constructs. (G) Growth of IL-3–dependent Ba/F3 cells infected with the different constructs. (H and I) Flow cytometry and RT-PCR analysis of cells 
coexpressing FLT3-LM/YFP and AML1-ETO/GFP, isolated from a representative leukemic mouse. FL, FLT3 ligand; PB, peripheral blood.
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confirmed the diagnosis of AML: blasts were positive for myeloper-
oxidase but showed differentiation into more mature myeloid cells 
with positivity for chloracetatesterase (mouse no. 14; Table 2 and 
Figure 5, B, C, and F). In the second mouse with AML, infiltration of 
organs with cells expressing mast cell–specific tryptase and CD117 
could be confirmed in the primarily and secondarily transplanted 
mouse, indicating the presence of a malignant infiltrating mast cell 
population in this animal (mouse no. 16).
The leukemias were readily transplantable and had the same his-
tomorphology within 106 days after transplantation (median sur-
vival 68 days, range 57–106 days; n = 5) (Figure 3 and Figure 5, G–O). 
Southern blot analyses of BM from leukemic mice revealed modest 
numbers of proviral integrations, consistent with double infection 
and monoclonal or, at most, oligoclonal disease (Figure 6A). Mono-
clonal or oligoclonal disease is consistent with the relatively small 
transplant doses used but could also reflect a possible contribution 
of retroviral insertional mutagenesis to the transformation process. 
To further explore this latter possibility, 10 retroviral integration 
sites were subcloned and sequenced from 4 leukemic mice; all 10 sites 
were unique, and thus there was no indication of a common integra-
tion site associated with the leukemic transformation. Moreover, 5 
sites were intergenic or not linked to known genes. The remaining 
sites were in introns in a 5′ to 3′ orientation most likely to lead to 
gene knock down rather than activation (Figure 6B and Table 3).
Since we observed coexpression of CD4 in leukemic cells of the 
majority of mice who developed AML in our model, we analyzed 
expression of CD4 and cytoplasmic (cy) CD3 in patients with 
AML1-ETO–positive AML; 17 of 52 patients analyzed (32.7%) and 
39 of 50 patients analyzed (78%) were positive for CD4 or cyCD3, 
respectively. Furthermore, 31 of 52 patients (59.6%) expressed the B 
cell antigen CD19, 27 of 52 patients cyCD22 (51.9%), and 38 of 39 
patients cyCD79a (97.4%) (Figure 7). There was no difference in the 
extent of coexpression of lymphoid antigens in AML1-ETO–posi-
tive AML with additional activating mutations of FLT3, KIT, and 
NRAS (n = 14) versus cases without this class of mutations (n = 38) 
(data not shown). This indicates that coexpression of lymphoid 
and myeloid antigens in myeloblastic leukemia, which is detected 
in the murine model, is a common characteristic in patients with 
AML1-ETO–positive AML.
Discussion
The translocation t(8;21)(q22;q22), which generates the AML1-ETO 
fusion gene, is one of the most frequent chromosomal translocations, 
detected in 12% of all AML patients and in up to 40% of FAB-M2 
AML patients (10, 11). The translocation targets AML1 (RUNX1), a 
member of the RUNX family characterized by a DNA-binding Runt 
domain at the amino terminus that is retained in the fusion gene 
(12). This domain is necessary for DNA binding and heterodimer-
ization of AML1 with CBFB, the non–DNA-binding subunit of the 
complex. As predicted by the discovery that the AML1 gene is rear-
ranged in human hematopoietic disease, the AML1/CBFB complex 
was shown to be a key regulator of definitive hematopoiesis, and loss 
of either of these genes resulted in embryonic lethality with complete 
lack of definitive HSCs (13). In addition, it was recently reported that 
AML1+/– adult mice suffer from a 50% reduction of long-term repopu-
lating stem cells (14). Although it is yet not fully understood how the 
Figure 2
Analyses of CFU-S frequencies. (A) Primary BM cells retrovirally trans-
duced with GFP, AML1-ETO, AML1-ETO-L148D, FLT3-LM, or FLT3-
LM-KD vectors or with combinations of the different vectors were isolated 
by FACS 48 hours after infection and injected into lethally irradiated mice 
to assess initial (day 0) CFU-S numbers. CFU-S frequency per 1 × 105 
initiating BM cells was determined in 3 independent experiments. The 
number of analyzed mice and the P value compared with the GFP con-
trol are indicated. (B) CFU-S frequency of primary BM cells infected 
with GFP or with both AML1-ETO and FLT3-LM and treated with the 
inhibitor PKC412 for 48 hours compared with untreated controls.
Figure 3
Survival of transplanted mice. Survival curve of mice transplanted with 
BM cells expressing AML1-ETO (n = 9), FLT3-LM (n = 9), or GFP (n = 12), 
of mice transplanted with marrow cells coexpressing AML1-ETO and 
FLT3-LM (n = 11), and of secondarily transplanted mice (n = 5).
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AML1-ETO fusion gene contributes to leukemogenesis, it is thought 
that 1 key mechanism is the suppression of AML1- and C/EBPa-
dependent activation of genes responsible for myeloid development 
(15, 16). Perturbation of hematopoiesis by expression of AML1-ETO 
results in an increase in the replating capacity of murine clonogenic 
progenitors and in the growth of primitive human progenitor cells in 
vitro (6, 17). Furthermore, in vivo and ex vivo analyses demonstrated 
alterations in the differentiation pattern and proliferative capacity of 
murine hematopoietic cells expressing the fusion gene (8, 9, 18, 19). 
However, numerous murine in vivo models documented that AML1-
ETO on its own is not able to induce leukemia (6, 7, 9, 18, 19). The 
observation that AML1-ETO as a single factor is nonleukemogenic 
is further supported by findings that nonleukemic AML1-ETO–
expressing progenitor cells can be isolated from healthy individuals 
as well as AML patients in remission, which suggests that additional 
mutations in these AML1-ETO–positive progenitors are necessary 
for the transformation into leukemia-initiating cells (20–22). The 
importance of collaborating genetic events in the pathogenesis of 
AML1-ETO–positive leukemias has indeed been shown in different 
murine models, such as a conditional AML1-ETO murine model as 
well as an hMRP8–AML1-ETO transgenic mouse model. Only mice 
treated additionally with ENU developed AML or T cell lymphoma 
(6, 7). Furthermore, retrovirally expressed AML1-ETO induced myelo-
blastic transformation in vivo only in a background deficient in the 
IFN-regulatory factor IFN consensus sequence-binding protein (18). 
These data strongly suggest that genetic alterations cooperating with 
AML1-ETO play a role in inducing leukemia. 
In order to characterize genetic alterations that potentially col-
laborate with AML1-ETO, we screened 135 patients with AML for 
activating mutations of signal transduction pathways or mutations 
affecting the MLL gene. Whereas MLL-PTD mutations, which exem-
plify genetic alterations involved in transcriptional regulation, were 
not found at all, 28% of the patients were positive for activating 
mutations such as FLT3-LM, FLT3D835, KITD816, or NRAS. The 
frequent coexistence of such mutations with AML1-ETO fits well 
in the model of leukemogenesis in which the collaboration of 2 
classes of genetic alterations, 1 affecting transcription factors asso-
ciated with hematopoietic differentiation, the other affecting signal 
transduction pathways associated with cell proliferation, is neces-
sary for the malignant transformation of hematopoietic progenitor 
cells (3). Using the murine BM transplantation model, we obtained 
direct evidence for a functional collaboration of AML1-ETO with 
FLT3-LM in inducing leukemia, supporting the aforementioned 
model of leukemogenesis. Furthermore, these data demonstrate 
the collaboration of the 2 most frequent genetic alterations in AML, 
providing an important model for the understanding of both the 
AML1-ETO–positive and the FLT3-LM–positive leukemias.
Of note, 4 of 7 AML mice reported here expressed the T cell anti-
gen CD4. Although the mechanisms underlying the coexpression 
of myeloid and lymphoid antigens in AML1-ETO–positive myeloid 
leukemia are not clear, one possibility is that in this AML subtype 
an early progenitor cell with a lineage-overlapping mixed phenotype	
is the target of leukemogenic transformation, as recently proposed 
for hematological malignancies (23). Of note, it was recently demon-
strated that, in AML1-ETO–positive leukemia, evidence of lineage 
overlap is not restricted to the expression of cytoplasmic or surface 
antigens but extends to the transcriptional apparatus, since PAX5 
is selectively expressed in one-third of patients with t(8;21) AML in 
Table 2
Hematological parameters of analyzed experimental mice
Mouse		 Retroviral		 Day	of		 rbc/ml	 wbc/ml		 Spleen	size		 Spleen	weight		 BM		 Spleen		 PB		
no.	 construct	 sacrifice	 	×	109 ×	106 (mm)	 (mg)	 %	blasts	 %	blasts	 %	blasts
1 GFP  ND 4.8 7.6 ND ND 1 0 0
2 GFP  ND 6.4 8.1 ND ND 0 0 0
3 GFP  90 7 5 14 × 4 51 2 0 0
4 GFP  ND 5.4 9 ND ND 0 0 0
5 GFP  689 5.6 4.5 15 × 4 78 0 0 0
6 GFP  721 7.25 3.5 ND ND 3 0 0
7 AE 444 6 13 13 × 3.5 63 8 0 0
8 AE 479 3.1 15 14 × 4 60 11 0 0
9 AE 493 5.7 6.9 14 × 4 82 2 0 0
10 AE 615 5 7.6 16 × 5 117 14 0 0
11 FLT3-LM 88 4.5 10 15 × 4 95 4 ND 0
12 FLT3-LM  ND 4.5 13 ND ND 2 ND 0
13 FLT3-LM  ND 5.6 8.3 ND ND 1 ND 0
14A AE/FLT3-LM 233 ND 23 27 × 7 600 80 52 20
15A AE/FLT3-LM 100 0.85 26.5 19 × 6 166 48 80 75
16A AE/FLT3-LM 612 1.7 12.5 14 × 4 118 20 50 25
17B AE/FLT3-LM 84 ND 430 24 × 9 572 80 22 60
18B AE/FLT3-LM 84 4.4 3.3 21 × 7 270 85 43 62
19B AE/FLT3-LM 94 7.7 7.2 12 × 4 ND 85 20 95
20B AE/FLT3-LM 96 3.8 60 21 × 6 310 40 95 60
21A AE/FLT3-LM 269 4 2 28 × 9 650 38 62 30
22A AE/FLT3-LM 303 2.6 10 15 × 3 200 24 76 38
23A AE/FLT3-LM 304 2.6 2.5 29 × 10 1,400 27 55 78
24A AE/FLT3-LM 359 2.5 35 28 × 9 760 39 77 64
AAML; BALL. PB, peripheral blood; ND, not determined; AE, AML1-ETO.
research article
2164	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 115      Number 8      August 2005
contrast to all other cytogenetically defined AML subtypes (24). Fur-
thermore, both myeloblastic and lymphoblastic leukemias of B and 
T cell type developed in this model of AML1-ETO and FLT3-LM coop-
eration. This observation was also reported in other murine models: 
in a conditional AML1-ETO murine model, mice treated additionally 
with ENU developed AML as well as T cell lymphoblastic lymphoma, 
although most of the T cell neoplasms did not express the fusion 
gene (6). Similar observations were reported from an hMRP8–AML1-
ETO transgenic mouse model, which developed AML as well as 
T-ALL/lymphoma after ENU treatment (7). In addition, expression 
of AML1-ETO might contribute to the lymphoid phenotype of the 
leukemias in our model, as it was reported that FLT3-LM is able to 
induce a long-latency T cell lymphoma–like disease in the C57BL/
C3H background (25). However, the association of FLT3-LM with a 
lymphoid disease seems to depend on the genetic background of the 
mouse strain, as FLT3-LM induced a myeloproliferative syndrome in 
BALB/c mice (26). In our model, also using the C57BL/C3H back-
ground, constitutive expression of FLT3-LM alone did not induce any 
perturbation of the hematopoietic development in vivo; this result 
was also recently reported in a mouse model of collaboration of 
FLT3-LM with MLL-SEPT6 using the C57BL/6 strain (27).
Of note, overexpression of FLT3 and activating FLT3 mutations 
are associated with ALL in humans, in particular in cases of ALL 
with hyperdiploidy or MLL rearrangement, characterized by a primi-
tive B cell or a mixed lymphoid-myeloid phenotype (28–30). The 
observations that ETV6-PDGFBR, which already by itself causes 
a lethal myeloproliferative syndrome in transplanted mice, induc-
es exclusively a myeloblastic leukemia when coexpressed with 
AML1-ETO might point to the importance of the collaborating 
partner for the phenotype of the induced leukemia (31). Another 
possible explanation for the development of lymphoid malignan-
cies in our model is that, in individual mice, lymphoid-commit-
ted stages of differentiation were hit by the retrovirus, resulting 
in lymphoblastic leukemia in these animals. This would poten-
tially be a key difference from the human situation, in which 
both AML1-ETO and FLT3-LM are already present in the HSC 
pool (21, 32). An important question is whether the results were 
influenced by retroviral insertional mutagenesis. Most of the leu-
kemic animals were transplanted with a low transplant dose and 
then suffered from monoclonal or oligoclonal disease. Although 
the number of retroviral integration events was low in the mice, 
insertional mutagenesis might have contributed to the leukemo-
genesis. However, analyses of the retroviral integration sites in the 
diseased animals showed integration into intergenic regions or 
introns of genes, more likely resulting in their knock down than 
in their activation. These data suggest that retroviral insertional 
mutagenesis might not play the key part in disease development, 
an issue that might be more accurately addressed in mouse mod-
els expressing AML1-ETO from an endogenous promoter. The 
long latency of the leukemias, even of secondary disease, however, 
strongly argues that additional secondary in vivo genetic events 
in the animals contributed to disease development.
To our knowledge, this is the first functional evidence of a leu-
kemogenic collaboration of AML1-ETO with a complementary 
class of mutation, recurrently found in patients with t(8;21). It 
facilitates our understanding of acute leukemias associated with 
2 of the most frequent genetic alterations in this disease. Further-
more, our experimental data support recent reports that show 
the functional relevance of activating mutations in patients with 
CBF leukemias [AML1-ETO or CBFB-MYH11] by demonstrating 
a significantly shortened overall and event-free survival for AML1-
ETO–positive leukemias harboring activating mutations of FLT3 
or KIT compared with those without these mutations. In contrast, 
RAS mutations did not affect the treatment outcome (S. Schnittger, 
unpublished observations) (33, 34). In line with these findings, it 
was recently shown that in patients with AML1-ETO–positive leuke-
mia, most leukemic cells at diagnosis additionally harbored muta-
tions in KIT, whereas in 3 patients analyzed in complete remission, 
only the fusion gene, but not the KIT mutation, could be detected 
by PCR; this strongly supports the concept of a stepwise develop-
ment of disease involving 2 collaborating genetic aberrations (35). 
These observations encourage the systematic screening of activating 
mutations in patients with CBF leukemias in prospective clinical 
trials to evaluate more precisely their prognostic impact, and they 
form a rationale to consider treatment strategies targeting the signal 
transduction apparatus in this AML subtype.
Methods
Patient samples. BM samples from 135 adult patients with newly diagnosed 
AML — de novo AML (n = 118), secondary AML after treatment of a previ-
ous malignancy (n = 13), and AML at relapse (n = 4) — were analyzed. The 
diagnosis of AML was performed according to the French-American-Brit-
ish criteria and the WHO classification (36, 37). Cytomorphology, cyto-
chemistry, cytogenetics, and molecular genetics were applied in all cases 
Figure 4
Immunophenotype and morphology of hematopoietic cells recovered from 
leukemic mice. The plots show representative FACS profiles from BM cells 
in comparison with cells from GFP control animals, with indication of the 
proportion of positive cells within the GFP+/YFP+ compartment. The pho-
tographs show cytospin preparations (H&E; magnification, ×630) from 
peripheral blood (A, right image; B and C) and from BM (A, left image). 
(A) AML with a dominant mast cell population (marked by arrows) (mouse 
no. 16). (B) B-ALL (mouse no. 17). (C) T-ALL (mouse no. 20).
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as described below. Both animal and human studies were approved by the 
Ethics Committee of Ludwig Maximilians University and abided by the 
tenets of the revised World Medical Association Declaration of Helsinki 
(http://www.wma.net/e/policy/b3.htm).
Cytogenetic and FISH analysis. Cytogenetic analyses were performed using 
standard techniques. For FISH, a commercially available AML1-ETO probe 
was used according to the manufacturer’s instructions (Vysis Inc.) (38).
PCR. Molecular genetic analysis for AML1-ETO (38), MLL-PTD (39), FLT3-
LM (4), NRAS mutations, FLT3D835, and KITD816 (40) in patient samples was 
performed as has been described previously (41).	In leukemic mice, expression 
of AML1-ETO and FLT3-LM was assessed by RT-PCR in animals transplanted 
with BM cells coexpressing AML1-ETO/GFP and FLT3-LM/YFP. Preparation 
of cDNA was performed as previously described (41). For AML1-ETO the prim-
er forward 5′-ATGACCTCAGGTTTGTCGGTCG-3′ and the primer reverse 
5′-TGAACTGGTTCTTGGAGCCTCCT-3′ (corre-
sponding to positions nucleotide 395 and nucleo-
tide 633 of GenBank accession number D13979, 
respectively) were used; for FLT3-LM the primer 
forward 5′-GCAATTTAGGTATGAAAGCCAGC-
3′ and the primer reverse 5′-CTTTCAGCATTTT-
GACGGCAACC-3′  (corresponding to positions 
nucleotide 1,704 and nucleotide 1,920 of GenBank 
accession number NM_004119, respectively) were 
used. The annealing temperature was 57°C. The 
number of PCR cycles for each gene was chosen 
to stop the reaction in the linear phase of ampli-
fication (35 cycles for AML-ETO and FLT3-LM). 
The integrity of the RNA in all samples was con-
firmed by mβ-2 microglobulin RT-PCR.
For the linker-mediated PCR (LM-PCR), inte-
grated long-terminal repeats (LTRs) and flank-
ing genomic sequences were amplified and then 
isolated  using  a  modification  of  the  bubble 
LM-PCR  strategy  (42,  43).  Aliquots  of  the  cell 
lysates from leukemic mice were digested with 
PstI or Ase (New England Biolabs Inc.), and the 
fragments were ligated overnight at room tem-
perature  to  a  double-stranded  bubble  linker 
(5′-CTCTCCCTTCTCGAATCGTAACCGTTCG-
TACGAGAATCGCTGTCCTCTCCTTG-3′ and 5′-
ANTCAAGGAGAGGACGCTGTCTGTCGAAGG-
TAAGGAACGGACGAGAGAAGGGAGAG-3′). 
Next, a first PCR (PCR-A) was performed on 10 µl 
(one-tenth) of the ligation product using a linker-
specific Vectorette primer (5′-CGAATCGTAACC-
GTTCGTACGAGAATCGCT-3′) (Invitrogen Corp.) 
and an LTR-specific primer (LTR-A: 5′-CAACACA-
CACATTGAAGCACTCAAGGCAAG-3′) under the 
following conditions: 1 cycle of 94°C for 2 min-
utes, 20 cycles of 94°C for 30 seconds and 65°C 
for 1 minute, and 1 cycle of 72°C for 2 minutes. 
The bubble linker contains a 30-nucleotide nonho-
mologous sequence in the middle region that pre-
vents binding of the linker primer in the absence 
of the minus strand generated by the LTR-specific 
primer. A 1-µl aliquot of the PCR-A reaction (one-
fifteenth) was then used as a template for a second 
nested PCR (PCR-B) using an internal LTR-specific 
primer  (LTR-B:  5′-GAGAGCTCCCAGGCTCA-
GATCTGGTCTAAC-3′) and the same linker-spe-
cific Vectorette primer as was used in PCR-A, with the following conditions: 
1 cycle of 94°C for 2 minutes, 30 cycles of 94°C for 60 seconds and 72°C for 
1 minute, and 1 cycle of 72°C for 2 minutes. Ten microliters (one-half) of 
the final PCR-B product was electrophoresed using 2% agarose tris-acetate-
EDTA gel. Individual bands were excised and purified using the QIAEX 
II Gel Extraction Kit (QIAGEN) and then cloned into PCR2.1 (Invitrogen 
Corp.) before sequencing of the integration site of the retrovirus.
Multiparameter flow cytometry. Immunophenotypic analyses were per-
formed as previously described (44). The following combinations of anti-
bodies were used: CD34/CD2/CD33, CD7/CD33/CD34, CD34/CD56/
CD33, CD11b/CD117/CD34, CD64/CD4/CD45, CD34/CD13/CD19, 
CD65/CD87/CD34, CD15/CD34/CD33, HLA-DR/CD33/CD34, CD4/
CD13/CD14, CD34/CD135/CD117, CD34/CD116/CD33, CD90/CD117/
CD34, CD34/NG2(7.1)/CD33, CD38/CD133/CD34, CD61/CD14/CD45, 
Figure 5
Histological analyses of leukemic mice. (A–F) Histological analyses of AML (mouse no. 14). 
Original magnifications: A–C, ×200; inset in C, ×1,000; D and right side of E, ×250; inset in D, 
×650; left side of E, ×400; F, ×400. (G–O) Histological analyses of AML with a dominant mast 
cell population (mouse no. 16). (G–L) Primary recipient. (M–O) Secondary recipient. Original 
magnifications: G and M, ×100; H, J, and N, ×200; I, K, and O, ×400; L, ×600. Mast cells with 
metachromatic granulation in the Giemsa stain are indicated by an arrow. MPO, myeloperoxi-
dase; CAE, N-acetyl-chloroacetate esterase.
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CD36/CD235a/CD45, CD15/CD13/CD33, CD9/CD34/CD33, CD38/
CD34/CD90,  CD34/CD79a/CD19,  TdT/cyCD33/cyCD45,  myeloper-
oxidase/lactoferrin/cyCD15, TdT/cyCD79a/cyCD3, and TdT/cyCD22/
cyCD3. All antibodies were purchased from Beckman Coulter Inc., except 
for CD64 and CD15 (Medarex Inc.), CD133 (Miltenyi Biotec), and myelo-
peroxidase and lactoferrin (CALTAG Laboratories). For the analysis of 
cytoplasmic antigens, cells were fixed and permeabilized before staining 
with FIX & PERM (CALTAG Laboratories). Multiparameter flow cytom-
etry analysis was performed with a FACSCalibur flow cytometer (BD).
The purity of all samples was 80–100%. Furthermore, immunophenotyp-
ing was performed with triple staining in all cases as indicated above, test-
ing simultaneous expression of myeloid and lymphoid antigens to exclude 
contaminating normal lymphoid cells.
In mice, immunophenotypic analysis of single-
cell suspensions from BM, spleen, and peripheral 
blood was performed by flow cytometry (FACS-
Calibur cytometer; BD) using PE-labeled Sca-1, 
Gr-1, Ter-119, and CD4 antibodies and allophy-
cocyanin-labeled Mac-1, Kit, B220, and CD8 anti-
bodies (all from BD Biosciences — Pharmingen), 
as previously described (45). The surface expres-
sion of the FLT3-LM construct and the FLT3-
LM-KD mutant of Ba/F3 cells was confirmed 
by FACS analysis (Figure 2B) using anti–human 
CD135–PE mAb (BD) and an isotype-matched 
IgG1-PE control (Beckman Coulter Inc.).
cDNA constructs and retroviral vectors. For retro-
viral gene transfer into primary BM cells, AML1-
ETO cDNA was subcloned into the multiple clon-
ing site of the modified murine stem cell virus 
(MSCV) 2.1 vector (41) upstream of the enhanced 
GFP (EGFP) gene and the internal ribosomal entry 
site (IRES). The FLT3-LM cDNA was subcloned 
into the identical MSCV vector construct carrying 
the enhanced YFP (Figure 1A). The MSCV vector 
carrying only the IRES-EGFP cassette was used as 
a control. The cDNA of FLT3-LM was kindly provid-
ed by D.G. Gilliland (Harvard Medical School, Bos-
ton, Massachusetts, USA) and contained a 28–amino 
acid duplicated sequence (CSSDNEYFYVDFREYEY-
DLKWEFPRENL) inserted between amino acids 610 
and 611. The AML1-ETO cDNA was provided by S.W. 
Hiebert (Vanderbilt University School of Medicine, 
Nashville, Tennessee, USA).
The  FLT3-LM-KD  mutation  K672R  (a  point 
mutation of Lys644 to Arg that disrupts an ion pair 
with Glu661 that is critical for nucleotide binding 
in FLT3-WT; ref. 46), and the L148D AML1-ETO 
point mutation (31, 47) to prevent AML1-ETO DNA 
binding, were generated from the full-length human 
FLT3-LM cDNA and the AML1-ETO cDNA, respec-
tively, using the QuikChange Site-Directed Muta-
genesis Kit (Stratagene) according to the manufac-
turer’s instructions. The correct sequences of the 
constructs were confirmed by complete nucleotide 
sequencing, and expression was proved by Western 
blot and FACS analysis (Figure 1).
Cell culture. Gag-pol and envelope (GP+ E86) packag-
ing cells, NIH 3T3 cells, and 293T cells were grown in 
DMEM with 10% FBS and 1% penicillin/streptomy-
cin in a humidified incubator at 37°C and 5% CO2. Primary murine BM cells 
were plated in transplant medium consisting of DMEM supplemented with 
15% FBS, 1% penicillin/streptomycin, 6 ng/ml IL-3, 10 ng/ml IL-6, and 100 
ng/ml SCF (tebu-bio GmbH). IL-3–dependent Ba/F3 cells stably expressing 
the empty vector alone, FLT3-WT, FLT3-LM, and FLT3-LM-KD were seeded 
at a concentration of 0.05 × 106 per milliliter in the presence or absence of IL-3 
and FLT3 ligand, as described previously (48). At 72 hours, viable cells were 
counted in a standard hemacytometer after staining with trypan blue.
Retrovirus production. High-titer helper-free retrovirus was produced with 
the constructs above by individual cotransfection of each construct with 
Ecopac (Cell Genesys Inc.) into 293T cells using calcium chloride precipita-
tion. The retrovirus was subsequently collected in the conditioned medium. 
Figure 6 
Analysis of proviral integrations. (A) Southern blot analysis of genomic DNA from differ-
ent primary mice and a secondary recipient to detect clonal proviral integrations. DNA was 
digested with EcoRI, which cuts once in the proviral sequence, and blots were hybridized to 
a GFP/YFP probe. The mouse numbers are indicated (corresponding to those in Table 2). 
S, spleen; PB, peripheral blood; sec. of 21, second mouse of 1° mouse no. 21. (B) Bubble 
PCR analyses of retroviral integration sites in diseased mice. The bands (A–I) were isolated, 
subcloned, and sequenced. A description of the PCR products is given in Table 3. Asterisk 
indicates resolution as 2 unique bands after subcloning and sequencing of integration sites.
Table 3
Identity of retroviral integration sites in diseased mice
LaneA	 PCR		 Gene	 Protein		 Chromosome	 Mouse		
	 productA	 	 family	 	 no.
2 A 1 Intergenic  17qE3 15
 A 2 Intron 1 of Rnf8 alias AIP37 Ring finger  17qA3 
  and 5 kbp 3′ of Pim1 protein 8
3 B  Intergenic  15qE2 16
 C Intron 1 of Ptp4a3 Protein tyrosine  15qD3 
   phosphatase 4a3
4 D Hypothetical gene  10qC2 12
 E Intron 3 of GATA Transcription  6qD1  
   factor
5 F Intergenic  18qD3 
 G Intron 4 of SF3b Splicing factor  8qE1
   subunit b3
6 H Intergenic in intron   3qF1 18
  of hypothetical gene
 I Intergenic in intron   16qA1  
  of hypothetical gene
ALanes and PCR products according to Figure 6B.
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To optimize transduction efficiency, the virus-containing medium (VCM) 
of different constructs was used to transfect GP+ E86 cells to establish sta-
ble packaging cell lines, or to directly infect 5-FU–mobilized BM cells in the 
case of FLT3-LM. Ba/F3 cells were transfected with the different constructs 
as previously described (48, 49).
Mice and retroviral infection of primary BM cells. Parental-strain mice were 
bred and maintained at the GSF animal facility. Donors of primary BM 
cells  [(C57BL/6Ly-Pep3b × C3H/HeJ) F1  (PepC3) mice] and recipient 
mice [(C57BL/6J × C3H/HeJ) F1 (B6C3)] were more than 8 weeks old. Pri-
mary mouse BM cells were transduced as previously described (41). For 
transduction of AML1-ETO, cells were cocultured in transplant medi-
um with AML1-ETO/GFP producer cells irradiated with 40 Gy of 137Cs 
γ-radiation. For infection with the FLT3-LM virus, BM cells were cultured 
in FLT3-LM/VCM, supplemented with cytokines (IL-3, IL-6, and SCF), to 
achieve optimal transduction efficacy. For coinfection with the FLT3-LM 
and AML1-ETO retroviruses, BM cells were cultured on a mixture of 30–50% 
AML1-ETO/GFP and 50–70% FLT3-LM/YFP producer cells in transplant 
medium or FLT3-LM/VCM supplemented with IL-3, IL-6, and SCF. Retro-
viral transfection of primary BM cells with the AML1-ETO mutant L148D 
and the FLT3-LM-KD mutant was performed as described for FLT3-LM, 
by cultivation of the BM in VCM supplemented with IL-3, IL-6, and SCF. 
All transductions were performed with the addition of 5 µg/ml protamine 
sulfate. Infected cells were highly purified (FACSVantage; BD) based on 
expression of GFP (for AML1-ETO alone), expression of YFP (for FLT3-
LM alone), or coexpression of GFP and YFP (for AML1-ETO/FLT3-LM 
cotransduction) before transplantation.
BM transplantation and assessment of mice. FACS-purified transduced BM 
cells or ratios of transduced and nontransduced cells (if less than 3 × 105 
transduced cells per recipient were available) were injected into the tail vein 
of 8- to 10-week-old irradiated recipient F1 (B6C3) mice (800 cGy from a 
137Cs γ-radiation source). Peripheral blood or BM cell progeny of transduced 
cells were tracked using the GFP and/or YFP fluorescence in vivo (41). For 
transplantation of secondary mice, 1 × 106 to 2 × 106 cells of diseased pri-
mary animals were injected into the recipients after 800 cGy irradiation.
CFU-S and ∆CFU-S assay. 5-FU–mobilized primary BM cells  from F1 
(PepC3) donor mice were retrovirally transduced with AML1-ETO; AML1-
ETO-L148D; FLT3-LM; FLT3-LM-KD; both AML1-ETO and FLT3-LM; 
both AML1-ETO and FLT3-LM-KD; or both AML1-ETO-L148D and 
FLT3-LM. Cells transfected with the empty GFP vector served as control. 
Successfully transduced cells were isolated 48 hours after termination of 
infection by FACS (FACSVantage; BD). To assess initial (day 0) CFU-S 
numbers, purified cell populations were injected into lethally irradiated 
F1 (B6C3) recipient mice 96 hours after the start of infection (45). To 
study the effect of the selective protein tyrosine kinase inhibitor PKC412 
on double-positive cells, freshly sorted cells were cultured in transplant 
medium with 0 and 100 nM PKC412. After 48 hours, the cells were injected 
into lethally irradiated mice as described above, and the day 0 equivalent of 
the CFU-S frequency was calculated for both experimental groups. In this 
∆CFU-S assay the base-line frequency of CFU-S is lower than in the CFU-S 
assay. The recovery of CFU-S cells was quantified by determination of the 
number of macroscopic colonies on the spleen at day 12 postinjection	after 
fixation in Telleyesniczky’s solution.
Southern blot. Genomic DNA was isolated from BM, spleen, and peripheral 
blood of diseased mice with DNAzol as recommended by the manufacturer 
(Invitrogen Corp.). Southern blot analysis was performed as previously 
described (45). DNA was digested with EcoRI and probed with a 32P-labeled 
GFP/YFP DNA. Hybridizing bands were visualized by autoradiography.
Western blot. Protein expression of AML1-ETO, AML1-ETO-L148D, FLT3-
LM, and FLT3-LM-KD was demonstrated by Western blotting using stan-
dard procedures (41). Membranes were probed with an anti-ETO polyclonal 
goat antibody and an anti-FLT3 polyclonal rabbit antibody (Santa Cruz 
Biotechnology Inc.). Protein expression of FLT3-LM showed 2 bands, as 
previously reported: in detail, the FLT3 receptor occurs in 2 different forms 
due to glycosylation that can be resolved in SDS-PAGE gradient gels — a 
158- to 160-kDa membrane-bound protein that is glycosylated at N-linked 
glycosylation sites in the extracellular domain and an unglycosylated 130- 
to 143-kDa protein that is not membrane bound (50–52). Phosphorylation 
of FLT3 was tested by Western blot using 293T cells that were starved for 12 
hours at 37°C, 5% CO2. After cell harvesting and lysis, 300 µg of the lysates 
was immunoprecipitated with polyclonal rabbit anti-FLT3 antibody (s-18; 
Santa Cruz Biotechnology Inc.). Immunoprecipitates were analyzed by 
SDS-PAGE with mouse monoclonal anti-phosphotyrosine antibody (PY-99; 
Santa Cruz Biotechnology Inc.) and reprobed with anti-FLT3 antibody.
Histology. For histological analyses, sections of selected organs were pre-
pared and stained at the Academic Pathology Laboratory, GSF (Munich, 
Germany), using standard protocols, as previously described (41). The mast 
cell–specific tryptase and the CD117 antibody were purchased from Dako-
Cytomation. All the tumors were histopathologically classified according 
to the Bethesda proposals for classification on nonlymphoid and lymphoid 
hematopoietic neoplasms in mice (53, 54).
Statistical analysis. Data were evaluated using the 2-tailed Student’s 
t  test for dependent or independent samples (Microsoft Excel 2002, 
Microsoft Corp.). Differences with P values less than 0.05 were consid-
ered statistically significant.
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Figure 7
Expression of lymphoid antigens on 52 samples of patients with AML1-
ETO–positive AML, determined by immunophenotyping. Samples 
were defined as negative for expression of cytoplasmic antigens when 
less than 10% of the cells stained with the antibody, and as negative 
for expression of surface antigens when less than 20% of the cells 
stained with the antibody (shaded areas).
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Summary
A challenge for the development of therapies selectively targeting leukemic stem cells in acute myeloid leukemia (AML) is
their similarity to normal hematopoietic stem cells (HSCs). Here we demonstrate that the leukemia-propagating cell in mu-
rine CALM/AF10-positive AML differs from normal HSCs by B220 surface expression and immunoglobulin heavy chain rear-
rangement. Furthermore, depletion of B220+ cells in leukemic transplants impaired development of leukemia in recipients.
As in the murine model, human CALM/AF10-positive AML was characterized by CD45RA (B220)-positive, IG DH-JH rear-
ranged leukemic cells. These data demonstrate in a murine leukemia model that AML can be propagated by a transformed
progenitor with lymphoid characteristics, which can be targeted by antibodies that do not crossreact with normal HSCs.Introduction
For most cancers, the cell that propagates tumor growth and is
thought to play a key role in recurrence of disease is unknown.
The study of normal and malignant hematopoiesis has formed
a roadmap for the detailed analysis of the concept of the tu-
mor-initiating cell and has demonstrated that, in leukemia, the
malignant clone is organized in a hierarchy in which only a small
subpopulation of cells—the leukemic stem cells (LSCs)—are
able to initiate and propagate the disease (Hope et al., 2004).
In AML most studies indicate that malignant transformation tar-
gets cells within the hematopoietic stem cell compartment.
However, more recent data demonstrated that multipotentialCANCER CELL 10, 363–374, NOVEMBER 2006 ª2006 ELSEVIER INC. Dprogenitors or more committed myeloid progenitors can also ac-
quire leukemic stem cell properties when transformed by appro-
priate oncogenes (Cozzio et al., 2003; So et al., 2003). These re-
ports clearly demonstrated that cells other than hematopoietic
stem cells can be the target of fully transforming oncogenes,
which are characterized by their ability to transfer self-renewal
potential to committed stages of differentiation (Huntly et al.,
2004; Jamieson et al., 2004). The identification of leukemic
stem cell properties is a key step for an improved understanding
of the biology of acute leukemias and might also have clinical im-
plications: because of its essential role for the initiation and
maintenance of the leukemic clone, a curative therapeutic strat-
egy should be able to eradicate the LSC in the diseased patients.S I G N I F I C A N C E
The identification of tumor stem cells is one of the major goals of cancer research. We report on a murine model demonstrating that
myeloid malignancies such as acute myeloid leukemia can be propagated by a transformed progenitor with lymphoid characteris-
tics. These data extend our previous knowledge about leukemia stem cell candidates in acute leukemia and indicate that leukemia-
propagating cells in AML might differ from the myeloid blast population as well as from the normal hematopoietic stem cell in their
surface antigen profile. These findings suggest that such leukemic stem cell candidates can be targeted with antibodies that spare
the normal stem cell pool. This may pave the way for innovative antibody-based therapeutic strategies in this disease.OI 10.1016/j.ccr.2006.08.023 363
A R T I C L EAt the same time, such a strategy should spare normal hemato-
poietic stem cells (HSCs) to avoid intolerable therapy-associ-
ated stem cell toxicity. However, the major challenge for the de-
velopment of such therapeutic approaches is the often striking
similarity between leukemic and normal HSC, e.g., with regard
to their cell surface markers (Reya et al., 2001; Warner et al.,
2004). The limitations of the therapeutic tools available today
are well known: although standard chemotherapy is highly effec-
tive in inducing remissions in patients with AML, the majority of
patients finally relapse and succumb to this disease (Hiddemann
et al., 2005). One of the reasons for treatment failure is that even
dose-intensive conventional chemotherapy is not able to effi-
ciently target the LSC, demonstrated, for example, by the obser-
vation that patients in morphological complete remission harbor
CD34+/CD382 progenitor cells with the leukemia-specific ge-
netic alteration in their bone marrow (Feuring-Buske et al.,
1999). A major step toward the development of stem cell-tar-
geted AML therapies would be the identification of key differ-
ences between normal HSCs and the LSC. It has been reported
that the LSC differs from its normal counterpart by the expres-
sion of CD90 or the interleukin-3a receptor, and in a preclinical
NOD/SCID mouse model a diphtheria toxin (DT) human interleu-
kin 3 fusion protein (DT388IL3) was able to selectively kill LSCs in
patients with different subtypes of AML (Blair et al., 1997; Feur-
ing-Buske et al., 2002; Jordan et al., 2000).
The recent reports demonstrating that acute leukemias can
also arise from transformed committed progenitor cells might
improve the chances to define biological differences between
the LSC and the HSC (Huntly et al., 2004; So et al., 2003). How-
ever, leukemic stem cell candidates such as multipotent progen-
itor cells (MPPs) might be difficult to distinguish from normal
HSCs, although first strategies were established in mice to dis-
criminate MPPs from long-term repopulating stem cells by im-
munophenotype (Forsberg et al., 2005; Morrison et al., 1997).
In this report we present experimental evidence that acute mye-
loid leukemia can be propagated by a transformed progenitor,
which differs from normal hematopoietic stem cells by surface
expression of B220 and immunoglobulin heavy chain (IG
DH-JH) rearrangement. We established a murine model of
CALM/AF10 (C/A)-positive acute myeloid leukemia using the
bone marrow transplantation model and retroviral gene transfer
to constitutively express the fusion gene in hematopoietic pro-
genitor cells. The established model well predicted our findings
in patients with C/A-positive AML, who showed a cell population
expressing CD45RA, the human homolog of B220. This human
CD45RA+ cell population displayed IG DH-JH rearrangements,
was positive for the fusion gene as detected by fluorescence in
situ hybridization (FISH), and was able to form CFU-blast colo-
nies in vitro. In these patients the fusion gene is formed by the
translocation t(10;11) (p13;q14), which involves the CALM gene
(associated with clathrin-mediated endocytosis) and AF10 (a
putative transcription factor). This fusion gene is found in a vari-
ety of leukemias, which are all characterized by a very poor prog-
nosis (Dreyling et al., 1998). Of note, the malignant phenotypes
associated with C/A span AML, undifferentiated leukemia, acute
lymphoblastic leukemia, and T cell lymphoma, thus making it
appealing to determine the nature of the leukemic stem cell
candidate(s) in C/A-positive disease. The results of this study
demonstrate in a murine leukemia model that a transformed
progenitor cell population with lymphoid characteristics can
play a key role in propagating C/A-positive AML.364Results
CALM/AF10 induces acute myeloid leukemia in mice
To test the impact of constitutive expression of C/A on murine
hematopoietic development, we employed the murine bone
marrow (BM) transplantation model. The fusion gene was ex-
pressed in a murine stem cell virus (MSCV)-based retroviral con-
struct carrying the C/A cDNA upstream of an internal ribosomal
entry site (IRES)-green fluorescence protein (GFP) cassette that
has been shown to efficiently transduce hematopoietic stem
and progenitor cells (Figures S1A–S1C in the Supplemental
Data available with this article online).
All mice (n = 13) transplanted with highly purified GFP+ C/A
transduced cells (median retroviral transduction efficiency of
5.7, range 1.2%–16.4%) with or without nontransduced helper
cells developed a disease after a median of 110 days posttrans-
plantation (range 46–366) (Figure 1A) and suffered from ca-
chexia, lethargy, and shortness of breath. Detailed analyses of
the hematopoietic compartments showed a more than 10-fold
elevated white blood cell count in the peripheral blood (PB)
of all animals with a median of 4.9 3 107 cells/ml (range 3.2–
8.5 3 107) compared to the GFP control (median 0.48, range
0.32–0.8 3 107) (p < 0.002). Furthermore, mice were anemic,
with a 7.3-fold reduced median red blood cell count of 0.75 3
109 cells (range 0.6–1.25 3 109) versus 5.5 3 109 (range 4.8–7 3
109) in the control mice (p < 0.0001), and suffered from spleno-
megaly (Table 1). Panoptic staining of PB smears and cytospin
preparations of BM and spleen cells revealed an accumulation
of blasts accounting for medians of 32%, 40%, and 39%, re-
spectively, of all cells (Table 1; Figure 1B). The spleen showed
a massive infiltration with myeloid cells (median of 86.9%
Mac1+ cells [range 72.8%–91.1%] versus 12% in the control
[range 7%–26.5%] and 62.5% Gr1+ cells [range 40%–76.2%]
compared to 9.5% in the control [range 7.5%–11.3%]) (Fig-
ure 1B). Histological sections demonstrated infiltration of blasts
in multiple nonhematopoietic organs, including the brain (Fig-
ure 1C). Immunohistochemistry showed positivity of the blasts
for myeloperoxidase (MPO) and chloracetate esterase and
negativity for B220 and CD3, indicating the myeloid nature of
the population (Figure 1D). Taken together, the mice suffered
from acute myeloid leukemia according to the Bethesda pro-
posal for classification of nonlymyphoid and lymphoid hemato-
poietic neoplasms in mice (Kogan et al., 2002; Morse et al.,
2002).
Transplantation of BM cells of leukemic mice into secondary
recipients (n = 22) rapidly induced leukemia with the same char-
acteristics after a median of 15 days (range 14–21 days) post-
transplantation (Figure 1A). Bone marrow aspirations of anes-
thetized primary recipients 8 weeks posttransplantation did
not show any myeloproliferative or lymphoproliferative syn-
drome before the onset of leukemia (n = 5). Analysis of proviral
integration sites demonstrated oligoclonal disease in primary
and secondary mice (Figure S2). Sequencing of the retroviral in-
tegration sites (n = 18) in the diseased mice showed 10 out of 18
sites in or near regions described as common integration sites
(CIS) in the RTCGD database (http://rtcgd.ncifcrf.gov/) (Akagi
et al., 2004). No recurrent integration sites or any association
of the leukemic phenotype with individual proviral integrations
were observed (Table S1). In summary, these data demon-
strated that constitutive expression of CALM/AF10 induced
short-latency AML in transplanted animals.CANCER CELL NOVEMBER 2006
A R T I C L EFigure 1. CALM/AF10 induces transplantable AML
A: Survival curve of mice transplanted with BM cells expressing CALM/AF10 (n = 13, originating from five independent sets of transduction experiments). The
control group was transplanted with BM infected with the GFP empty retrovirus (n = 6). The survival time of secondary recipient mice, transplanted with BM
from diseased primary CALM/AF10 mice or tertiary recipient mice injected with BM from leukemic secondary mice, is indicated. C/A, CALM/AF10.
B: Cytospin preparations from PB, BM, and spleen and immunophenotype of the spleen of a representative leukemic CALM/AF10 mouse in comparison to
a GFP control animal. Cells were stained for the myeloid markers Gr1 and Mac1 and the lymphoid markers B220, CD4, and CD8. The proportion of positive
cells within the GFP+ compartment is indicated; the CD4/CD8 costaining was gated for GFP+ cells. BM, bone marrow; PB, peripheral blood. Scale bar, 10 mm.
C: Histological analysis of diseased CALM/AF10 mice. Blast infiltration in the different organs is shown (brain, intestine, glomerular and tubular areas of the
kidney, sinusoidal and portal areas of the liver, spleen, and lungs) Scale bar, 100 mm; scale bar in inset picture of spleen, 25 mm.
D: Histochemical and immunohistological analysis of the spleen and liver of a diseased CALM/AF10 mouse. Anti-B220 (Da and Db) and anti-CD3 staining
(Dc) of spleen sections and hematoxylin-eosin (Dd), CAE (De), MPO (Df), and anti-CD3 staining (Dg) of liver sections. MPO, myeloperoxidase; CAE, N-acetyl-
chloroacetate esterase. Scale bars, 100 mm in Db–Dg, 25 mm in Da, 50 mm in Dd.CALM/AF10-induced leukemia is propagated by
a transformed B220+, immunoglobulin DH-JH
rearranged progenitor cell
More detailed analyses of the leukemic BM population (GFP+
cells) revealed that, in addition to a majority of cells expressing
myeloid markers (MM) (Mac1+ cells, 82.9% [68.6]; Gr1+ cells,
86.4% [63.7]), there was a small B220+/MM2 cell population
in all animals obtained from five independent sets of experi-
ments, which accounted on average for 6.7% (62.1%) of theCANCER CELL NOVEMBER 2006cells, comparable to the proportion of these cells in control
mice (on average 9.4% 6 3%). An average of 26.0% (68.6)
and 32.5% (613.2) of the BM cells coexpressed B220 with
Mac1 or B220 with Gr1, respectively (n = 4) (B220+/MM+). Highly
purified cells of the B220+/MM2 population had an immature,
blast-like appearance, whereas the B2202/MM+ population in-
cluded blasts as well as terminally differentiated myeloid cells
(Figure 2A). Interestingly, all three subpopulations, including
the cells expressing solely the MMs Mac1 or Gr1, showed DJ365
A R T I C L ETable 1. Hematological parameters in representative experimental mice
Mouse no.
Retroviral
construct
Day of
sacrifice RBCs/ml 3 109 WBCs/ml 3 107
Spleen
weight (mg)
Percent
BM blasts
Percent spleen
blasts
Percent
PB blasts
IgH DJ
rearrangement
1 C/A 10 0.75 3.5 700 30 32 27 ND
2 C/A 78 0.75 5.0 400 40 30 33 +
3 C/A 85 0.6 8.5 250 65 60 61 +
4 C/A 121 0.82 5.2 300 38 38 31 +
5 C/A 85 0.6 4.8 200 78 40 ND +
6 C/A 86 1.25 3.2 400 ND 42 32 +
7a C/A 67 4 2.5 240 32 29 33 +
8a C/A 98 2.65 ND 350 36 ND 28 2
9 GFP 90 6 0.45 150 0 0 0 ND
10 GFP 157 4.8 0.32 200 0 0 0 ND
11 GFP 85 5 0.36 200 0 0 0 ND
12b GFP ND 4.8 0.76 ND 1 0 0 ND
13 b GFP ND 6.4 0.8 ND 0 0 0 ND
14 GFP 90 7 0.5 51 2 0 0 ND
C/A, CALM/AF10; ND, not determined; RBC, red blood cell; WBC, white blood cell; BM, bone marrow; PB, peripheral blood.
aMice were injected with highly purified B220-negative progenitor cells with IgH in germline configuration.
bDetermined by bone marrow aspiration and bleeding of the mouse.rearrangements of the heavy chain of the IgH locus, indicating
that the myeloid population originated from DJ rearranged cells
(Figure 2A). The bulk leukemic population isolated from dis-
eased mice showed unlimited IL3-dependent growth in vitro
and retained its characteristic phenotype with appearance of
the B220+/MM2 as well as the B220+/MM+ and the B2202/
MM+ population (n = 3).
To determine whether the growth potential differed between
the three subpopulations, single cells of the B220+/MM2,
B220+/MM+, and the B2202/MM+ population were sorted
and tested for their proliferative capacity: strikingly, only the
B220+/MM2 population displayed high clonal proliferative po-
tential at the single-cell level, with a mean seeding efficiency
of 29.3% compared to 1% in the other two populations
(Figure 2B). When competitive transcriptional profiling of highly
purified B220+/Mac12 and B2202/Mac1+ cells was performed
by cDNA microarray analysis, 944 genes out of a total of 3643
present genes were differentially expressed between the two
populations. The gene categories, which were significantly
overrepresented in the B220+/Mac12 cells, comprised genes
linked to mitosis and S phase, to response to DNA damage, to
translation, and to DNA repair and replication. In contrast, the
B2202/Mac1+ cells showed overrepresentation of genes be-
longing to the categories cell death, cell communication, and
actin cytoskeleton organization, reflecting the profound differ-
ences in the transcriptome and the proliferative status between
the two populations (http://www.ncbi.nlm.nih.gov/geo/; GEO
accession number GSE5030) (Figure 2C). Importantly, a single
B220+/MM2 cell isolated from leukemic mice could give rise
to the B220+/MM+ and the B2202/MM+ populations in vitro, fur-
ther indicating the hierarchical organization of the leukemic pop-
ulation (Figure 2D). These B2202/MM+ cells were functionally in-
tact myeloid cells and were able to actively phagocytose yeast
cells (Figure 2D). Furthermore, all the B220+/MM+ and the
B2202/MM+ cells derived from a single B220+/Mac12 cell in vitro
displayed identical genomic DJ rearrangements like the original
progenitor (Figure 2E). In conclusion, these data demonstrated
that the B220+/MM2 cells isolated from leukemic mice are able
to give rise to DJ rearranged myeloid cells and have the highest
proliferative potential at the single-cell level compared to the
MM+ subpopulations.366Next it was determined whether highly purified B220+/MM2
cells generated from a single cell in vitro would be able to cause
acute myeloid leukemia in vivo: all animals (n = 3) succumbed
to acute myeloid leukemia after a short latency time of 35 days
posttransplantation when 1 3 106 cells per mouse were injected.
Thus, the data demonstrated that single B220+/MM2 cells iso-
lated from a leukemic mouse can initiate the leukemia of the
same phenotype as bone marrow cells freshly transduced with
CALM/AF10 retrovirus. In order to test the hypothesis that the
leukemia-propagating cell resides in the B220+/MM2 compart-
ment, we purified the three distinct populations from leukemic
primary recipients and performed limiting dilution transplanta-
tion assays that allowed us to determine the frequency of the leu-
kemia-propagating cell in the three different subpopulations as
previously described (Kroon et al., 1998). Importantly, the fre-
quency of the leukemia-propagating cell was 1 in 36 cells in
the B220+/MM2 population as opposed to 1 in 437 cells in the
B220+/MM+ and 1 in 19,717 cells in the B2202/MM+ compart-
ment. Thus, the frequency of the leukemia-propagating cell
was over 548-fold higher in the B220+/MM2 population com-
pared to the B2202/MM+ population (Figure 3A; Table S2). Strik-
ingly, in our model removal of the B220+ cells from the leukemic
transplant prevented the development of leukemia in mice, in
contrast to the animals, which were transplanted with leukemic
B220+/MM2 cells and died after a median of 34 days posttrans-
plantation (Figure 3B).
To test the possibility that the leukemic stem cells would also
reside in the cell compartment lacking expression of B220 and
the MMs Gr1 and Mac1 (B2202/Gr12/Mac12), bone marrow
cells of leukemic mice were costained with B220-APC, Gr1-
PE, and Mac1-PE: the proportion of this cell population in the
bone marrow was very small, with a median of 0.03% (range
0.01%–0.05%) in four mice tested. Furthermore, only very few
cells expressed the stem cell-associated markers Sca1 and c-
Kit (Figure S3A). To test this population functionally, we highly
purified this subpopulation from leukemic mice and compared
the clonogenic potential of these cells with the B220+/MM2 sub-
population: while the B2202/Gr12/Mac12 population was not
able to form any colonies in vitro, an equal number of B220+/
MM2 cells generated replatable colonies with a frequency of
85 6 13 blast colonies per 1000 cells (data from three miceCANCER CELL NOVEMBER 2006
A R T I C L EFigure 2. Transformed B220+/MM2 cells are IgH DH-JH positive and can generate IgH DH-JH rearranged myeloid cells at the single-cell level
A: Morphology and genomic DH-JH recombination of the immunoglobulin locus in different populations. Wright-Giemsa-stained cytospins of highly purified
B220+/MM2, B220+/MM+, and B2202/MM+ cells and the genomic DH-JH status in different highly purified subpopulations from a representative leukemic
CALM/AF10 mouse. DH-JH status in B220+/Mac12, B220+/Mac1+, B2202/Mac1+, B220+/Gr12, B220+/Gr1+, and B2202/Gr1+ cells is indicated; the myeloid cell
line 32D was used as a DH-JH naive germline control. GL, germline; MM, myeloid marker. Scale bar, 10 mm.
B: Seeding efficiency of the different populations. Single-cell sorting of the three subpopulations, B220+/Mac12, B220+/Mac1+, and B2202/Mac1+, isolated
from a leukemic bulk cell population was performed in 96-well plates, and single-cell growth was determined after culture for 4–5 weeks in IL3-supplemented
medium. The mean seeding efficiency for each population is indicated (n = 3, plotted as mean values 6 SD).
C: Distribution of gene categories significantly overrepresented in highly purified B220+/Mac12 compared to B2202/Mac1+ cells (Ca) and in B2202/Mac1+ ver-
sus B220+/Mac12 cells (Cb). Analysis was performed by DNA microarray-based expression profiling using a chip with 20,172 PCR-amplified, sequence-verified,
gene-specific DNA fragments (LION Biosciences).
D: Phagocytosis by B2202/Mac1+ cells derived from a single-cell-sorted B220+/Mac12 cell. Single-cell-sorted B220+/Mac12 cells were expanded in vitro, and
the B2202/Mac1+ cells generated from these cells were tested for phagocytosis of the yeast S. cerevisiae. A representative picture of a B2202/Mac1+ phago-
cytosing cell is shown. Scale bar, 5 mm.
E: Clonal DH-JH rearrangements in the three subpopulations. B220+/Mac12, B220+/Mac1+, and B2202/Mac1+ cells generated from a single B220+/Mac12
sorted cell all showed the identical clonal DH-JH3 and DH-JH4 biallellic rearrangements. Genomic DNA from splenic cells from a nontransplanted mouse
and the myeloid cell line 32D were used as positive and negative controls for recombination, respectively. B, B220+/Mac12; B/M, B220+/Mac1+;
M, B2202/Mac1+.transplanted initially with independently transduced bone mar-
row; input number 100–1000 cells/dish in both arms). Impor-
tantly, the B2202/Gr12/Mac12 cells did not show leukemic
engraftment into secondary recipients or induced leukemia,
whereas as few as 25 B220+/MM2 cells caused leukemic en-
graftment of the same phenotype as described before (input
number between 25 and 113 cells for the B2202/Gr12/Mac12
cells [n = 5] and an equal number of cells per mouse for
the B220+/MM2 population [n = 5]) (Table S3). Taken together,
the high frequency of the leukemia-propagating cell in theCANCER CELL NOVEMBER 2006B220+/MM2 population, together with its ability to proliferate
and to give rise to a myeloid DJ rearranged cell population, dem-
onstrated that the leukemia-propagating cell resided in the
B220+/Mac12 cell compartment in this murine model.
More detailed analysis of the cell surface phenotype of
the B220+/MM2 cells characterized them as CD43+/AA4.1+/
CD24low-pos/FLT3med/IL-7Rlow-neg, c-Kitlow-neg, CD192, and
Sca12 (Figures 4A and 4B). The cells did not express CD21,
CD23, sIgM, l5, Bp1, or Igb (Figures S4A and S4B), or CD4 or
NK1.1 (data not shown). Transcriptional profiling by RT-PCR367
A R T I C L Eshowed lineage-promiscuous expression of the lymphoid fac-
tors EBF, VpreB, and Rag2 and the MM MPO (Figure 4C;
Figure S4C). Importantly, there was no transcription of Pax5,
which is compatible with the incomplete rearrangement status
at the IgH locus (data not shown) and the CD19 negativity of
the cells (Figure 4B). In the B220+/Mac1+ and in the B2202/
Mac1+ cells, transcripts for the M-CSF receptor became detect-
able, whereas transcription for EBF was downregulated. There
was no detectable transcription of Gata3, Zfpn1a3 (Aiolos)
(Figure 4C), or mb1 and only low expression of l5 transcripts
(Figure S4C). In addition, we could not detect rearrangements
of the TCRg receptor, specifically Vg 1.1-Jg4, Vg 2/4-Jg1, or
Vg 5/7-Jg1 by PCR (data not shown). The surface marker ex-
pression as well as the transcription factor expression profile
collectively defined the B220+/MM2 population as a lymphoid
progenitor (Figure S5).
In an effort to determine whether an earlier B220-negative cell
could be transformed by the CALM/AF10 fusion gene, we next
analyzed whether transduction of CALM/AF10 into highly
purified B220-negative cells with IgH germline configuration
Figure 3. Frequency of leukemia-propagating cells
A: Determination of the frequency of leukemia-propagating cells. Cohorts
of secondary mice were injected with highly purified B220+/Mac12, B220+/
Mac1+, and B2202/Mac1+ populations from primary leukemic mice in a lim-
iting dilution assay. The frequency of leukemia-propagating cells in each
population is indicated. Details of cell numbers, number of mice per arm,
and the median latency of disease are described in Table S2.
B: Survival of mice transplanted with leukemic BM depleted of B220+ cells
(B2202/Mac1+cells, n = 11; 50 cells [n = 4], 500 cells [n = 4], and 5000 cells
[n = 3] isolated from the primary leukemic population). In comparison the sur-
vival of mice (n = 12) transplanted with B220+/Mac12 cells with the same
range of cell numbers (50 [n = 4], 500 [n = 4]), and 5000 cells [n = 4]) is shown.368resulted in the induction of AML of the same phenotype as de-
scribed for the transduction of unfractionated bone marrow:
two of two animals tested developed acute myeloid leukemia af-
ter transplantation of 1–2 3 105 B220-negative cells proven to
have IgH germline configuration by PCR before injection, indi-
cating that early B220-negative progenitors with IgH germline
configuration can acquire leukemogenic potential after CALM/
AF10 transduction. However, whereas one of the AML cases
showed B220+ cells with IgH DJ rearrangement as described
before, the other case did not display a B220+ subpopulation.
In addition, the leukemic bulk had a germline IgH configuration,
a phenotype not observed in the transplantation assays using
5-FU-mobilized unfractioned bone marrow for viral infection
(Figure S3B and Table 1). In contrast to early B2202 progenitors,
murine cell populations comprising pro-B cells (B220+/CD43+/
CD252; input number 2 3 106 cells per mouse; transduction
efficiency, 10%) and pre-B cells (B220+/CD43+/CD25+ cells;
input number 2 3 105 cells per mouse; transduction efficiency,
2%) did not acquire in vivo repopulating activity with no short-
or long-term engraftment in lethally irradiated mice 4 or 8 weeks
posttransplantation, respectively (data not shown).
To examine whether our findings in the murine CALM/AF10
leukemia model parallel characteristics of human CALM/AF10-
positive AML, patient samples were analyzed for IG DH-JH rear-
rangement status and the presence of a CD45RA (the human
homolog to B220) population. In addition, we further character-
ized the CD45RA+ population by performing CFU-blast colony
assays in vitro and FISH analysis for the presence of the
CALM/AF10 fusion gene. Table S4 summarizes the characteris-
tics of patients diagnosed with AML or in one case with acute
undifferentiated leukemia (AUL); two of the nine patients were
children, six of nine patients had additional genetic alterations
to the CALM/AF10 t(10;11) translocation. Treatment consisted
mainly of chemotherapy with high-dose Ara-C and anthracy-
clines, and outcome was dismal in all the patients with longer
follow-up. Multiplex PCR and clonality analysis by GeneScan-
ning techniques showed that seven out of nine AML samples
demonstrated clonal IG DH-JH rearrangements (Table 2 and
Figure 5A). We could also detect immature TCRd (Dd2,Vd2)
and TCRb (TCRb DJ) as well as TCRg (Vg10) rearrangements
in six out of six patients tested (Table 2).
In all three patients tested, a substantial proportion of
CD45RA+ cells could be detected, ranging from 50.6% to
99.8% of bone marrow cells. In two of the three patients, the
CD45RA-positive population coexpressed CD34. In all the pa-
tients tested, the CD34+/CD45RA+ cells harbored the CALM/
AF10 fusion gene as detected by FISH analysis (Figure 5Bb)
(Table 3). Furthermore, CD34+/CD45RA+/CD10+ cells, corre-
sponding to the stage of early human lymphoid progenitors
(Haddad et al., 2004), were also positive for the fusion gene
(data not shown). The involvement of the CD45RA population
in the malignant transformation process was further supported
by the observation that the CD45RA population generated my-
eloid CFU-blasts (Table 3) in vitro, which showed the identical
IG DH-JH rearrangement status at a single-colony level as de-
tected in the myeloid bulk population (Figure 5C). To test
whether early CD34+/CD45RA2 cells could be positive for the
CALM/AF10 fusion gene, we highly purified CD34+/CD45RA2/
lineage marker (lin)-negative (lin: CD382/CD192/CD102) cells
of one patient with C/A-positive AML. Notably, the fusion gene
could be detected in the majority of cells (92%) in this primitiveCANCER CELL NOVEMBER 2006
A R T I C L EFigure 4. Leukemic B220+/Mac12 cells express lymphoid markers
A: Expression of B cell-associated markers on leukemic B220+/Mac12 cells: flow cytometric analysis after staining with various markers as indicated.
B: Expression of early and late markers on leukemic B220+/Mac12 cells propagated in vitro for Sca1 (Bb) and c-Kit (Bc) or CD19 (Be); Ba and Bd are controls
as indicated.
C: RT-PCR analysis of lineage associated genes. B220+/MM2, B220+/MM+, and B2202/MM+ cells clonally generated from a single B220+/Mac12 cell were an-
alyzed for the expression of genes associated with different hematopoietic lineages as indicated. B220+ sorted cells from the spleen, Mac1+ sorted cells from
the bone marrow, and unsorted BM cells (all populations isolated from a nontransplanted control mouse) were used as controls for lymphoid and myeloid
transcripts, respectively. MPO, myeloperoxidase; EBF, early B cell factor; HPRT, hypoxanthine phosphoribosyl transferase; B220+/MM2, B220+/Mac12 cells;
B220+/MM+, B220+/Mac1+ cells; and B2202/MM+, B2202/Mac1+ cells.cell compartment (Figure 5Ba, patient number 9), indicating the
involvement of early CD45RA-negative cells in the transforma-
tion process in this patient. In summary, these findings indicate
that patients with CALM/AF10-positive AML are characterized
by IG DH-JH rearrangements of their leukemic blasts and
a CD45RA-positive population, which is positive for the leuke-
mia-specific fusion gene and is able to generate myeloid blast
colonies with the clonal IG DH-JH rearrangement ex vivo,
reminiscent of several characteristics of murine CALM/AF10-
induced AML in transplanted mice.
Discussion
Leukemias are considered to originate from a rare subset of
transformed cells, which are able to initiate and maintain theCANCER CELL NOVEMBER 2006disease. In particular, studies in patients with acute myeloid leu-
kemia have shown that the transformation process involves
early hematopoietic progenitor cells characterized by expres-
sion of CD34 and lack of CD38 and the different lineage markers
(Blair et al., 1998; Dick, 2005). The concept that hematopoietic
stem cells (HSCs) are a key target of leukemic transformation
was further supported by murine models, which demonstrated
that HSCs could acquire leukemic stem cell properties by forced
expression of appropriate oncogenes, recurrently found in pa-
tients with AML (Huntly and Gilliland, 2005; Reya et al., 2001).
Furthermore, inactivation of certain transcription factors such
as JunB caused leukemia only when the targeted deletion
took place in the HSC compartment and not in the more dif-
ferentiated cell pool (Passegué et al., 2004). However, more
recent data have provided in vivo evidence that also more369
A R T I C L ETable 2. IgH DJ and TCR rearrangements in CALM/AF10 AML patients
Patient
no. Type
IgH DJ rearrangements TCR rearrangements
IgH DJ IgH DJ sequences TCRg TCRd TCRb DJ
1 AML M0 monoclonal
DH3
D39/ATTTTGACTGGTTATTATAAC*GT*CTGGTACTT
CGATCTCTGGGGCCT/JH2
monoclonal Vg10 Dd2 biallelic polyclonal
2 AML M2 monoclonal
biallelic
DH2 DH6
D2-15/TGGTAGCTGCTACTC*TT*TACGGTATGGAC
GTCTGGGGCCA/JH6B D6-13/GGGTATAGCAG
C*GGCTACAAGGGT*ACTACTGGGGCCA/JH4B
monoclonal Vg10 Vd2 monoclonal D1
3 AML M1 polyclonal
DH1–7
— polyclonal Dd2/Dd3 biallelic polyclonal
4 AUL monoclonal
DH1
DH1-26/TATAGTGGGAGCTACT*GTG*CTACTGG
GGCCA/JH4B
monoclonal Vg1-8
and Vg10-11
Dd2 monoclonal TCRb
DJ and TCRb JA
5 AML M1 monoclonal
DH7
ND polyclonal Dd2 biallelic polyclonal
6 AML M1 monoclonal
DH7
ND monoclonal Vg10-11 Dd2 biallelic monoclonal
TCRb DJ
7 AML M1 monoclonal
DH6
DH6-6/TATAGCAGCTCGT*TGT*ACTACTTTGACT
ACTGGGGCCA/JH4B
ND ND ND
8 AML monoclonal
DH7
DH7-27/TAACCACTGGGGAC*CTCCCGGG*
CTTTGACTACGGGGCCA/JH4B
ND ND ND
9 AML M5a polyclonal
DH1-7
— ND ND ND
ND, not determined.differentiated cells can acquire properties of leukemic stem
cells: in a murine bone marrow transplantation model, retrovir-
ally driven expression of the MLL-GAS7 fusion gene induced370acute leukemias with myeloid, lymphoid, or mixed phenotype.
Immunophenotyping, transcriptional profiling, and the ability of
the LSC to induce three distinct leukemia subtypes indicatedFigure 5. CALM/AF10-positive human AML samples show IgH DH-JH rearrangements and express CD45RA(B220)
A: GeneScanning analysis of IgH DH-JH rearrangements in nine cases of human CALM/AF10-positive AML using bone marrow of the leukemic patients with
>80% myeloid blasts and polyclonal nonleukemic control cells. GeneScanning demonstrated a clonal IgH DH-JH rearrangement in seven out of nine cases.
Unspecific background peaks resulting from annealing to nonrearranged alleles in the reactions are indicated with an asterisk.
B: Detection of the CALM/AF10 rearrangement in flow-sorted patient cells. Ba: A representative CD34+/CD45RA2/lin2 cell with the CALM/AF10 fusion, showing
a normal AF10 (red) and a normal CALM (green) locus as well as two red/green signals, indicating the two reciprocal fusion genes (arrowheads) (92% of the cells
were positive for the fusion gene; one representative CALM/AF10-negative cell of the same compartment is shown in Bc) (patient number 9). Bb: A represen-
tative CD34+/CD45RA+ cell carrying the CALM/AF10 fusions, showing the same signal pattern as in Ba (fusion signals are indicated by arrowheads) (patient num-
ber 7). Bc: A CD34+/CD45RA2/lin2 cell without CALM/AF10 fusion showing two normal AF10 (red) and two normal CALM (green) signals (patient number 9).
C: Myeloid blast colony formation in methylcellulose of CD45RA+ cells of a representative human AML patient (patient 7, magnification 1003). Lower panel
shows the clonal IgH DJ rearrangement peak from a singly isolated myeloid blast colony analyzed by GeneScan. The rearrangement was identical to the re-
arrangements detected in the leukemic bulk of the patient (Figure 5A).CANCER CELL NOVEMBER 2006
A R T I C L ETable 3. Proportion of CD45RA-positive cells and CFU-blast frequency of C/A-positive AML patients
Patient no.
CD34+/
CD45RA+
Overall
CD45RA+
CD34+/
CD45RA2/lin2b
Positivity for CALM/AF10c
CFU-blast
frequencya
IgH DJ of CFU-blast
coloniesCD34+/CD45RA+ CD34+/CD45RA2/lin2
3 94.52% 98.59% 0.13% + ND 92 6 14 NA
7 96.21% 99.8% 0.01% + ND 12 6 3 monoclonal DH6
9 1.68% 50.6% 33.07% ND + ND ND
ND, not determined; NA, not applicable.
aPer 106 CD45RA+ bone marrow cells isolated from C/A AML patients (0.2–2 3 105 cells plated per dish).
bLineage markers comprised CD38, CD19, and CD10.
cAs determined by CALM- and AF10-specific FISH probes.that the fusion gene targeted a multipotential progenitor in this
murine model (So et al., 2003). In addition, retroviral expression
of the MLL-ENL or MOZ-TIF2 fusion gene in murine myeloid
committed progenitor cells clearly demonstrated that commit-
ted progenitor cells can function as leukemic stem cells in these
models and that transformation of HSC is not mandatory for the
development and maintenance of acute leukemia (Cozzio et al.,
2003; Huntly et al., 2004). The murine data presented here now
provide evidence that a progenitor cell with lymphoid character-
istics can propagate acute myeloid leukemia. Detailed charac-
terization of the leukemic stem cell showed that the cells ex-
pressed B220, CD43, AA4.1, and CD24 but lacked expression
of MMs as well as Sca1. Importantly, transcriptional profiling
demonstrated a lineage-promiscuous expression of lymphoid
factors such as EBF, VpreB, and Rag2 (Busslinger et al., 2000)
with progressive downregulation following differentiation into
the B220+/Mac12 and the B2202/Mac1+ cells together with
the MM MPO. Of note, we did not detect transcription of
Pax5, which is compatible with our finding that the B220+ cells
had an incomplete rearrangement status at the IG DH-JH locus
and did not express CD19. Even though this progenitor showed
characteristics of the early B lineage, the classification of this
CALM/AF10 leukemia-propagating cell according to the differ-
ent B cell classification systems remains difficult because of
its leukemogenic characteristics and the potential impact of
the fusion gene on its cell surface phenotype and transcriptional
network. The phenotype we observed differed from the B220+/
CD19+ cell stage, which is associated with Pax5 positivity and
the entire commitment to the B cell lineage (Hardy, 2003), but
also from the profile of the earliest lymphoid progenitor, the
common lymphoid progenitor (CLP), which lacks expression
of B220 (Kondo et al., 1997).
In our model, a single transformed Pax5-negative progenitor
with lymphoid characteristics was able to generate myeloid
cells with IgH immunoglobulin rearrangements. Interestingly,
Pax52/2 B cell progenitors show lineage-promiscuous tran-
scription of B-lymphoid and myeloid genes, display a remarkable
multilineage potential in vitro, and are able to be directed into the
myeloid lineage (Heavey et al., 2003; Schaniel et al., 2002). In ad-
dition, the latent myeloid differentiation capacity of the CLP,
which does not express Pax5 yet, has become obvious due to
the observation that it can be redirected to the myeloid lineage
by retrovirally induced IL-2Rb chain or GM-CSF receptor
expression (Kondo et al., 2000). Thus, one intriguing possibility
is that CALM/AF10 instructed myeloid development of an early
Pax5-negative lymphoid progenitor in our model. This com-
mitment into the myeloid pathway was irreversible in the C/A
model, as highly purified B220+/Mac12 cells were not able toCANCER CELL NOVEMBER 2006differentiate along the B lineage pathway in vitro on stromal
OP9 feeders in lymphoid growth medium (data not shown).
The scenario that expression of C/A directs the lineage
choice of Pax5-negative lymphoid progenitors is only one po-
tential explanation for the myeloid phenotype of the leukemia.
We cannot exclude that the fusion gene instructed myeloid lin-
eage decision at the later stage of Pax5-positive cells, as it was
recently shown that the myeloid transcription factors C/EBPa
and C/EBPb could convert Pax5-positive B cells into macro-
phages by downregulation of Pax5 expression and upregula-
tion of myeloid genes (Xie et al., 2004). However, we could
not observe any significant downregulation of Pax-5 expression
following CALM/AF10 expression for 48 hr in the in vitro culti-
vated murine pro-B cell line Ba/F3 or primary murine fetal
pre-B cell lines by real-time quantitative PCR and did not ob-
serve repopulating ability of murine pro-B or pre-B cells in le-
thally irradiated mice after transduction with CALM/AF10
(data not shown).
Another important scenario would be that the CALM/AF10 fu-
sion gene targets a rare and early B220-negative progenitor with
IgH germline configuration and activates lymphoid develop-
mental programs in these cells, resulting in a B220+/MM2 IgH
rearranged cell population with high leukemia-propagating po-
tential as described in the murine model. Indeed, highly purified
B220-negative progenitor cells with IgH germline configuration
acquired leukemogenic properties in vivo in two independent
experiments after infection with the CALM/AF10 retrovirus, indi-
cating that an early progenitor cell can be transformed by the fu-
sion gene. Interestingly, one of the mice developed an AML that
lacked a B220+ population and displayed an IgH germline con-
figuration, which was never observed when unfractionated bone
marrow was infected with the CALM/AF10 retrovirus and trans-
planted into recipients. One explanation for this might be that
C/A can target IgH rearranged B220+ lymphoid progenitors, giv-
ing rise to AML with the consistent phenotype of a B220+ trans-
formed progenitor population, as well as early B2202 progeni-
tors with IgH germline configuration, resulting in AML with or
without the B220+ cell population.
Importantly, the experiments performed in this study do not
rule out the other possibility, that the CALM/AF10 fusion gene
had an instructive effect on myeloid progenitors, initiating a lym-
phoid-specific program in these cells. In this scenario a myeloid
cell would acquire lymphoid characteristics as a result of trans-
formation by an appropriate oncogene. Another possibility is
that C/A directly transformed a rare cell subset of B/macro-
phage progenitors, which was identified in fetal liver but also
in adult bone marrow (Lacaud et al., 1998; Montecino-Rodri-
guez et al., 2001). However, this cell was described to be371
A R T I C L ECD19/Pax5 positive and negative for CD45R/B220, a phenotype
different than the phenotype of the LSC described here.
Of note, these different scenarios would result in the develop-
ment of AML with a B220+/MM-negative cell population with
a very high frequency of leukemia repopulating cells, which
would be accessible to an antibody-based B220 depletion. In-
deed antibody-mediated depletion of the B220+/MM2 cells
from leukemic transplants efficiently prevented leukemic devel-
opment in mice, underlining the key role of this population for
disease propagation. One implication of our findings is that in
a subset of AML the leukemia-propagating cell might show a dis-
tinct cell surface and transcriptional phenotype, setting it apart
from the leukemic myeloid bulk population, but also from the
normal stem cell pool. In particular, the expression of lymphoid
antigens would allow to discriminate this cell from the normal he-
matopoietic stem cells, which would facilitate the development
of treatment strategies using the lymphoid surface antigens to
target the leukemia-propagating cell but to spare the normal
stem cell (Passegué et al., 2003). As illustrated in the murine
CALM/AF10 leukemia model, such a strategy would have thera-
peutic potential. Depletion of the B220+ transformed progenitor
cells would fail to eradicate the malignant clone, if a rare leuke-
mic B220-negative progenitor cell population existed, which
gives rise to the B220+/MM2 population described. But even in
this scenario, diminishing the B220-positive leukemia-propagat-
ing cells would promise clinical benefit, as mice transplanted
with B220-depleted bone marrow failed to develop leukemia
up to an observation time of 100 days, compared to rapid devel-
opment of AML in mice transplanted with B220+ transformed
progenitors.
Recently, substantial progress has been made to characterize
very early stages in human B cell development (Haddad et al.,
2004; Hou et al., 2005; LeBien, 2000; Ryan et al., 1997). These
reports have shown that similar to the murine system these early
human progenitors express the B220 human homolog CD45RA,
as well as CD34 and CD10, but lack CD19 and Pax5 expression.
In an effort to determine potential similarities between the mu-
rine CALM/AF10 AML and human disease, we analyzed nine pa-
tients with CALM/AF10-positive AML. Interestingly, the cases
tested showed a CD45RA population with coexpression of
CD34 in two of three patients. Furthermore, in seven out of
nine patients tested, clonal IgH immunoglobulin rearrangements
could be detected in the myeloid bulk. The leukemic nature of
the CD45RA population in these cases was indicated by the
presence of the fusion gene, its clonal IgH rearrangement, and
its ability to form CFU-blast colonies ex vivo. Interestingly, in
the CD34+/CD45RA2/lin2 progenitor compartment of one pa-
tient we detected a mosaic of cells carrying the fusion gene or
showing normal signal pattern by FISH, indicating that this cell
compartment might be involved in the malignant transformation
process.
In addition to IgH rearrangements, six of six patients were also
positive for clonal rearrangements of the T cell receptor (TCR).
These observations are in line with reports associating the
CALM/AF10 fusion gene with T-ALL, in particular with T-ALLs
expressing the g/d TCR (Asnafi et al., 2003). In the murine model
the constitutive expression of CALM/AF10 failed to induce T cell
leukemia, and the observed myeloid leukemias did not show the
TCRg rearrangements that were analyzed (Vg 1.1-Jg4, Vg 2/4-
Jg1, or Vg 5/7-Jg1). This could be attributable to various factors
predisposing the murine model to leukemias of the myeloid372lineage, such as the cell population initially used for retroviral in-
fection; the in vitro culture conditions with IL3, IL6, and SCF
stimulation before transplantation; or the level of expression of
the fusion gene in the murine system compared to human dis-
ease. However, real-time PCR quantification of CALM/AF10
transcripts showed low CALM/AF10 expression in both the mu-
rine and human myeloid bulk (data not shown). Insertional muta-
genesis was identified as an important factor in murine leukemo-
genesis (Akagi et al., 2004; Suzuki et al., 2002) and might explain
the predisposition to AML development in the CALM/AF10
model: in an analysis of the proviral integration sites in leukemic
mice, 10 of 18 detected sites were described before as common
integration sites or transposon-tagged cancer genes according
to the Retroviral Tagged Cancer Gene Database (RTCGD; http://
RTCGD.ncifcrf.gov/) (Akagi et al., 2004). However, there were no
recurrent insertion sites or a correlation of the integrations with
the consistent phenotype of the leukemias in this model. As de-
scribed for human CALM/AF10-positive T-ALLs (Dik et al., 2005;
Soulier et al., 2005), the murine AML cases also displayed aber-
rant expression of HoxA7 and Meis1 (unpublished data); further-
more, we also observed deregulation of HOX genes in patients
with CALM/AF10-positive AML (unpublished data). This indi-
cates that deregulation of this transcription factor family is a
common characteristic of CALM/AF10 leukemias independent
of the phenotype.
In summary, this murine leukemia model demonstrates that
a progenitor cell with lymphoid characteristics and a phenotype
that differs from that of normal hematopoietic stem cells and the
leukemic myeloid bulk, is able to propagate AML. These data
provide a rationale for the development of therapeutic strategies
targeting the leukemia-propagating stem cell without harming
the normal stem cell pool and raise the hope that such innova-
tive concepts may improve treatment outcome in a subgroup
of patients with AML in the future.
Experimental procedures
Retroviral transduction of primary bone marrow cells
and BM transplantation
Breeding and maintenance of the mice were conducted as described previ-
ously (Rawat et al., 2004). Production of high-titer helper-free retrovirus was
carried out following standard procedures by using the ecotropic packaging
cell line GP+E86 (Schessl et al., 2005). Lethally irradiated (0.80 Gy) mice were
transplanted with either highly purified EGFP+ cells alone (4 3 105 cells per
mouse) (FACSVantage, Becton Dickinson) or with a mixture of transduced
and nontransduced cells (on average 1.76 3 105 transduced cells with 1.9 3
105 nontransduced cells per mouse). Lethally irradiated secondary and
tertiary recipients were injected with 1 3 106 BM cells from a primary and
secondary diseased mouse, respectively, with an equal number of nontrans-
duced cells from a syngenic disease-free mouse bone marrow for radiopro-
tection. Both animal and human studies were approved by the Ethics
Committee of Ludwig Maximilians University and abided by the tenets of
the revised World Medical Association Declaration of Helsinki (http://www.
wma.net/e/policy/b3.htm).
In order to determine the frequency of leukemia-propagating cells, B220+/
Mac12, B220+/Mac1+, and B2202/Mac1+ cells were isolated and highly pu-
rified from the BM of a leukemic primary mouse. The sort purity of these cells
was analyzed with the FACSCalibur and determined to be over 98%. In each
cohort 10-fold serial dilutions of these cells were injected intravenously (50
cells to 5 3 105 cells per mouse cohort) into lethally irradiated secondary re-
cipient mice. Carrier cells (1 3 106) (nontransduced BM from a syngenic dis-
ease-free mouse) were added to each sample for radioprotection. Diseased
mice were sacrificed and assessed for leukemia development. Mice that did
not develop disease within 20 weeks posttransplantation were sacrificed andCANCER CELL NOVEMBER 2006
A R T I C L Etested for engraftment. The frequency of leukemia-propagating cells was
calculated using Poisson statistics using the L-Calc Limiting dilution analysis
software (Version 1.1 StemSoft Inc., Vancouver, Canada) (Buske et al., 2002).
Patient samples
BM samples from adult patients diagnosed with AML were analyzed. The di-
agnosis of AML was performed according to the French-American-British
criteria and the World Health Organization classification (Bennett et al.,
1985; Harris et al., 1995). Cytomorphology, cytochemistry, cytogenetics,
and molecular genetics were applied in all cases as described below. The
clinical features of patients are provided in Table S4. The study abided by
the rules of the local internal review board and the tenets of the revised
Helsinki protocol (http://www.wma.net/e/policy/b3.htm).
Sorting of cells from human AML patient samples
Frozen mononuclear peripheral blood or bone marrow cells from patients
with AML were rapidly thawed and were washed twice in IMDM with 10%
FBS, resuspended in PBS, and stained with various antibodies. For lineage
depletion experiments, immunostaining was done with FITC-labeled anti-hu-
man CD34 (Beckman Coulter, Marseille, France) and PE-labeled anti-human
CD38, PE-labeled anti-human CD19, PE-labeled anti-human CD10, and PE-
labeled anti-human CD45RA (all from BD Pharmingen, Heidelberg, Ger-
many). Cells were incubated with appropriate antibodies for 20 min on ice
and washed with cold PBS prior to sorting. The trial was approved by the re-
sponsible local ethics committees, and all patients gave written informed
consent according to the Helsinki Declaration.
FISH
Dual Colour Dual Fusion (DCDF) probes were developed with bacterial artifi-
cial chromosome (BAC) clones RP11-418C1 for the 50-AF10 region (Texas
Red; red in Figure 5B), RP11-249M6 for the 30-AF10 region (red), RP11-
12D16 (FITC, green) for the 50-CALM region, and RP11-90K17 (green) for
the 30-CALM region (kindly provided by Dr. Mariano Rocchi, Bari). BAC
DNA preparation, labeling, and FISH were performed as described (Cre-
scenzi et al., 2004). Normal nuclei display a two-red and two-green (2R2G)
hybridization pattern, whereas nuclei carrying the translocation display
a one-red, one-green, twored/green fusion (1R1G2F) pattern. Other hybrid-
ization patterns, e.g., 1R1G1F (found in 0.5%–2% of nuclei) or 1R1G3F
(found in 0.5%–1% of nuclei), were interpreted as technical artifacts.
The cells were directly sorted onto aminoalkylsilane-coated slides (Silane-
Prep Slides, Sigma, Germany) with or without preloading of 15 ml 3% bovine
serum albumin solution in PBS and fixed in 1:3 acetic acid-methanol fixative.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures, five
supplemental figures, and five supplemental tables and can be found with
this article online at http://www.cancercell.org/cgi/content/full/10/5/363/
DC1/.
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